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Dear Dr. Greenberg:
I am writing to transmit to you the Bureau's Risk A$S&:;,"'Srnent Poll~v
document, prepared by Norman T. Anderson and peer-reviewed by Maine's
Scientific Advisory Panel (SAP). This document has evolved to its present
form as an internal workinav document over a lono period of time. It has
attained a level of . technical excellence, comprehensiveness, and
consistency that SAP now deems appropriate for its intended use as an
official guidance document for risk assessments to be conducted or judged
acceptable by the Bureau of Health, including assessments conducted as
part of Maine's Hazardous Air Pollutant Program. Accordingly, it is being
published at this time to also serve as a resource for members of State
agenc1es and the public seeking guidance in preparing or evaluating risk
assessments in Maine.
y

In this context, it 1s important for users to understand .the
evolutionary nature of this pollcy document. Its ongoing evolution is·.
anticipated because the risk assessment process .freq~ently poses issues
'Nhich have not been addressed in the Bureau's. prior assessments, and ·
because the state of the art in risk assessment is currently advancing at" ·a:
rapid pace. Neither of these sources tends to introduce changes at r.eguJar ·
intervals. To release this document while also accommodating polity.
evolution, the Bureau has suggested and SAP has endorsed use of' a 1ooseleaf format which can be updated as appropriate by occas1onal·reprat:e.- ·
ment of outdated pages. Users are, the ref ore, counse 1ed to .consulf·the ,
Bureau to de term 1ne current dates of a11 pages, and acquire replacements
as needed from the Bureau, prior to use of the document.
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A1though no forma 1 procedure has been estab 1i shed by the Bureau for
soliciting public input about this policy document, SAP believes that any
po 1icy-related fact(s) brought to the Bureau's attention should be accorded
due cons1deration as a possible basis for augmenting or altering the
present document. Such responsiveness can exert only a positive effect
upon the docurnent's overa11 qual1ty and its ability to serve the citizens of
Maine during its continued evolution.
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Preface

As the Maine Bureau of Health has become increasingly involved with
conducting and evaluating risk assessments, the need has arisen for the
establishment of a risk assessment policy. The intent of this document is to
identify relevant risk assessment policy issues, and to provide science
policy guidance for addressing these issues. The scope of this document is
broad enough to be applicable to any situation requiring risk assessments for
toxic substances.
The scope of each risk assessment should be defined by its purpose. For
example, the word "environment" is used extensively in this document. The
term refers not just to the ambient environment, but to the total ~pvironment
surrounding an organism or group of organisms. This distinction is ·_important,
as it does not limit the scope of the policy to any single exposure: medium
(such as air, water, or food), or to any particular category of exposure (for
example, indoor air pollution in residential environments v~rsus ?iJ;;.P9llution
in occupational environments).
It is possible that some' assessments may
require the evaluation of all exposure media and exposure categories.
Conversely, other risk assessments may require only a limited evaluation of
exposure, or perhaps none at all.
·
Sufficient latitude is also required in defining the scope of the health
assessment. The health effects identified in the policy are not restricted to
any disease endpoint or group of endpoints. Unless specifically st?t~d in the
assessment's purpose (for example, that the assessment will only ~onsider
carcinogenic effects), this policy allows the · :~. assessments ,sufficient
flexibility to consider all potentially relevant parameters ef. · adverse
biological effects. Consideration of all relevant pa:r~meters ~9-Y.~: provide a
better scientific insight into both the biological basis for ari:y· pa~ticular
effect, or for the mechanisms of toxicity, than" .~would bet·,~athfeved by
consideration of a limited number of health endpoints.
It should be continually emphasized, however, that risk ·asse~srtie~t is a
tool, not a substitute, for the determination .of responsible .sochn policy.
It is an attempt to combine wha~ is known and what is not ~kn.Qwn about a
chemical into an abstract concept loosely defined a.s an "~_<; 1t(ofl,. level." As .
such, it generates a dynamic process which inevitably iniprove:s-~·'the methods by
which risk assessments are conducted.
It does not, unfortunately, provide
much comfort when our scientific understanding fails to meet the challenges we
increasingly impose upon it.
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EXECUTIVE SUMMARY

Since the inception of its Environmental Health Unit in 1981 (M.R.S.A.,
1981), the Maine Bureau of Health has become increasingly involved with
conducting and evaluating risk assessments. With this responsibility has come
the growing need for the Maine Bureau of Health to develop a risk assessment
policy. This document describes the issues of potential concern in risk
assessment, and the Bureau's policies regarding how these issues should be
addressed.
The policy considerations contained in this document are guided by three
basic principles: 1) that uncertainties associated with the assessment of
health risk should be reflected by a conservative approach towards the
protection of public health, 2) to the extent feasible, all relevant data
should be evaluated in the assessment process, and 3) that risk assessments
should reflect the best scientific understanding of chemically related health
effects. Conformity to these princip~es results in a dynamic approach to risk
assessment while ensuring that the public is given adequate health protection.
Risk assessments consist of four basic steps:
exposure assessment,
hazard identification, hazard assessment, and risk characterization. Within
the first three risk assessment steps, specific parameters need to be evaluated. These parameters provide the basis for an overall characterization of
risk.
It is in the evaluation of these parameters that specific risk
assessment policy choices must be made. Criteria are either followed or
established to provide guidance in making these choices.
Inadequacies
identified in this process are incorporated into the recommendations for
further study.
Risk assessment policy issues begin with defining the scope of the
assessment and, subsequently, with the procedures by which studies are
identified and selected for evaluation. The goal of identifying and reviewing
all relevant data must be weighed against the limitations of data availability
and the extent to which resources can be devoted to the assessment. The
procedure should indicate how priority is given to studies critical to key
risk assessment issues and specify those studies which were selected for
review but could not be retrieved.
Studies selected for risk assessment are used to identify and evaluate
key exposure and health parameters. Because this process generally requires
information from several lines of investigation, it is important that the
selection process identify different types of studies as well as different
risk assessment parameters. Exposure parameters may need to be evaluated for
different environmental media and for different exposure routes. Relevant
exposure information may come from either monitoring or modelling studies.
Health parameters should describe effects as a function of exposure duration
and exposure dose. Relevant health information may come from epidemiological
studies, controlled human exposure studies, animal studies, and cell culture
studies.
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Studies reviewed in the exposure assessment are used to determine how much
is known about the extent and magnitude of population exposure. Studies
reviewed in the hazard identification section are used to determine what is
known and what needs to be known about the hazard potential of a chemical.
Estimates of the health risks, which are derived in the hazard assessment
section, need to consider both what is known and what is not known. Specific
areas of uncertainty considered in the exposure assessment and hazard
assessment sections should be identified. In addition, manner in which these
uncertainties are quantitatively or qualitatively addressed should be
specified.
The distinction between the _contributions of the empirical
findings and those of the uncertainty factors to the risk estimates should be
clearly made in the assessment.
The findings of the hazard assessment section are commonly expressed
quantitatively in terms of action levels. Exposures greater than the action
levels indicate a basis for health concern; exposures less than the action
levels indicate an insignificant health risk. For threshold effects, action
levels are estimates of no adverse effect levels for the general population.
For non-threshold effects, such as carcinogenesis, any level of exposure is
associated with some degree of risk. Action levels for non-threshold effects
thus depend on the level of risk which society is willing to assume. In the
absence of specific risk management policy: guidance, exposure doses
corresponding to lifetime cancer risks of 10 -5, 10 -6, and 10-7 should be
presented in the risk assessment. The action level is the exposure dose
In the risk
corresponding to a lifetime cancer risk of lo-5.
characterization section, the action levels for threshold and non-threshold
effects are compared with the exposure estimates to determine whether a
current or projected exposure warrants a significant health concern.
The derivation of action levels relies on the use of reasonable worst case
assumptions for estimating the health risks associated with chemical
exposure. By using worst case assumptions, a plausible upper bound can be set
on the estimation of uncertainty. Uncertainty exists in both the exposure
assessment and the hazard assessment. Worst case assumptions thus need to be
developed in both of these steps, as well as in the final, risk
characterization step.
Given the uncertainties associated with risk
estimation,, risk assessments may also describe approaches using less
conservative assumptions. Unless these alternative assumptions reflect a
greater certainty in the estimation of the actual exposure and toxicity,
however, estimates based on these less extreme assumptions lack the scientific
confidence necessary to ensure that the public's health is adequately
protected.
After the risk assessment has been completed and sufficiently reviewed,
its findings should be communicated to the appropriate agencies or
individuals.
While a procedure exists for chemicals evaluated in the
Hazardous Air Pollutant Program, risk assessments done for other purposes have
no defined risk communication procedures. The development of such procedures
would enhance the effectiveness of risk assessment as a tool in public
policymaking.
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SECTION I: INTRODUCTION

1.

Purpose of Risk Assessment.

The National Research Council (1983a) defines risk assessment as "the
qualitative or quantitative characterization of potential health effects of
particular substances on individuals or populations." Often in the risk
assessment process, choices must be made from an array of scientifically
plausible alternatives. These choices which are made in risk assessment
comprise the risk assessment policy (NRC, 1983a).
The general goal of a risk assessment is to identify and evaluate the
contribution of chemical exposure to the adverse human health effects. Risk
assessments are conducted for a variety of reasons. They may be done to
assess the health impacts of a current or anticipated exposure to a toxic
substance. They may be conducted to assess chemical impacts from specific
environmental media, or on specific population groups. Risk assessments may
also be conducted to provide the basis for regulatory guidelines or
standards. The purpose will, therefore, define the scope and focus of the
risk assessment, the parameters which need to be evaluated, and the specific
criteria which the assessment should address.
Once a risk assessment is completed, its findings need to be presented to
interested, or potentially interested, parties. This process is called risk
communication. Often, a risk assessment provide health criteria to be usea-In
establishing public policies for particular chemicals or mixtures of
chemicals.
The process by which public policies are established for
regulating population exposures to chemicals is called risk management (NRC,
1983a). Risk management decisions reflect a number of criteria in addition to
health criteria. They include economic and political factors, statutory
requirements, analytical limitations, technological feasibility, and impacts
of alternative actions.
Since the inception of its Environmental Health Unit in 1981 (M.R.S.A.,
1981), the Maine Bureau of Health has become increasingly involved with
conducting and evaluating risk assessments. In particular, the Hazardous Air
Pollutant Program (M.R.S .A., 1984) mandated the Bureau of Health to conduct
risk assessments on potentially hazardous air pollutants emitted in the
state. The legislation \vhich established the program also established a peer
review committee of scientists, the Scientific Advisory Panel, to provide
critical review of these assessments. While carrying out their res pons ib ili ties, both the Bureau of Health staff and the Scientific Advisory Panel
have realized the need for a consistent and scientifically defensible approach
to risk assessment. This need has also been expressed by representatives from
state regulatory agencies who request the Bureau of Health's advice on various
environmental health issues.
This risk assessment policy document was
developed in response to these concerns.
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This document has three principal uses. Structurally, it specifies the
general format which the Maine Bureau of Health will use when conducting
formal risk assessments. In terms of content, it identifies the specific
parameters which assessments may need to consider when evaluating the· health
risks of toxic chemicals. Thirdly, it states the general science policy
issues associated with the evaluation of these risk assessment parameters, the
criteria used in their evaluation, and the general approaches recommended by
the Bureau of Health when a policy judgment needs to be made. In many cases,
establishment of all parameters may not be necessarye Decisions to evaluate
or not evaluate parameters depend on the purpose and scope of the assessment.,
The policy considerations contained in this document are guided by three
basic principles. The first principle is that the uncertainties associated
with the assessment of health risk should be reflected by a conservative
approach towards the protection of public health.
In this context, a
conservative approach means that when confronted with scientific uncertainty,
errors associated with the pol icy choices should be in the direction of
increased public health protection. The second principle is that, to the
extent feasible, all relevant data should be evaluated in the assessment
process. The third principle is that the risk assessments should reflect the
best scientific understanding of chemically related health effects.
COnformity to these choices implies a complex and dynamic approach to risk
assessment policy. Specific risk assessment policy issues have been evaluated
by the International Agency for Research on Cancer (!ARC, 1980), National
Research Council (1977a-b, 1986), the U.S. Environmental Protection Agency
(USEPA, 1986a-e), the Occupational Safety and Health Administration (OSHA.,
1985), and the Office on Science and Technology Policy (OSTP, 1985), among
others. The criteria developed by such organizatioo.s as these provide the
science policy guidance for most of the issues examined by the Maine Bureau of
Health. Policy choices associated with these specific issues are modified as
new scientific information becomes available.
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2.

Substance Identification and General Properties.

Once the purpose of the assessment is defined, the investigation of the
substance begins with its chemical identification.
This chapter contains
information of the chemical formula, synonyms, and important identification
codes for the substance being assessed. This chapter also contains a short,
qualitative description of the substance's general characteristics, its major
physical and chemical properties, and appropriate conversion factors.
This
information is useful to several areas of the assessment. In the exposure
assessment, for example, such data may be helpful in determining likely routes
of exposure and the substance's ability to be transferred across different
environmental media. The data may also be useful in the pharmacokinetics
chapter (Chapter 10), when specific data concerning partition coefficients
within the body are not available.
Finally, information on sustance's
properties may provide assistance when describing the mechanism of action
( Olapter 14 .4).
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SECTION II:

MElliODS

The procedure by which information is systematically identified, retrieved
and evaluated is described in the Methods section. Although the degree of
information gathering and analysis depends on the purpose of the assessment,
there is a general protocol which is applicable to all assessments. First,
the scope of the assessment is defined. Definition of the scope is followed
by the procedure for 1) selecting the studies to be assessed, 2) how these
studies are to be evaluated, and 3) how these findings of the assessment are
to be communicated.

3.

Scope of the Risk Assessment.

The scope of the assessment broadly determines its nature and the level of
effort to be applied to it. The failure of the assessment to consider certain
key areas may lead to erroneous conclusions. The assessment may also suffer
from the failure to include information not directly related to its primary
purpose, but which may provide insight into the overall nature of the problem. On the other hand, consideration of information not directly relevant to
the assessment's purpose may create a drain on available resources and time
which could better directed elsewhere. At a minimum, the scope should include
those areas critical to satisfying the primary purpose of the assessment.
Decisions to include additional areas should consider how such additional
effort would divert resources from other environmental health assessments.
3.1 Risk Assessment Steps.
Risk assessment steps are the general areas of investigation and analysis
which risk assessments should consider. According to the National Research
Council, risk assessment contains one or more of the following steps: exposure
assessment, hazard identification, hazard (or dose response) assessment, and
risk characterization (NRC, 1983a). The extent to which these steps are
investigated depends on the assessment's scope.
The National Research
Council's recommendations concerning how risk assessment steps should be
combined and integrated into the risk management process is presented in
Figure 3.1. The Maine Bureau of Health follows this general guidance when
conducting risk assessments.
3.2

Risk Assessment Parameters and Criteria.

Assessment of each risk assessment step requires consideration of specific
risk assessment policy issues. Resolution of these issues is important if the
health and exposure parameters critical to the assessment of human health
risks are to be appropriately determined. In many cases, these parameters are
determined by using specific risk assessment criteria. Health parameters
identified in the Hazard Identification section (Section IV) are evaluated in
the Hlzard Assessment section (Section V). The assessment of these parameters
in combination with the exposure parameters (Section III) provides a
characterization of the types and severity of potential health effects at
exposure levels of concern (Section VI).
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The param~ters identified and evaluated in the Exposure Assessment address
the potential for human exposure from various emission· sources and through
different exposure routes, and the fate of the substance in the environment.
These parameters are used in the derivation of quantitative exposure estimates
and estimates of the body burdens. Criteria need to be followed or developed
in order to judge the validity and precision of these exposure values.
The Hazard Assessment contains both a qualitative and a quantitative
evaluation of health risk. The qualitative assessment analyzes all findings
from the Hazard Identification which relate to a qualitative basis for
toxicological concern. Hazard identification parameters for a particular
substance are identified from studies on pharmacokinetics, health effects,
environmental effects, and comparisons with other substances which have
similar biological or chemical characteristics. From this information, an
overall weight of evidence determination is made which relates substance
As with the exposure assessment
exposure to potential health effects.
section, criteria should be followed or developed in this section from which
to judge weight of evidence and other qualititative measures of toxicological
concern.
Once the potential for a health effect to occur is established, parameters
for estimating the quantitative relationship between dose and response should
be determined. Included in these determinations should be an evaluation of
the adequacy of the database for quantitative risk assessment purposes. If a
sufficient quantitative basis exists for risk estimation, the assessment could
benefit from a discussion of how different assumptions or results may
influence the estimation process. This sensitivity analysis should provide an
appreciation for the robustness of the estimates. Because the approach to
quantitative assessment is different for threshold and non-threshold effects,
such derivations must be done separately. Criteria discussed in this section
concern the basis for the quantitative adjustments made to the data described
in the Hazard Identification section.
In the final, Risk Characterization, section on the assessment (Section
VI), estimates of the actual health risks associated with substance exposure
are presented. These estimates are developed from information reviewed or
derived in the previous sections. This overall assessment of health risk
represents criteria from which decisions may be made regarding risk
communication ·and risk management. Thus, the risk characterization section
presents information which should be considered within the broader contexts of
public health and social policy, where stricti y scientific criteria are not
the only areas of interest.
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4.

Selection of Studies.
4.1

Selection Procedure for Chemical Mixtures.

Risk assessments are generally conducted on individual chemicals.
Knowledge of the toxicological properties of individual chemicals may not be
sufficient indicators of toxicity, however, when chemicals are present in a
mixture.
Chemicals may interact in a number of ways.
They may react
chemically in the environment, thus possibly producing additional toxic
substances (USEPA, 1986c). They may also modify each other's pharmacokinetics
and activity at biological receptor sites (USEPA, 1986c).
Because these chemical interactions can be complex, the desired approach
regarding the assessment of chemical mixtures is to evaluate information on
the mixture as a whole. If the information on the mixture is found to be
inadequate for risk assessment, subsequent efforts should be directed towards
the assessment of the most toxic components of the mixture. This approach has
been used in the chemical ranking system and formal risk assessment process
developed for Maine's Hazardous Air Pollutant Program (Anderson, 1986).
4.2

Identification and Retrieval of Information.

Once the relevant steps and parameters of the risk assessment have been
identified, the method for identifying and selecting applicable information
should be described. Initial efforts usually focus on surveys of pertinent
databases, bibliographic references in recent secondary sources, and
information contained in the files of federal regulatory agencies. Relevant
studies may then be identified from these information sources.
Risk assessment policy implications are associated with the manner in
which the information sources are identified and selected.
Failure to
identify and retrieve critical studies may limit the ability of the assessment
to reflect current scientific understanding. Consequently, findings based on
a limited data set may be substantially different from those based on a more
complete information base, even though the same risk assessment assumptions
are applied in both cases. On the other hand, a thorough review of all
relevant studies may easily overwhelm the risk assessor's capacity. In this
case, such an expectation may preclude an assessment from being done in a
timely fashion.
The level of effort devoted to the identification of risk assessment
information is subject to the scope and purpose of the assessment, as well as
to the amount of time, money, and personnel that can be committed to the
search. Factors influencing this process include the number and nature of the
available databases, and how they are searched. The identification process
also depends on the quality and comprehensiveness of the secondary sources,
the extent to which they are reviewed, and the amount and avai lability of
information contained in the government files.
The overall degree of
identification is thus a function of the data avai lability and the resources
that can be devoted to identifying the data. As the resulting level of effort
may change with each assessment, the procedure by which information was
identified should be described in each case.
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A description of the procedure for selecting studies is also neededG The
selection of studies should be consistent with the purpose and scope of the
assessment. When many relevant studies have been identified, a hierarchy
should be established to ensure that a manageable amount of the most important
information is reviewed. Specifically, decisions must be made regarding which
issues can be adequately addressed by review of secondary sources, and which
issues require and in depth analysis of primary sources. As a result, the
process of selecting studies is apt to be a dynamic one; as the review of the
scientific literature progresses, issues are identified which warrant
particular scrutiny.
In certain situations, studies critical to the assessment are not
available for review. These situations may occur when the studies are
considered to be proprietary information, when they have been written in a
foreign language for which no translation is available, or when they are still
works in progress. Problems associated with access to proprietary information
may be overcome if arrangements to maintain confidentiality. can be made with
the sources of that information.
Because the inability to retrieve
information may significantly influence the findings of the assessment,
mention should be made when such critical studies have been identified but
could not be retrieved.
4a3

Types of Exposure Assessment Studies.

Data in the Exposure Assessment (Section 3) are analyzed in order to
derive quantitative estimates of exposure for each exposure medium and
exposure route. This information comes from two areas of investigation:
monitoring and modelling.
Precision varies with the analytical methods
employed and the extent of the analysis.
Monitoring information is generally considered to be more important that
modelling information, in that monitored values reflect actual exposure
concentrations.. Varying degrees of uncertainty are associated with these
values, however. Apart from factors influencing the precision of the sampling
and analytical procedures, substance levels may vary temporally and
spatially. They may also be present in media not where no sampling has been
conducted. These potential gaps and fluctuations introduce uncertainty as to
whether or not the monitored values represent the true exposure patterns.
Selection criteria should therefore address the need to reduce this
uncertainty.
When monitoring data do not adequately reflect the true exposure patterns,
assessments must rely on modelling information in order to estimate the extent
and magnitude of exposure.
Different types of modelling information
information may be necessary for assessments which consider exposures from
more than one pathway. Models are not able to consider all of the factors
which influence the fate and transport of the substance in the environment,
however.
Therefore, the correlations between model results and actual
exposure conditions may vary substantially from one location to the next.
Consequently, selection criteria for modelling information should therefore
consider the types of exposure information required in the assessments and the
extent to which monitoring data must be supplemented by modelling information.
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4.4

Types of Hazard Identification Studies.

Health effects information on a chemical comes from four principal areas
of study:
observational epidemiology, experimental epidemiology (that is,
environmentally controlled studies with human volunteers), whole animal (in
vivo) toxicology, and in vitro experiments. Each area of study has its own
set of advantages and Olsadvantages, and each can provide information on an
aspect of a chemical's toxicity unobtainable from other areas of research. In
some instances, experiments are performed using both in vivo and in vitro
procedures, such as the host mediated assay (!ARC, 1980)--. Thus, evaluation of
information from all study categories should contribute to the overall
understanding of a substance's toxicity.
4 .. 4 .. 1 Observational Epidemiological Studies·.
Observational epidemiological investigations concern the study of disease
patterns in human populations.
Observational studies may either be
predominantly descriptive or predominantly analytical. Descriptive studies
are usually undertaken when very little is known about the risk factors for a
particular disease. In its simplest form, a descriptive study may involve the
identification of a potential risk factor in a case or cluster of cases.
Ecologic studies involve larger groups of people, most often defined
geographically. Disease patterns are studied either over time or in relation
to different exposure parameters.
Both types of descriptive studies are
useful for generating specific hypotheses regarding the association between a
potential risk factor and disease. Generally, however, they do not provide
enough information on the exposed and non-exposed populations from which a
causal inference may be made.
Analytical studies include cross-sectional studies, case-control studies,
and cohort studies (Kleinbaum et al., .1982; MacMahon and Pugh, 1970). In a
cross-sectional study, prevalence rates at a particular time are compared
among populations with different .risk factor characteristics. Cross-sectional
studies are particularly useful when the risk factors are stable over time and
when the diseases are those which occur frequently and which have long
durations (Kleinbaum et al., 1982). By only considering prevalence, however,
cross-sectional studies cannot establish a temporal association between the
risk factor and disease.
In a case-control study, individuals with a disease are compared with
individuals without a disease to identify potential risk factors within the
diseased individuals. A case-control study is especially useful when the
disease of interest rarely occurs.
It is limited, however, by several
factors. Firstly, risk factor information is obtained in this type of study
after the occurrence of the disease (Kleinbaum et al., 1982). Also, it is
difficult to ensure that the cases and non-cases in the study population are
similar with respect to extraneous risk factors (Kleinbaum et al., 1982).
Finally, because it concerns a specific disease outcome, a case-control study
may not be appropriate when a variety of possible health effects are being
investigated (Kleinbaum et al., 1982).
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In a cohort study, populations are identified in relation to an
independent
study variable
(for
example,
exposed and non-exposed
populations). A retrospective study investigates relevant data bases to
determine whether the incidence of a particular disease differs significantly
between the exposure groups. A prospective study follows these individuals
over time to determine whether disease incidence varies significantly between
the groups. Cohort studies, particularly prospective studies, are useful for
establishing temporal associations between a risk factor and diseaseo On the
other hand, these types of investigations are likely to be expensive,
especially if the disease of interest occurs with a rare frequencye Also,
certain kinds of studies, such as prospective studies, may take many years to
complete. In the meantime, many people may suffer disease as a result of
exposure, and many more may be at risk of developing disease even after the
exposure is reduced or discontinued.
For risk assessment purposes, analytical studies are most useful for
establishing causal associations between chemical exposure and disease. They
thus represent the strongest evidence for a toxic effect. Establishing causal
relationships is difficult, however, because there are usually other agents in
the environment which have the potential to cause the same health effects .
Also, differences in lifestyles and exposure patterns among members of the
study and control populations preclude any precise characterization of these
cohorts.
In addition, exposure information is rarely determined with
prec1s1on. This last shortcoming affects the ability of epidemiological
studies to establish dose-response relationships in the populations under
studys
Because of these limitations, most epidemiological studies are
inherently capable of detecting only comparatively large increases (50
percent) in the relative risks of chronic health effects (OSHA, 1980).
4.4.2

Experimental Epidemiology Studies.

Some of the problems associated with observational epidemiological studies
can be eliminated if controlled studies with human volunteers are undertaken.
In these studies, direct causal relationships can be more easily established
because
potential
confounding
factors
are
removed.
Dose-response
relationships can be precisely derived because the exposure to the substance
is monitored and controlled.
Traditionally, controlled human exposure studies have been undertaken to
test the effects of pharmaceuticals. In these cases, the study populations
were likely to benefit greatly from a successful experiment. Human volunteers
do not benefit from exposure to toxic, non-therapeutic chemicals, however.
Thus, the use of experimental epidemiology for assessing the human health
impacts of chemical contaminants is very circumscribed. For ethical reasons,
therefore, experimentation with human subjects is not carried out when the
chemical in question may produce irreversible effects, or at dose levels at
which severe reversible effects may occur. Thus, controlled human studies
have limited usefulness in risk assessment, which is mainly concerned with the
irreversible effects of long-term exposure. Rather, environmental health
studies using controlled human exposures are primarily designed to detect
subtle and reversible acute effects.
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4.4.3

Whole Animal Studies.

Whole animal (or in vivo) studies provide much of the substance-specific
information on toxicity. -rnls is particularly true when information is needed
on irreversible effects, or when toxicological and pharmacological information
can only be obtained by invasive means. Animal studies can be performed under
carefully monitored and controlled conditions and are therefore capable of
being reproduced or compared. They also can provide precise dose-response
information.
They are generally cheaper than large-scale epidemiological
studies and can be completed in relatively short periods of time.
For new substances, toxicological studies can detect potentially
irreversible effects, such as cancer, and thus serve as a screen for the
introduction of potentially hazardous substances into the marketplace. For
substances currently in use, they may identify harmful substances not
identified through epidemiological investigations.
On the other hand,
significant interspecies differences may exist in a substance's toxicity, and
there is generally no a priori way of knowing whether the response of any
particular species is tlie most predictive of the response in human beings.
Thus, it is possible that an effect found to occur in any laboratory animal
may also occur in human beings. Similarly, if the same effect occurs in
different species or strains, it is possible that the most potent response
observed in the test animals is also representative of a human response.
Exceptions to the use of the most sensitive species may be considered if the
experiment contained significant flaws or if it can be demonstrated that the
response is not qual ita ti ve ly or quanti ta ti ve ly similar to the response in
human beings. Generally, however, these findings can only be made during the
course of the assessment. The study selection process, therefore, should be
especially directed towards the retrieval of studies which indicate the lowest
observed effect levels without regard as to whether or not the studies are
relevant to human health. One ini tia 1 source of this information is the
Registry of Toxic Effects of Chemical Substances, or RTECS (NIOSH, 1986).
RTECS lists by effect and species the study in which the most sensitive
response was observed.
4.4.4

In Vitro Studies.

Given the large numbers of chemicals in and entering the marketplace, it
is unlikely that existing laboratory facilities ·will be able, financially or
logistically, to provide an adequate data base on chemical hazards (OTA,
1981). Because in vitro studies can be done quickly and inexpensively, they
are critical for setting priori ties on which chemicals should undergo more
extensive testing, or for providing a toxicological basis for concern in the
absence of adequate data on human beings or laboratory animals. Also, use of
in vitro techniques can help to elucidate the biochemical basis for toxicity,
and---u:> predict structure- activity relationships.
Understanding the
mechanisms by which a toxic effect is produced provides the conceptual basis
for interpreting the results of epidemiological or animal toxicology studies,
or for predicting the toxicity of a substance in the absence of such data.
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5.

Analysis of Study Results.
5.1

Biological and Statistical Significance.

Health effects studies may demonstrate a positive association between
chemical exposure and an adverse response. They cannot, however, prove the
absence of an adverse response. At most, they can only demonstrate that the
magnitude of the response in the exposed population was below the level at
which the study could detect a statistically positive association. When a
significantly positive association between exposure and effect is found in a
properly designed and conducted study (that is, when there is a sufficiently
low probability that the association may have ·occurred by chance), the study
is referred to as·a "positive" study for that health parameter. Studies which
fail to demonstrate a significantly positive association are referred to as
"non-positive" studies. Non-positive studies may include "negative" studies,
or those studies in which clearly no positive associations were observed.
There may also be studies in which positive responses or trends were
suggested, but whose findings lacked statistical significance ("suggestive"
studies). Finally, apart from issues of statistical significance, studies
which had deficiencies in their design or conduct are limited in their
abilities to produce biologically meaningful results. Depending on the nature
of these deficiencies, these studies may be referred to as - either
"inconclusive" or "inadequate."
From a statistical standpoint, the ability of a study to detect a
significantly positive association depends on the significance level used, the
size of the exposed and control populations, and the background incidence of
the effect. Most cancer epidemiology studies, for example, are unable to
identify a positive association unless the response in the exposed population
is SO percent above the background rates (OSH~, 1980). In the case of animal
bioassays, the finding of no tumors in a test population of 100 animals does
not demonstrate that a zero cancer risk is associated with exposure to the
chemical. Instead, a statistical analysis would demonstrate that we can be 95
percent confident that the actual incidence of tumors is no more than 4.5
percent ( OTA, 1981).
Thus, statistical methods may be employed on
non-positive studies to estimate an upper bound on potential risk.
In addition to statistical analyses, study results may be evaluated on the
basis of their biological significance. Information related to the assessment
of biological significance may come directly from the epidemiological or
animal bioassay studies in which the effect was investigated. It may also
come from other toxico logical areas, such as genetic toxicity, biochemical
assays, and structure-activity relationships.
As an example of such an
assessment, an elevated incidence for a rare tumor in an exposed population
may be judged to be biologically significant despite a lack of statistical
significance relative to concurrent controls.
Similarly, several studies
showing non-significant elevations in the same tumor type may indicate a
biologically significant effect. When considering such suggestive findings,
the assessment should also be made concerning whether or not the design and
conduct of the experiment were likely to increase or decrease the study's
ability to detect a positive response. Conversely, a study may identify a
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statistically significant association between exposure and effect which has
limited biological significance. For example, a positive teratogenicity study
in which the mother was administered toxic doses of a chemical may not be able
to dissociate the direct effects on the embryo from the secondary effects
resulting from maternal toxicity.
5.2

The Use of Worst Case Risk Assessment.

Estimates of the health risks associated with exposure to a substance
depend on the assumptions employed in the risk assessment. A worst case
assessment of public health risks is defined by the consistent use of
reasonable worst case assumptions.
If the current or projected exposure
levels are below the levels derived from worst case risk assessment, then the
conclusion can be drawn that, on the basis of the available information,
exposure to the substance does not present a significant public health risk.,
If current or projected levels are at or above the levels derived from a worst
case assessment, however, it may become necessary for risk assessments to more
rigorously investigate the worst case assumptions. The intent of such an
evaluation is to determine if less extreme assumptions are justified based on
the best available data for the chemical in question. It is also possible
that closer scrutiny may determine that assumptions more extreme than the
worst case should be applied.
The worst case assumptions are used to set a plausible upper bound on the
level of health risk associated with a particular exposure, or a plausible
lower bound on the exposure level below which no significant health effects
are expected to occure If worst case assumptions are replaced by assumptions
more reflective of the substance's observed toxicity, the confidence in the
resulting degree of protection provided to the population depends on how
closely the response of the study population reflects the response of the
general population. Justification for this procedure may come from pertinent
data on the exposure-response relationships, variations in population
susceptibility and sensitivity, or the mechanisms of action.
If greater
certainty can be achieved, the confidence belt surrounding a risk estimate can
be narrowed with no loss of public health protection.
If, however, the
confidence be 1t surrounding a particular estimate of risk is narrowed in the
absence of greater certainty, a loss of public health protection may result.
Worst case assessment is, therefore, the primary means by which risks
associated with chemical exposures are identified.
If predicted exposure
levels are less than those associated with health risks under worst case
assumptions, a more rigorous analysis of these assumptions may be unnecessary. In the absence of a more thorough analysis, or if the data are
inadequate to precisely characterize the uncertainty regarding the toxic
response to exposure, the worst case risk risk assessment represents the
procedure upon which public health policy recommendations must rely.
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5.3 Derivation of Action Levels.
The analysis of the relationship between exposure and response results in
an estimate of an "action level," or an exposure level above which there is a
basis for health concern. The nature of the health concern is a function of
the degree of analysis performed in the assessment, the severity and nature of
the adverse effect, and the characteristics of the exposed population. Action
levels are determined by considering the most sensitive effect of biological
significance for the various exposure durations of concern. Action levels
protective against the most sensitive effects consequently provide protection
against the less sensitive effects as well.
Depending on the risk
extrapolation process, or the degree .of uncertainty associated with the
assessment . of human risk, a range of potential action levels may be
presented. Public health recommendations can then be developed using these
action levels as a basis.
The method by which action levels are derived depends on whether or not a
threshold is presumed to exist. If a threshold is presumed, exposure to a
substance below a certain level should not increase health risks.
Non-threshold effects may occur through even a single interaction between a
substance and a biologically critical molecule, and no exposure level can be
estimated for which there is an absence of risk. Most health effects are
considered to exhibit thresholds, although the existence of thresholds cannot
be experimentally determined solely on the basis of quantal responses from
whole animal or epidemiological data (IRLG, 1986; Klaasen, 1986).
A
non-threshold response is presumed when an effect may occur through a single
irreversible lesion, as could occur when a substance interacts with DNA. This
is a presumed mechanism of action for many chemical carcinogens (Flamm and
Lorentzen, 1985; OTA, 1981; USEPA, l986a; Tomatis et al., 1982).
Some
carcinogens, referred to as "epigenetic" carcinogens (Shank and Barrows,
1985), . may exert their effects through indirect mechanisms for which
thresholds may exist. There is currently much uncertainty regarding the
characterization of epigenetic carcinogens.
Unless the dose-response
relationship is developed to the degree that a threshold model can be
presumed, therefore, action levels for carcinogenic substances should be
derived using non-threshold assumptions.
For threshold effects, the action level should be the estimated no adverse
effect level (ENAEL). This estimation process involves the application of
various uncertainty factors and adjustment factors to a response level
determined from a health effects study. For non-threshold effects, any
exposure is associated with some degree of health risk. Thus, the ENAEL for a
chemical carcinogen is zero unless it can be demonstrated that its effect is
produced through a threshold mechanism. In some cases, such as when decisions
are made concerning whether or not a chemical should be produced commercially,
a qualitative finding of carcinogenicity implying a zero action level may be
sufficient. In the majority of cases, however, a non-zero estimate of an
action level is needed. Instead of an estimated no adverse effect level, a
level is specified for non-threshold effects at which the risk is considered
to be insignificant. As a general principle, a lifetime risk one per one
hundred thousand is used as a reference. Risk levels above one per one
hundred thousand indicate the presence of a health concern, and that decisions
regarding risk communication or risk management should reflect this concern.
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Science policy decisions to use assumptions less extreme than the worst
case in intraspecies and interspecies extrapolations result in higher
estimates for recommended action levels. Action levels would be higher, for
example, if the decision is made to use the median response from animal
bioassays, rather than the most sensitive reponse, as a basis for estimating
human risk. Action levels-would also be higher if the dose equivalency among
animals is based on body weight when there is reason to believe that a surface
area adjustment is warrantede In keeping with the principles of this policy,
action levels based on less extreme toxicological assumptions than the worst
case should be accompanied by documentation as to why these less ·extreme
assumptions were chosen.
Action levels may also increase as the assumptions regarding the degree
and duration of exposure become less extreme. Cancer risk estimates, for
example, are commonly expressed in terms of continuous exposure over a 70 year
lifetime.
Less extreme assumptions may sometimes be warranted if the
exposures are intermittent or if the exposure occurs only during a fraction of
one's lifetime. Other risk assessments may evaluate the degree of risk
associated with food contaminants. In these cases, worst case estimates of
risk are based on assumptions of maximum contaminant levels found or predicted
to be found in food. These worst case risk estimates may be lowered if data
are available from which to derive more certain estimates of exposure. As
with the toxicological assessment, adequate documentation is needed if action
levels are based on exposure assumptions less extreme than the worst case ..
It should be emphasized, however, that the cornerstone of public health
policy is the prevention of disease. It is not the intention of the Maine
Bureau of Health, therefore, to advocate a deterioration in environmental
quality to the level of the derived action level. Conversely, if background
levels of a substance are high enough to present a health concern, public
health policy would indicate that exposure levels not be significantly
increased over background concentrations, and even that they be decreased when
it is feasible.
So4

Peer Review of Risk Assessments.

Peer review is necessary to the proper evaluation of a scientific issue.
Peer review of risk assessments is especially important in that these
assessments often involve consideration of information from several scientific
disciplines. Agencies or organizations conducting risk assessments rarely
have expertise in all relevant disciplines.
Instead, assurance that the
studies are properly conducted and that sound judgments are drawn from them
can be accomplished by peer review from appropriate scientists.
The Maine Bureau of Health has a peer review committee, the Scientific
Advisory Panel (SAP), which was established by the same legislation which
created the Hazardous Air Pollutant Program (M.R~S.A., 1984). The SAP reviews
the Bureau of Health's assessments on hazardous air pollutantso The Panel may
also review the health risks pertaining to other environmental issues, if such
additional reviews are determined by the Bureau of Health to be justified. In
carrying out its review, the SAP may request further assistance of experts in
particular scientific disciplines.
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Because of its principal role as a peer review committee for risk
assessments, the Scientific Advisory Panel has been asked, and has agreed, to
review this risk assessment policy and may review all subsequent additions and
revisions. By separating the science policy issues from issues pertaining to
the interpretation of scientific studies, the attention given to the
development and review of risk assessments can be more clearly focused. This
increase in the efficiency of the risk assessment process greatly assists the
Bureau of Health and the SAP in their efforts to have the assessments reflect
the best scientific understanding of the issue.
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6.

Risk Communication.

Risk assessment findings provide the health criteria for the assessment of
environmental quality. As suCh, they influence both individual and societal
decisions regarding the control of exposures to toxic substances. Because
they must often be considered in a such contexts, these findings must be
communicated in a way that is comprehensible to the public. Communication is
made both to individual citizens who must make decisions regarding the
management of their own health status, and to risk managers who must make
societal decisions regarding acceptable health risks.
The precise communication of risk assessment findings is perhaps the most
difficult part of the entire risk evaluation process. There are few areas of
consensus among the scientific community on risk assessment policy issues.
While this lack of agreement is beneficial to the development of better risk
assessment methods, it may result in much confusion when risk assessment
findings provide a basis for political decisions. Furthermore, many of the
studies useful to risk assessment are not directly translatable into a
description of human health risks. This limitation is particularly relevant
when the health risks of low-leve 1, long term exposures are to be estimated.
Finally, given the increasing numbers of chemicals present in the environment
with the potential to cause adverse effects, as well as the growing
recognition of the hazards associated with accidents involving toxic
substances, risk communication efforts must recognize the cumulative impacts
on society's perception of risk resulting from the identification of new
environmental health threats. In order for the scientific process to remain
credible, the limitations of the underlying database must be described. Also,
the extent of our knowledge and ignorance about a particular exposure
situation should be adequately translated into an appropriate measure of
health concern.

'

(
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SECTION I II.

EXPOSURE ASSESSMENT

The objective of the exposure assessment is to characterize as fully as
possible the potential for, and degree of human exposure to a substance. This
includes a qualitative or quantitative estimate of the exposure level, as well,
as estimates of the exposure durations associated with each exposure level.
As will be demonstrated later, this exposure information applies directly to
the quantitative assessment and to the ultimate determination of whether or
not exposure to this substance presents a public health threat.
Information on exposure may be direct or indirect. Direct information
includes actual measurements of chemical concentrations in ambient or indoor
environments, biological tissues, or food.
Indirect sources of information
include data related to the sources of chemical release into the environment.
Another indirect estimate of exposure can be obtained through the use of
various theoretical models.
7.

Sources of Exposure

The source assessment provides information on the sources of exposure to
the substance under investigation. Its purpose is to identify all potential
avenues of human exposure to the substance.
It begins with a general
description of the substance's production and use, followed by a quantitative
description of the releases of this substance into the indoor and ambient
environments.
7.1

Production and Use.

Information presented in this subchapter should include a description of
the amount of the substance produced and how it is produced. Special mention
should be made of any production facilities in Maine. Production and use
information also includes a description of how and to what extent this
substance is used, again emphasizing usage information in Maine. From this
information, an assessment can be made of prevalence of exposure, as well as
the areas of the state where significant exposures are most likely to occur.
7.2

Bnissions.

Information presented here describes the substance's ability to be emitted
into various environmental media.
Emissions can be described both
qualitatively and quantitatively. A qualitative description involves a review
of the substance's physical and chemical properties, as well as production and
usage characteristics.
The quantitative description is a presentation of
either emission factors or actual test results regarding substance levels in
air or water effluents.
These kinds of quantitative data are generally
unavailable, but could be very useful for modelling purposes if they are
obtained. The Maine Bureau of Health recognizes the potential health risks
associated with occupational environments, and the growing concern that
non-occupational indoor exposure to toxic substances may present significant
health risks. Thus, these exposure situations may need to be discussed in
addition to the discussion of the emissions into the ambient environment.
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7s2.1

Methods of Estimation or Measurement.

Quantitative estimates of human exposure to a toxic substance may depend,
at least in· part, on estimates of its emissions into the environment., These
emissions estimates may vary according to the measurement or estimation method
method employed. Thus, in developing its exposure assessment findings, the
risk assessment may consider the methodologies used to produce the
quantitative estimates.
Depending on the importance of the emissions estimate to the exposure
assessment, a discussion of the methods used to derive emissions may require
discussion. This discussion may include a description of what emission
factors are available, the methods associated with the actual measurement of
emissions, or how physical and chemical properties are to be evaluated when
emissions estimates cannot be derived by more direct means. A discussion
concerning the quality of the estimation or measurement methods should also be
included.
7.2.2

Emissione into Occupational Environments.

Little quantitative information exists on substance emissions in
occupational environments. MUch of the available information is qualitativeo
Based on the physical and chemical properties of the substance, and the
industrial processes involved in its use or formation, some assumptions may be
made regarding emissions. Volatile substances, as well as combustion or
comminution processes leading to air entrainment of particles, are of
particular concern in this regard.

.

)

The usefulness of these emissions estimates depends on the methods used,
and the uncertainties associated with their design and conduct. A discussion
of these uncertainties may be necessary in order to place the quantitative
findings into a qualitative perspective of their significance.
The
uncertainties associated with emissions estimates in occupational environments
may be relatively unimportant if sufficient exposure monitoring data are
available. When, however, exposure monitoring data are inadequate, emissions
estimates from specific sources may provide valuable information for use in
the estimation of exposure levels.
7.2.3

Emissions into Non-Occupational Indoor Environments.

Toxic substance emissions in non-occupational indoor environments may come
from a variety of sources. Air contamination of indoor environments may
result from the same volatilization, or from combustion or communition
processes, just as they do in occupational environments. Volatilization may
occur from either solid or liquid surfaces. Combustion emissions may result
from cigarette smoking, or from utilization of gas stoves or indoor heating
devices. emissions may also result through the use of a particular consumer
product. Generally, quantitative information is limited with regard to toxic
substance emissions of this type. Qualitative information, based on the
substance's physical and chemical properties or product usage rates, may
provide general guidance for the estimation of emission potential in the
absence of quantitative data.
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Uncertainties associated with the estimation of emissions in these indoor
environments need to to discussed. This discussion is particularly relevant
when the · air emissions of volatile substances · in drinking water are
estimated. These emissions, while as yet poorly quantified, may contibute
significantly to the human exposure. (NRC, 1986).
7.2.4

Emissions into the Ambient Environment.

Emission factors or emission test results may be available for certain
substances emitted into the ambient environment from specific sources.
In
addition, generic emission factors may exist from which environmental releases
can be estimated in the absence of source-specific data. In general, however,
few data exist for emission sources of toxic substances. Thus, the same
concerns regarding the adequacy of emissions data on occupational or indoor
environments apply as well to the discussion of most chemical emissions into
the ambient environment.
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8.

Parameters for Deriving Quantitative Estimates of Exposure
8.1 Monitoring Information

Monitoring information is the key exposure component for quantitatively
assessing risks presented by chemical substances. It is an important factor
in the evaluation of epidemiological studies and is needed in order to assess
the health significance of current exposures. Monitoring data provide actual
measurements of exposure, and thus provide concrete evidence concerning the
extent and magnitude of an environmental problem. For this reason, monitoring
data are highly relevant to risk assessment.
Unfortunately, several limitations must be considered when evaluating
moni taring information. The adequacy of the monitoring data base must be
considered, therefore, when deriving conclusions concerning the correlation
between exposure and effect. Monitoring data are rarely collected in any
systematic way.
Except when published in scientific journals, they are
difficult to access. Moreover, consideration needs to be made that the
presence of other substances in the environment could confound the health
assessment. This is true for assessments of situations in which not all of
the potentially toxic substances may have been identified, including those
which must make use of historical information for chronic disease
investigations.
In addition to design considerations, attention should be given to
limitations in the sampling and analytical procedures. The assessment should
specify negative data within the context of sampling and analytical
limitations, and the degree of assurance that the monitoring was conducted in
the right place or during the right time periods. For example, even if
monitoring indicates the presence of a substance, it may be possible that
higher levels of the substance were present in an area which was not
monitored. Also, detection limits and analytical sensitivities vary for
different compounds or when different sampling and analytical protocols are
used.
8.1.1

Sampling and Analytical Methodologies.

There are various methodologies available for measuring substance
concentrations. It is important that these methodologies be described for the
particular substance under investigation. Of primary importance are the
sampling time, and the accuracy, precision, reliability, and detection limits
of the analysis with regard to different environmental media. Also of concern
are the potential for losses during sampling and analysis and the possible
interferences resulting from the presence of other substances. Many of these
concerns could be addressed by suitable quality control and quality assurance
procedures. Depending on the purpose and scope of the risk assessment, these
procedures may warrant discussion.
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8.1.2

Levels in Occupational Environments.

Monitoring data from occupational environments is used to relate exposure
to the observed health effects. Relevant information includes the type of
industry monitored, the type of job monitored within that industry, the range
of measured values, the averaging times, the analytical methodology used, and
the number of samples taken. Because many studies examine chronic effects,
this criterion should also reflect historical trends in these parameters. For
chemicals which show significant acute effects, such as the aggravation of
asthma, exposure data should include short-term or peak concentrations. For
chronic effects, such as cancer, information relevant to the determination of
long-term average concentrations is needed.
8.1.3 Levels in Non-Occupational Indoor Environments.
Monitoring information from non-occupational indoor environments includes
data on contaminant levels in water supplies, indoor air, and on surfaces.
Contaminated water supplies have received considerable attention, as evidenced
by the passage of the Safe Drinking Water Act and the development of health
advisories and standards by such agencies as the U.S. Environmental Protection
Agency, the National Research Council, and the World Health Organization.
Attention to indoor air pollution problems has been considerably less
involved.
For certain chemicals, such as radon and formaldehyde,
epidemiological studies have been conducted in non-occupational indoor
environments (see, for example, Vaughan et al., 1986). Such monitoring data
thus provides a needed exposure database for conducting risk assessments on
these environments, as well as a quantitative basis for comparing the health
risks in non-occupational environments to occupational settings. Even when
monitoring data from non-occupational indoor environments are available,
however, they are not 1 ikely to be accompanied by relevant or useful health
data.
Nonetheless, this monitoring information could still be used to
identify potentially significant sources of exposure and, possibly, sources of
potential health risk.
The presence of toxic substances in residential environments may be of
particular concern with respect to infants and small children.
Skin
absorption of substances may be high in infants, especially premature infants,
relative to other human populations (Dugard, 1987).
In addition to
pharmacological concerns, there are also behavioral factors associated with
infants, whose oral exploration of their environment may include a wide
variety of substances not normally regarded as food (WHO, 1986).
8.1.4

Levels in the Ambient Environment.

Exposure to toxic substances in the ambient environment may come from the
air, water, or soil. A single emissions source may have impacts on more than
one environmental mediume For example, air emissions of persistent compounds
may be deposited on land, where they can accumulate in the soil and, possibly,
throughout the food chain. Conversely, chemicals adsorbed onto soil particles
may create an air pollution concern through particle re-entrainment.
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Environmental sampling may be conducted to assess impacts from particular
point sources, or to assess the general environmental quality of urban, rural,
and remote locations. Ambient air concentrations for a particular substance
depend on the meteorological conditions and the rate at which 'the substance is
released into the ambient air. Thus, several samples may be needed to assess
the peak and average air concentrations of a substance at a particular
location. Ambient water measurements are done to assess the quality of
surface or groundwater supplies. Concentrations of toxic substances in water
may vary depending on the proximity of these substances to a contamination
source, the rate at which they are released into the environment, and the
depth at which water samples are taken. Finally, surface and subsurface soil
samples may be taken. Surface samples measure levels resulting from spills,
intentional land spreading, or the deposition of airborne substances on land
or water. Measurement of soil contamination is especially important when
considering risks to young children, who may ingest or absorb through their
skin potentially harmful levels of these chemicals (WHO, 1986). Subsurface
samples are taken to measure contamination resulting from leaking underground
storage or waste sites, or the percolation of contaminants through the soil.
8.1.5

Levels in Food.

Certain substances have the potential to be· present in food. This may
result from direct or inadvertant application of pesticides, through treatment
of animals with antibiotics or hormones, or through food processing.
Quantitative exposure information on these substances come predominantly from
the U.S. Food and Drug Administration. Other data sources may include market
basket surveys from industry or state agencies.
All of these data,
unfortunately, are generally quite limited (GAO, 1986).
·
In addition to raw and processed foods, a particularly important source of
food contamination is human milk (WHO, 1986). Levels of highly persistent,
fat soluble chemicals may accumulate in breast milk to levels which are
potentially harmful to the infant. As with chemical monitoring of foods, more
data are needed to properly assess this important route exposure to
potentially harmful chemicals.
8.1.6

Levels in Biological Tissues.

Compounds which bioaccumulate in biological tissues can indicate their
presence when levels in other environmental media are too low to be
detectable. Monitoring tissue levels of these compounds can also indicate
exposures which may be missed by ambient sampling due to spatial or temporal
variations in environmental levels.
In addition to data on environmental levels, monitoring can also help to
provide direct estimates of body burden. These include the measurement of
compounds in plants and animals consumed by human beings. Data on human
tissue levels are also direct parameters of exposure. Levels of the parent
compound or its metabolite in blood, exhaled air, or urine are indicative of
current or past exposure. Levels of substances in fatty tissues may be used
to assess cumulative exposures. These measurements are particularly useful
for fat soluble compounds, such as dioxins and polychlorinated biphenyls,
especially when assessing the exposure of breast fed infants to toxic
substances.
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8.1.7

Levels of Substances Occurring in Mixtures.

The presence of chemicals in addition to the substance of concern may also
have an impact on the risk assessment. In some cases, these additional
compounds may actually be responsible for the observed or suspected health
effect. Should this occur, a health effect may be ascribed to a particular
substance simply because the presence of these other substances was not
adequately considered.
This concern was raised, for example, in the
interpretation of epidemiological studies which indicated a correlation
between skin diseases and arsenic levels in drinking water (NAS, 1977).
Similarly, if an analysis of a water supply does not indicate the presence of
priority pollutants, a potential cause may be missed if the causative agent is
a non-priority pollutant. A potential cause may also be missed if the
pollutant scan indicates the presence of compounds that may eventually prove
to be the causative agents, but which, because of their known toxicological
characteristics or concentrations, are not be considered to be associated with
the health effect of interest.
Consideration of exposure to other substances is also important to the
assessment of possible combined or interactive effects. Exposure to one
chemical may produce additive, synergistic, or antagonistic effects on the
toxicity of another chemical. Monitoring information on compounds which have
the potential to interact with the substance under investigation is therefore
an important component in assessing the public health threat presented by a
particular exposure situation.
8.2 Mbdelling Information.
For situations in which adequate emissions data are available, population
exposures may be estimated using mathematical models. When monitoring data
are available, modelling data may be used in conjunction with the actual
exposure information. Modelling data may, for example, identify probable
areas of high pollution impacts from air pollution sources, and thus be useful
in the siting of monitoring devices. For cases in which monitoring data are
not available, modelling data may provide the only quantitative estimate of
MOdelling data are thus particularly useful for estimating
exposure.
exposures resulting from anticipated emissions. They may also help in the
estimation of impacts which are not measurable by available monitoring
techniques.
\•.

Modelling data, however, are subject ~to limitations. Although they help
to overcome some of the uncertainties of spatial and temporal fluctuations
which limit the precision of contaminant impact estimates based on monitoring
data, the reliability of modelling results also depends upon a number of
assumptions. The degree of confidence placed on these assumptions depend on
the quality of the input data, the appropriateness of the model to the
assessment of the exposure situation of concern, and the extent to which the
Of particular
models have been verified in similar field situations.
importance is the ability of the models to produce reasonable exposure
estimates consistent with the assumptions of worst case risk assessment.

8-4

(88)

8.3

Assessment of Body Burden from Different Exposure Routes

Estimation of the total intake of a toxic substance is needed in order to
determine whether a critical dose or a reference risk level is reached. The
body burden criterion is thus important in the proper derivation of action
levels, and in determining whether or not an action level has been exceeded in
a particular exposure situation. Exposure from a combination of sources may
produce a health effect or significant health risk, while exposure to any
single one of these sources would not. One such circumstance would be in
derivation of acceptable drinking water levels for contaminants ingested by
human beings through inhalation or dermal exposure routes. Also, in the
assessment of the health impacts from a source of environmental contamination,
indirect as well as direct sources of exposure may need to be considered.
Lead emitted in the air exhaust of a smelter, for example, will deposit on the
ground, and thus may present a health risk for children playing in the
surrounding area. Therefore, the health risk could be underestimated if the
risk assessment evaluated only the impacts of the air emissions.
The information obtained from the monitoring and modelling subchapters may
be used to estimate the body burden from different routes of exposure and from
different environmental media. As was mentioned above, uncertainties are
associated with both of the exposure estimation approaches.
Typically,
therefore, exposure estimates are presented as a range of values.
Consideration of the uncertainty provides the upper and lower limits of this
range.
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9.

Environmental Fate and Transport.
9.1

Environmental Dispersion and Chemical Transformations.

Once a substance is released into the environment from an emission source,
it may undergo modifications which could influence -its toxicity. Dispersion
through air, water, or soil may reduce the concentrations to which human
beings are exposed, and thus, the level of health risk. The substance may
also be chemically transformed in these media to a form that is either less
toxic or more toxic than the parent compound. The extent to which these
substances persist in the environment should also be considered, as
persistence influences the potential for cumulative exposure impacts over
time.
Knowledge of a substance's environmental persistence or its
transformation products is also important in assessing the degree to which
such processes may influence population exposure.
9.2

Bioconcentration and Bioaccumulation.

In addition to processes which disperse a substance once it is released
into the environment, there are processes which result in its concentration.
Substances such as metals and lipid soluble compounds can bioconcentrate in
plant and animal tissues. Furthermore, these substances may bioaccumulate
through the food chain. Bioaccumulation enhances the health risks for human
beings, who occupy the highest level of the food chain. Consideration of
bioconcentration and bioaccumulation is especially important when assessing
long-term, low level emissions of substances into the environment; exposures
which may initially appear to have negligible environmental importance may be
of significant health concern when these concentrating mechanisms are
evaluated.
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SECTION IV. HAZARD IDENTIFICATION
Information relevant to the identification of a substance's toxicity is
evaluated in the Hazard Identification section. The manifestation of an
adverse health effect is a function of the concentration of the toxic
substance at the site of action and its duration and biological activity at
the site (Renwick, 1982; Tichy, 1983). The toxicity of a substance may vary
substantially between different species, strains, or sexes. It may also vary
within the same species, sex, or strain when the substance is administered
through different routes of exposure or at different levels of exposure.
Variability is attributable to differences in the bioavailability of a toxin,
as well as to differences in the nature of the lesions formed by the interaction of the toxin with its biological receptor. The issue of bioavailabili ty is important to risk assessment in that a toxin's concentration and
duration at the site of action is related the pharmacokinetic characteristics
in the organism involved. Biological activity is influenced by specific
genetic and environmental factors. The kinds of biological activity required
to produce and adverse health response may be simple or complex. Also, some
kinds of biological activity may only require short periods of time before a
toxic response occurs, whereas others may require longer periods of exposure.
The Hazard Identification, therefore, reviews data on the substance's
pharmacokinetics, as well as on the kinds of biological effects it produces at
various dose levels and exposure durations. In this section, criteria may
need to be followed in order to determine the potential health significance of
particular study findings.
Such criteria are especially important when
determining the statistical significance of dose-response patterns between
exposed and non-exposed study populations. The overall health significance of
these toxicological investigations is evaluated in the Hazard Assessment
section (Section V).

10.

Identification of Relevant Pharmacokinetic Parameters

Assessment of the pharmacokinetic literature is needed in order to
understand how and to what extent a substance is absorbed, distributed,
metabolized, and excreted. These processes determine the dose of a substance
(or its metabolites) at the target site. These parameters may, in turn, be
influenced by the physiological characteristics of the organism, and by the
exposure regimen. Once at the target site, factors influencing cellular
uptake of a chemical include its rate of diffusion across and between cellular
membranes, and active or facilitated transport processes.
Figure 10.1
presents a summary of the routes by which chemicals are absorbed, distributed,
and excreted in the body.
Figure 10.2 presents a specialized summary
pertaining to the pharmacokinetic pathways in pregnant women.
Factors which affect any of the pharmacokinetic parameters may also affect
a substance's toxicity. Thus, comparisons of pharmacokinetic parameters may
help to identify reasons for interspecies and intraspecies differences in the
toxic response to chemical exposure. These comparisons may also provide a
basis for assessing the impacts of different exposure doses, durations, and
routes of administration on toxicity. Such analyses are needed for the Hazard
Assessment (Section V). In the Hazard Assessment, evaluations are made of
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Figure 10.1.
in the Body.

Routes of Absorption, Distribution, and Excretion of Toxicants

Source:
Klaasen, C.D9, 1986, "Distribution, Excretion, and Abso:rpti0n of
Toxicants," in C.,D. Klaasen et al. (eds.), Casarett and Doull's Toxicology,
Third Edition, ~1.'.lc~illan Publi<:hing Company, New York. P. 33 ..
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Representation of the Relation between Phar11acokinetics and
Pharmacodynamics. Ff = free toxicant; BT = bound toxicant; T.vi = toxicant
metabolite.
Source:
IRLG, 1982, Interagency Regulatory Liaison Group Workshop on
Reproductive Toxicity Risk Assessment, Environ. Health Perspect., Vol. 66, pp.

193-221.

findings from different studies in order to determine wi1ether or not the
findings from specific studies are directly relevant to human beings at the
exposure levels and exposure routes of concern.
The toxic respcas~ to a chemical exposure may be due to the action of the
parent compound, one or more of its metabolites, or a combination of both.
The neurotoxicity associated with exposure to trichloroethylene, for example,
is caused both by exposure to trichloroethylene itself, and one of its
metabolites, trichloroethanol (WHO, 1984). Of all pharmacokinetic }/1·operties,
metabolism is considered to be the most variable within and between species
rRall, 1969).
Therefore, intraspPcies and interspecies comparisons should
carefully consider differences in metabolism.
Particularly, differences in
the rate of metabolism and in the pathways leading to different metabolites
should be analyzed.
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Integration of Phase I and Phase II Biotransformation Reactions.

Source:
Sipes, I.G., and Gandolfi, A•.J., 1986, "Biotransformation of
Toxicants," in C.D. Klaasen et al. (eds.), Casarett and Doull's ~oxicology,
Third Edition, Mac\1illan Publishing Company, New York. p:-64--:--- ··

The nature and degree of metabolism depends on the concentration of the
substance at the site of metabolism, the biochemical characteristics of the
metabolizing tissue, and the presence of potentially modifying factors. The
liver is the principal metabolizing organ, although metabolism also occurs at
other sites, such as the lung, kidney, skin, and gastrointestinal mucosa
(Sipes and Gandolfi, 1986). The metabolic rates and capa·cities may not be as
high in these extrahepatic tissues.
Their contribution to the total
pharmacokinetic profile, however, may be significant for low level chemical
exposures over long periods of time (Sipes and Gandolfi, 1986).
Metabolism is especially important with regard to lipophilic chemicals,
which are easily absorbed but poorly excreted from the body. The primary
purpose of metabolism, therefore, is to make these compounds more water
soluble and available for excretion. The two general types of metabolic (or
biotransformation) rea.ctio:1s c.re presented in Figure 10.3. The first type, or
Phase I reactions, involve oxidation, reduction, or hydrolysis. In addition
to making these compounds more water soluble, Phase I reactions add or expose
functional groups which prepare the chemical for Phase II reactons (Sipes and
Gandolfi, 1986). The chemical is conjugated with endogenous molecules in the
Phase II reactions, which further increases its water solubility.
Whether or not a metabolite is toxic depends on the chemical and
structural properties of the parent compound, as well as on the biochemical
reactions it undergoes.
In addition, other chemicals may modify the
metabolism of the chemical under study. Several pathways may exist, each of
which may be described by parameters concerning its enzymatic affinity and
capacity. A chemical may also possess the potential for enzyme induction or
inhibition. Thus, a chemical may modify its own metabolism over time through
its effects on metabolizing enzymes.
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11.

Identification of Relevant Toxicity

Endpoin~s.

All known or suspected adverse health effects resulting from exposure to
the substance undergoing investigation should be identified.
This process
includes the identification of frank, clinical health effects (for example,
asthma), as well as subtler indications of toxicity (for example, small
changes in pulmonary function measurements). For risk assessment purposes, it
is important that the most sensitive effects of exposure are identified.
Identification of other, less sensitive responses should also de done. This
further effort provides the Hazard Assessment section (Section V) lvith the
basis to evaluate the constellation of health effects associated with
exposure, and the progression of effects which may occur as the exposure dose
increases.
In the health effects identification, therefore, the toxicological and
epidemiological literature on a particular substance is reviewed.
This
chapter is divided into three parts:
Identification of Critical Health
Effects (genetic toxicity, carcinogenicity, reproductive and developmental
toxicity, acute/chronic toxicity);
Identification of Multiple Chemical
Exposure Effects; and Identification of Sensitive Populations. The types of
effects requiring the extensive analysis in most risk assessments have been
genetic
toxicity,
carcinogenicity,
and reproductive and developmental
toxicity. Because these effects are of national public health significance,
and have been recognized as representing particular concern with regard to
toxic substance exposure, they have been segregated from the general
acute/chronic toxicity category.
The classification system for assessing the different types of health
effects follows the one developed by the National Institute for Occupational
Safety and Health (NIOSH) to organize health effects information in its
Registry of Toxic Effects of Chemical Substances (NIOSH, 1986).
It also
conforms f() the paradigm deveioped by the Maine Bureau of Health for ranking
hazardous air pollutants (Anderson, 1986).
These four health effects
categories may be further divided into subcategories when appropriate. For
example, as studies more fully document the low level exposure effects
regarding other health endpoints, such as immunotoxici ty and neurotoxicity,
this chapter should be modified accordingly.
The occurrence of a specific health effect in a study population depends .
largely on the exposure dose and the exposure period. The exposure conditions
are thus important considerations in evaluating all health effects studies.
Consequently, evaluation of these studies should be segregated on the basis of
the exposure periods. The types of responses observed during these exposures
can be classified according to whether they are reversible or irreversible,
and as to whether they are immediate, delayed, or latent. A summary of this
classification system is presented in Table 11.1.
For typical animal
bioassays, exposure periods follow this general classification system: acute
effects (one day or less), subacute effects (one month or less), subchronic
effects (one to three months), and c.ltronic effects (more than three months)
(Klaasen, 1986). These categories are generally applicable to the evaluation
of human responses as well. Differences may occur., however, especially in the
assessment of chronic exposure effects.
Thus, when defining the exposure
periods for a particular substance, the assessment should consider the
underlying health database.
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Table 11.1
Health Effects Categories

I.

ACUTE EFFECTS
A.

B.

II.

I I I.

Reversible
1. I!Til'1ediate
2. Delayed

SUBCHRO~IC

A.

Reversible

B.

Irreversible
1. Immediate
2. Latent

Irreversible
1. Immediate
2. Latent

IV.

SUBACLITE EFFECTS

EFFECTS

CHRONIC EFFECTS

A.

Reversible

A.

Re\·ersible

B.

Irreversible
1. Immediate
2. Latent

B.

Irreversible
1. Irn:rwjiate
2. Latent

The inclusion of the subchapters on interactive effects and sensitive
populations underscore the fact that most health effects may have several
potential causes. Most of the risk assessment is devoted to the investigation
of health effects with a focus on the toxicity of particular substance. The
purpose of these two subchapters, on the other hand, is to evaluate a
substance's toxicity within the context of actual or potential human exposure.

11.1
11.1.1

Identification of Critical Health Effects.
Identification of Effects on Genetic Material.

Genetic toxicity concerns the interaction of chemical and physicRl a~ents
with the pL'ocess of c~llular heredity (Thilly &~d Call, 1986). Genes, .!hich
comprise the basic units of heredity, are comprised of varying lengths of
dt:oAyribonucleic acid (DNA) and associated proteins. Genes are organized on
chromosomes.
The human somatic cell normally contains 23 pairs of
chromosomes. The total length of DNA in all of the chromosomes is more than 5
billion nucleotides (NRC, 1983b). Only a small part of the DNA (about 1
percent) is required for known gene functions (NRC, 1983b). The function of
most of the remaining DNA is unknown (NRC, 1983b).
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The ability of an agent to interact with genetic material may lead to
chronic irreversible effects such as cancer or effects on reproduction or
development. There is a close correlation between genetic toxicity and the
development of cancer in human beings and laboratory animals (!ARC, 1980;
OSTP, 1985). Genetic toxicity may also play a role in the development of
other chronic diseases such as atherosclerosis (NRC, 1983b).
Three general types of genetic toxicity can be defined (NRC, 1983a; Thilly
and Call, 1986). Gene mutation (point mutation) affects a single gene by
producing small changes In the DNA sequence.
A chromosomal mutation
(clastogenesis) affects blocks of genes in one or more chromosomes. A genomic
mutation (aneuploidy or polyploidy) affects the number of chromosomes without
altering the chromosome structure itself. All three major types of genetic
toxicity elicit DNA repair mechanisms (McQueen and Williams, 1985). These
mechanisms are described in Table 11.2.
These types of genetic toxicity may occur through a variety of different
mechanisms.
Chemicals may damage DNA by covalent binding, intercalation,
chromosomal protein binding, or by causing alterations in the synthesis and
structure of DNA precursors (Bradley et al., 1985). Other types of events may
occur by errors in DNA synthesis or repair (Bradley et al., 1985; OSTP, 1985),
by w1.emically-induced alterations in the regulation of gene expression
(Bradley et al., 1985; OSTP, 1985), or by stimulation via cytotoxic mechanisms
of chemicals which are capable of damaging DNA (such as free radicals)
(Halliwell, 1987).
Although an agent may effectively cause one kind of genetic damage, it
will not necessarily cause all kinds (Thilly and Call, 1986; NRC, 1983b).
This finding is understandable in light of the fact that these different types
of mutations may be created by very different mechanisms. Genomic mutations,
for example, are typically caused by a chemical interaction with spindle
fibers, whereas gene and ·chromosomal mutations require chemical interactions
with DNA (NRC, 1983b). Moreover, agents, such as radiation, can be very
effective at breaking chromosomes and causing chromosomal mutations, but are
less effective at producing changes in individual nucleotides (NRC, 1983b).
Other chemicals may react with DNA bases to produce gene mutations, but are
less effective at breaking chromosomes (NRC, 1983b).
Several tests for genetic toxicity have been developed to detect various
types of genetic damage.
A summary of these tests is presented in Table
11.3. In many cases, a substance may require metabolic activation to become
biologically active.
Therefore,
certain metabolizing enzymes may be
incorporated into in vitro genetic toxicity tests to address this possibility
(WHO, 1985).
Criterra-1tor evaluating genetic toxicity studies have been
developed by several academic and science policy organizations (NRC, 1983b;
!ARC, 1980; WHO, 1985; Jackson and Per tel, 1986). These criteria do not
differ substantially from each other, except in the level of attention they
devote to the specific genetic toxicity endpoints.
Appropriate criteria
should be followed, therefore, when the findings of these tests are to be
evaluated in the risk assessment.
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Table 11.2
:r.ta!llmalian DNA Repair Mechanisms

A.:ticr:
Rerr.:;ves t>:..:lky, ncncc,dir.g !esk...,~ fro!"'". the D~A in :1 ma:-;ner similar
but not identical \\-ith bacterial nucleotide excision repair

~o

Base excision repair

Permits reinsertion of the proper ba:5e into the gap left in the D:-JA by
' the action of enzymes that effect the excision of inappropriate bases
from D~A as the free base (DNA glycosylases), avoiding scission of the
DNA backbone, as well as a system similar to the bacterial one
requiring strand scission. Included are direct demethylation by transfer
of a methyl group to an acceptor protein and AP site repair (direct
repair of a removed base)

Strand break repair

Rejoins single- and double-strand breaks ~ith the addition of few or no
additional nucleotides through the action of a sealing enzyme

Photoreactivation

Light-activated mechanism specific for the breakage of the t.:V-induced
covalent bond attaching two pyrimidines in a cyclobutane-type ring

Recombination repair
(post-replication repair)

System once believed to occur in mammalian systems but now
controversial, by which bulky, noncoding lesions are transferred to
DNA synthesized after damage

Replicatior. bypass
(post-replication repair)

Process that may function in mammalian cell~ as an alternative to
recombination repair in which the bulky lesions are bypassed and the
gap created filled

Inducible DSA
repair systems

Still speculative (for mammalian systems) rt-pair system in which D~A
damage triggers the induction .of enzyme systems to remove the damage

Source:
OSTP (Office of Science and Technology Policy), 1985, "Chemical
Carcinogens; A Review of the Science and Its Associated Principles, February,
1985," Federal Register, Vol. 50, pp. 10371-10442.

Most genetic toxicity tests are unable to measure DNA damage directly.
Rather, they measure damage indirectly through observations of phenotypic
changes. Close surrogates, however, to the direct measurement of DNA damage
ar~ tests which measure DNA repair.
Because it is a measure of DNA repair,
unscheduled DNA synthesis (UDS) is among those tests with the broadest
sensi ti vi ty for detecting genotoxic chemicals (McQueen and Williams, 1985;
lARC, 1980). UDS is a step in the excision repair process that is elicited by
all major types of DNA damage (McQueen and Williams, 1985). Several other
methods have also been identified for measuring excision repair (See Table
11.4), although UDS is regarded as the simplest and most generally applicable
method for screening (IARC, 1980).
EJucid&ti·)n of genetic toxicity results may be achieved through studies
designed to assess the binding or biochemical interactions of chemicals with
cellular macromolecules s
Many carcinogens, for example, are electrophiles
capable of interacting covalently with DNA (Miller et al., 1966; Miller and
Miller, 1971). Every nucleoside has the potential for interacting covalently
with chemicals (Singer, 1975).
The interpretation of covalent binding
studies, however, is subject to considerable uncertainties.
The site of
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Table 11.3
Sumnkl.ry of C'1mmonly Used Genetic Toxicity Tests

1_.

2.
J•

4.

5.

Bacteric.l Mutation Assays (f:3. 1_mcne11a typhimurium, E::cherichia coli)
Yeast Cultures (Saccharomyces cerev1_sis1ae, Sa1lzos2ccharomyces---poirbe)
Higher Plants
Mammalian Cells
Unscheduled DNA Synthesis (Human fibroblasts, HeLa Cells, Rat Liver
Cells)
_
Cytogenetics and Sister Chromatid Exchanges (Chinese Hamster Ovary,
Human Peripheral Lymphocytes)
Cell ~utation Assays (V79, Chinese Hamster Ovary, L4178Y Mouse
Lymphoma)
Whole Animals
Sex-Linked Recessive Lethal Assay (Drosophila)
Cytogenetics: Bone Marrow Metaphase Analysis and Micronucleus Test
Dominant Lethal Assay

Source: Adapted from World Health Organi:ation, 1985, Guide to Short-Term
Tests for Detecting Mutagenic and Carcinogenic Chemica:rs;- Env1ronmental
Health Cr1ter1a sr:-worra-Health Organization, Geneva, pp. 24-125.

Table 11.4
Methods for Studying· DNA Excision Repair in Cultured Cells

Incision in region of D~A damage
Excision of damaged region

Resynthesis of excised region

Rejr,ining of strand

Alkaline sucrose gradients
Alkaline elution
Loss of damaged bases
Mass spectral analysis
Radioimmunoassay
Loss or enzyme-se11sitive sites
3H-thymidine incorporation
autoradiography, liquid scintillation
counting
lsopycnic gradients
Bromouracil ph0•olysis
BND-cellulose chromatography
Alkaline sucrose gradients
Alkaline elution

Source: McQueen, C.A., and Williams, G.M., 1985, '~ammalian Cell DNA Repair
Assays fof Carcinogens," in Flamm, W.G., and Lorentzen, R.J., (eds.),
Mechanisms and Toxicity of Chemical Carcinogens and ~futagens, Princeton
Scientific Publishing Co., Princeton, New Jersey, pp. 129-151.
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alkylation is a major determinant of a chemical's biological effect. Alkylation of the 06 postion of guanine, for instance, appears to be much better
correlated with mutagenic and carcinogenic potential than alkylation of the N7
positions (Bradley et al., 1985). In addition, the quantitative binding of
several· polynuclear aromatic hydrocarbons does not show a good correlation
between exposure to these compounds and species variability in susceptibility
to carcinogenesis (Phillips et al., 1978; Kuroki and Heidelberger, 1971).
Findings such as those described above strongly indicate that it is the
nature of the bio- logical interaction, rather than the overall extent to
which genetic lesions are formed,
that is toxicologically important.
Furthermore,
tissues may vary widely in their abilities to repair
chemically-induced lesions and this varia- bility may also influence the
overall tissue susceptibility to permanent genetic lesions (Bradley et al.,
1985).
Moreover, differences in binding and repair also exist between
mammalian and non-mammalian species, as well as among different mammalian
species (OSTP, 1985; Calabrese, 1983). These considerations should be taken
into account when evaluating the results of genetic toxicity studies.
The limitations associated with individual genetic toxicity tests can be
partially overcome through the use of a battery of tests. This approach has
been called into question recently with regard to carcinogenicity screening
(Tennant et al, 1987).
It does, nonetheless, help to characterize the
chemical's response spectrum by assessing a variety of genetic toxicity
endpoints (USEPA, 1987). Given the potential seriousness of a genetic effect,
any positive finding from a well conducted test should be considered significant, particularly if pharmacokinetic data are unable to demonstrate that
the chemical or its active metabolite are excluded from the site· of
interaction with the DNA, or if the type of interaction is considered not to
occur in human cells.
Vfuile genetic toxicity is correlated with certain chronic effects,
information is currently lacking from which to predict human health risk
solely on the basis of a chemical's action on genetic material. Conversely,
an understanding of the mechanisms for most chronic diseases is not well
enough developed to discount a laboratory or epidemiological finding in the
face of negative genetic toxicity findings. The best current uses of genetic
toxicity data,
therefore,
are
to support
the findings
from other
investigations, to help elucidate mechanisms of action, and to provide
indications of potential concern in the absence of an adequate data base for
health effects under investigation.
-- In the future, assessment of the toxicological impact from exposure to
chemical mutagens may be enhanced by tests designed to measure in vivo genetic
damage in human beings. These tests would be based on the premiSe-mat chemical mutagens produce characteristic patterns of mutations in human blood cells
(Thilly and Call, 1986). This information could provide a crucial component
to epidemiological studies designed to explore the relationships between
chemical exposure, genetic toxicity, and irreversible diseases (Thi lly and
Call, 1986).
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11.1.2

Identification of Carcinogenic Effects.

Cancer is a complex of diseases characterized by uncontrolled tissue
growth (Flamm and Lorentzen, 1985; Berkow, 1982). It is the second leading
cause of death in the country, next to heart disease. About one in five
Americans die from cancer ( OTA, 1981). As Table 11.5 shows, cancers of the
lung, large bowel, and breast account for nearly half of all the cancer deaths
in this country.
There are considerable variations in the patterns of cancer incidence
among human populations (Doll and Peto, 1981; Higginson, 1980; Page and Asire,
1985). It has been estimated, largely on the basis of these variations, that
60 to 90 percent of the cancers are caused by factors in our living or working
environments, and are thus theoretically preventable (Doll and Peto, 1981;
Tomatis et al., 1982). These factors include man-made or natural chemical
carcinogens, physical agents, radiation, viruses, nutritional deficiencies or
excesses, age at reproduction, and a variety of other personal or cultural
behavior patterns (OSTP, 1985; Doll and Peto, 1981; Higginson, 1980). The
main causative factors have been identified for about half of the
environmentally influenced cancers among men in North America and Europe,
although the percentage is much lower for women (Higginson, 1981). -A summary
of the factors associated with the major cancers thus far is presented in
Table 11.6. Despite its currently limited data base, this table demonstrates
that various combinations of endogenous and environmental factors may
contribute to the cancer risks.
Available information indicates that mortality rates for most cancers have
remained stable throughout this century (Higginson, 1981; Young and Pollack,
1982). For the white population, however, there have been sharp decreases in
the incidence of stomach and uterine cervix cancer, and increases in lung,
breast, uterine corpus, and prostatic cancer (Young and Pollack, 1982). Also,
there are also indications that incidence rates for bladder and kidney cancers
are also increasing in males (Young and Pollack, 1982).
Except for the
influence of tobacco smoking on lung cancer, the reasons for these trends are
not entirely clear (Young and Pollack, 1982). The apparent increases may be
real. They may also be influenced by increased awareness and more efficient
reporting methods (Young and Pollack, 1982). Conclusions regarding these
increases, however, will have to wait until a more thorough analysis of cancer
incidence trends can be conducted. In the meantime,' the possibility that
exposure to chemical carcinogens is responsible for increasing cancer rates
cannot be discounted.
A brief description of the carcinogenic process is outlined in Figure
11.1. The diversity of causative agents and the various possible mechanisms
by which cancers may be induced has prevented the establishment of any unified
theory of carcinogenesis (Flamm and Lorentzen, 1985).
It is generally
thought, however, that multiple, independent cellular changes must accumulate
before neoplastic transformation is expressed (Crawford, 1985; Higginson,
1981). This theory is supported by the fact that the induction of cancer in
human beings and laboratory animals proceeds through a series of
histologically distinct stages (Crawford, 1985; Williams and Weisburger,
1986). Each of these stages is subject to and controlled by a number of
modifying factors (Williams and We is burger, 1986), some or many of which may
be at least partly reversible (Higginson, 1981). In addition, latency periods
of at least 30 cell divisions between exposure to chemical carcinogens and the
development of cancer have been observed in vitro (Berkow, 1982). These
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Table 11.5
Numbers of Dezths Certifi0d as
United
Type of tumor

Cancer of the
Lung"
Large bowel (colon and
rectum)
Breast
Prostate
Pancreas
Stomach
29 other types or categories. b
each cont·ributing less
than 3'~ of deaths
Othu or unspecified tumors'
Total al! tumors

B~ing Due to
S~ates, 1978.

No. of

death~

Various Types of Tumor:

P~r~ent of
all deaths
frorr. tumor~

95.086
53.269

24}

34,609
21.674
20.777
14.452
128.705

9

13

j}

33.383
401.955

46

46

8
100

Source: Doll, R., and Peto, R., 1981, The Causes of Cancer:
Quantitative
Estimates of Avoidable Risks of Cancer 1n the Uni teo States Today, Oxford
Un1 vers1 ty Press, New Yoil(,J). IT97 ~
(2)

(1)
FARLY SI'AGE

INITIATION

(3)
L&..TE STAGE

SI'IMULI KlDIFYING
CARCINCCENESl 5
(intrinsic or extrinsic)
COWLEfE
OR

IRREVFRSIBLE

MODUL!,TING FACTORS

MIT AGENESIS
DNA REPAIR
EPI GE'lETI C

DIGESI'ION
ABSORPTION
~CTIVATION/INAC

TIVATION
It-.'DUCTION
SPECIFIC RECEPTORS

SPECifiC RECEPTORS
ETC.

~lYME

INCOWLEfE

_____ ....,... OR
REVERSIBLE

PROGRESSION

GRO~TH
PROOTIO~
I~IBITION

ENHA.NCEME!'-.'T
DIFFERE\'TIATION
SfATIJS
IH-1VNITY

NUTRITIO~

ETC.

EIC.

Figure 11.1 ..
A Simplified Diagram Showing the Hypothetical Stages ill
Carcinogenesis and Some of the Exogenous and Endogenous Factors Possibly
In\'Ol v&d.
Source: Higginson, J. 1981, "Rethinking the Environmental Causation of Human
Cancer," Food Cosmet .. Toxicol, Vol .. 19, p. 544.
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Table 11.6
Identified Risk Factors for the Major Cancers

Risk Factors

Cancer Site
Bi 1iary Tract

Gallstones, hormonal -changes in woaen

Brain and Other Servous
System Cancers

Industrial exposure to chemicals, farming, (exposure to
chemicals or viruses), ranching, x-rays, head trauma,
barbituates (pregnant women and children), family history

Breast

Hormonal chan!leS in w0111en, family history, previous breast
disease, radiation, high socioeconomic status, obesity,
high fat diet

Childhood cancers
(leul..emias, lymphomas,
CNS, bone)

Genetic disorders, congenital anomalies, radiation, exposure
to viruses (Burk.i tts l)'lllphoma}?

Colon/Rectum

Family history, history of
urbanization, high fat diet

Esophagus

Tohacco and alcohol, lo.., socioeconomic status,
nutrition, inflannatory diseases of the esophagus

lbjgl..ins Disease

Exposure to \' i ruses"

Leul..emia

<*netic an0111alies, exposure to
chemicals, exposure to viruses?

Liver

Hepatitis 13 infection, hor~~~ones,
radiation or industrial chemicals

inflarrvnatory

radiation

bowel

or

cirrhosis,

Tobacco, radiation, exposure to asbestos
industrial cht-micals, Vitamin A deficiency

poor

industrial
exposure
and

to

other

Family history, hormonal factors

Melanoma
~1

disease,

tiple Myeloma

Immune HStt'fll disorders, family
radiation.or industrial chemicals

history,

exposure

to

Non-Hodgkins Lymphoma

Immune system disorders, exposure to viruses, expesure to
pesticides

Oral Cavity and Pharynx

Tobacco, exposure to industrial chemicals
Hormona 1 chan~es, previous
exposure to asbestos

breast

or

ovarian

cancers,

Pancreas

Tohacco, diabett>s?, coffee?

Prostate

High fat diet, exposure to industrial chemicals

Skin Cancer
(Non 11e lanooa)

Radiation, fair skin, faaily history, other diseases
(tropical ulcers, burns, scars, chronic infectious, wounds)

Stomach

Diet, diseases that affect the st011ach lining (pernicious
anem1a, atrophic gastritis), family history, radiation,
Tobacco, low socioecon011ic status

Testis

Congenital anomalies, hoi"'IInal drugs

Urinary Tract

Tobacco, exposure to industrial chemicals, obesity

UtHine Cervix

JotJl t iJ:'l e sex partners, ag'" at first intercourse, venereal
disease!

ll~orin<-

S.ll'!l' as

Cuf1-u~

fc.~ brt".:~st

r.ancer

(F.nd~tri~)

Source:

Adapted from H.S. Page and A.J. Asire, 1985, Cancer Rates and Risks,
Third Edition, U.S. Dept. of Health and Human Services, Washington,
D.C., pp. 73-125.
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findings are consistent with the observations that most cancer risks increase
exponentially with age (Doll and Peto, 1981). Thus, the observation that most
cancers may not appear until late in life or after long latency periods should
be considered when evaluating the findings of toxicological or epidemiological
studies.
The latency period associated with exposure to chemical carcinogens
implies that some sort of mutational event occurs at an early stage of tumor
development (Flamm and Lorentzen, 1985). This event, commonly referred to as
initiation, has been weLL correlated with many known or suspected chemical
carcinogens (OTA, 1981). It has also been confirmed by experiments which
demonstrated a monoclonal origin of tumors (Yuspa and Harris, 1982).
Despite the identification of various stages and risk factors associated
with carcinogenesis, many areas of uncertainty still exist as to how chemicals
influence tumor development.
Given the lack of knowledge regarding the
underlying mechanisms of carcinogenesis (OSTP, 1985), a carcinogen or
carcinogenic risk factor is identified by its association with a significantly
adverse
tumor
response
in either
epidemiological
or
toxicological
investigations.
These associations are determined through the use of
statistical tests which compare tumor incidences between treated and control
groups, and by supporting evidence from cell culture studies.
Criteria and guidelines have been developed for deterimining the adequacy
of cancer epidemiology studies (USEPA, 1986a; OSTP, 1985). Factors affecting
the sensitivity of epidemiological studies include the proper selection and
characterization of the exposed and control populations, the exposure duration
and quality of follow-up, the proper identification and characterization of
confounding factors and biases, the appropriate consideration of the latency
period, the valid identification of the causes of morbidity and mortality, and
the ability to detect specific tumor types (USEPA, 1986a). Statistical tests
used to evaluate the significance of the exposure compare .the incidence of the
carcinogenic endpoint between case and control populations (for example, the
odds ratio), or the relative risk of the disease between exposed and
non-exposed populations (OSTP, 1985). Problems associated with the proper
identification and characterization of the exposed populations, together with
cost and time restraints, generally limit the sensitivity of most
epidemiological studies. Thus, it is useful for these studies to include
calculations of their statistical power to detect a positive response (USEPA,
1986a) and, if the results are negative, the upper confidence limits.
Various guidelines have been developed for evaluating the adequacy of
cancer bioassays (USEPA, 1986a; OSHA, 1980; IRLG, 1979; OSTP, 1985; IARC,
1980; NTP, 1984; CHDS, 1985). These guidelines have been designed to ensure
that the assays are well conducted, and that they have adequate sensitivity
for detecting carcinogenic chemicals. Risk assessment policy issues relevant
to bioassay sensitivity are described below.
Issues relevant to the
specificity of the bioassays, or their abilities to correctly identify
non-carcinogens, are discussed in Chapter 15.5.2.
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Considering the inherent limitations of epidemiological studies, many more
animal carcinogens have been identified than human carcinogens. All known
human carcinogens have been carcinogenic in laboratory animals (NRC, 1986).
Furthermore, because animals are the closest toxicological models to human
beings, results from animal bioassays are generally considered to be
qualitative predictors of the human response (NRC, 1986, IARC, 1982; OSTP,
1985; OTA, 1981). Although they provide less evidence than chronic animal
bioassays, in vitro cell transformation assays are also reliable qualitative
indicators O:rc~ogenicity (IARC, 1980).
The available data have not identified any single animal species as being
the most predictive model for the identification of human carcinogens (IARC,
1980).
Ideally, the most appropriate animal model for predicting human
carcinogenicity is one with no incidence of spontaneous tumors and a high and
specific susceptibility to all human carcinogens (IARC, 1980).
Because no
animal species is known, it is generally recommended that the chemical be
tested in at least two animal species (IARC, 1980; NTP, 1984). Most cancer
bioassays have been conducted on rodents, particularly on rats, mice, and
hamsters (IARC, 1980; OSTP, 1985; CDHS, 1985; IRLG, 1979). These animals have
been chosen primarily for practical reasons: relatively short life span (but
long enough to allow for the development of tumors), small size, and availability (CDHS, 1985; IARC, 1980; OSTP, 1985). Primates and dogs are not recommended for routine testing because their metabolic characteristics are generally no more closer to human beings than are those of rodents ( IARC, 1980).
Sex differences in responses to carcinogens have been found, however. Thus,
it has been recommended that bioassays routine test both sexes (IARC, 1980).
Positive results from any well designed and conducted animal bioassay,
therefore, may be sufficient to identify a substance as being capable of
producing cancer in human beings (CDHS, 1985; USEPA, 1986a). Also, more than
half of the known human carcinogens that have been adequately tested in
animals produced tumors in one or more animal species at organ sites different
from those produced in exposed human beings (OSHA, 1980).
Thus, the
specification of susceptible human tissues on the basis of bioassays of animal
carcinogens is subject to significant limitations.
Most carcinogen testing has been done on inbred or hybrid animal strains.
The advantages of using inbred strains is that there are generally abundant
data on the tumor rates at specific organ sites in the untreated animals, and
that their biological response is generally more pre.cise and stable than those
of out bred strains (OSTP, 1985). Out bred strains, on the other hand, are
hardier, less expensive to maintain, less prone to genetic drift, and perhaps
may more accurately reflect the human response than inbred strains (OSTP,
1985). The selection of any of these different types of strains may affect
the sensitivity of the assay. It is possible for example, that a particular
inbred strain may be especially resistant to the carcinogenic effects of the
chemical (IARC, 1980). On the other hand, the variabilities in the responses
of the out bred strains may be large enough to mask a positive response in a
sensitive animal population (IARC, 1980).
These issues have not been
adequately resolved, although most testing continues to be done on inbred or
hybrid strains. The National Toxiciology Program, for example, uses the male
and female inbred Fischer 344 rat and the hybrid in B6C3Fl mouse in its
bioassays (NTP, 1984). Its protocol is designed to reduce the likelihood that
a carcinogen will not be identified as a result of sex and strain differences.
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Concurrent control groups should be included in bioassays ( IARC, 1980;
USEPA, 1986a; OSTP, 1985). Use of concurrent controls reduces the potentially
variability caused by different experimental conditions, fluctuations in
spontaneous tumor rates, and different histopathological analyses.
It has
been argued that if historical rates are higher than the concurrent control
rates, less \veight may be given to positive results (NIP, 1984; USEPA, 1986a;
Gart et al., 1979). On the other hand, it is possible that experimental
conditions which depressed tumor incidence in the concurrent controls would
have, in the absence of treatment effects, depressed incidence in the treated
groups as well (Bickis and Krewski, 1985).
Furthermore, historical tumor
rates are of little value if they are unstable (Bickis and Krewski, 1985), as
the variabilities in the responses are best addressed through the use of
concurrent controls. Therefore, historical data should not be used to negate
the significance of a positive bioassay finding unless it can be demonstrated
that the concurrent controls are not suitable for analysis.
An important statistical consideration in the evaluation of bioassays is
the number of animals tested. On the one hand, because these animals are
serving as surrogates for approcimately 250 million people in the United
States, and possible many more worldwide, and because even modest increases
(for example, 0.01 - 1 percent) in cancer risks may be unacceptably high from
a social welfare standpoint, large numbers of animals are needed to detect
these small but significant elevations in cancer incidence. On the other
hand, cost and resource concerns often limit the number of animals that can be
tested (IARC, 1980; IRLG, 1979). To balance these concerns, it has been
recommended that each dose and control group should contain at least fifty
animals of each sex ( OSTP, 1985; IARC, 1980; NTP, 1984). This initial number
should be increased if interim sacrifices are planned (IARC, 1980; OSTP,
1985).
With this design, the minimum detectability of the assay has been
estimated to be about 10 to 15 percent (OSHA, 1980; CDHS, 1985). This is
still a relatively high detection limit; however, moderate increases in sample
sizes do not significantly increase the the sensitivity· of the assay (OSTP,
1985; IARC, 1980).

The sensi ti vi ty of the bioassay also varies with the "spontaneous" (or
background) incidence of tumors at specific tissue sites. Sites with very low
spontaneous incidence rates (one percent or less) are more likely to yield
false negative results than sites with higher spontaneous rates (OSTP, 1985;
Fears et al., 1977; Gart et al., 1979). Five-fold, or even ten-fold increases
in the tumor rate in such sites among the treated groups relative to the controls could probably go undetected under generally accepted bioassay protocols
(See Table 11.7). Similar comparisons are shown in Table 11.8. For example,
the false negative rate for a simple carcinogenicity screen is 87 percent when
a 5 percent spontaneous tumor rate is doubled to 10 percent in the treated
group.
The false negative rate drops to 36 percent, however, when a 20
percent spontaneous tumor rate is doubled in the treated group.
The
relatively high false negative rate for sites with low spontaneous tumor rates
may be counterbalanced to some degree by using historical control data. If
historical control tumor rates are stable and similar to the · concurrent
control rates, historical control data may be used to strengthen marginally
significant results at these sites (USEPA, 1986a; Gart et al., 1979; Bickis
and Krewski, 1985).
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Table 11.7
False Negative Error Rates for 5- and 10-Fold Increases in
Spontaneous Tumor Rates for the Simple 1-Dose and 2-Dose Screens
(SO Animals in the Control Group and Each of the Treated Groups)

SE£ntaneous Rates

s-f0ld increases

10-fo1d increases

P(FN: 1 dose)*
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.10

0.9335
0.6832
0.4357
0.2585
0.1471
0.0791
0.0393
0. 0179
0.0073
0.0025

0. 5761
0.1186
0.0157
0.0014
o. 0001
0.0000
0.0000
0.0000
0.0000
0.0000

P(FN: 2 doses)**
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.10

0.9935
0.8597
0.6252
0.4023
o. 2431
0.1377
o. 0711
0.0333
0.0140
0.0050

0. 7870
0.2073
0.0297
0.0028
0.0001
0.0000
0.0000
0.0000
0.0000
0.0000

* Probability of a fa1 se negative result with one treated group and one
control. A chemical is classified as a carcinogen if it is positive at some
tissue site of a 1-dose experiment with the specified sex and species.
**Probability of a false negative result with two treated groups and one
control. A chemical is classified as a carcinogen if it is positive at some
tissue site for both the high and low doses of a 2-dose experiment with the
specified sex and species.

Source: Fears, T.R., et al., 1977, "False Positive and False Negative Rates
for Carcinogenicity Screens," Cancer Res., Vol. 37, pp. 1941-1945.
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T&ble 11.8
False Negative Rates for a Simple Carcinogenicity Screena

Excess over
Spoma11eous R3t~ (\)b

Spontaneous Rate (\)

5
10
15

0

1

5

20

90

1

1

87
61
34
15
5

90

2

88
49
18
5

43
11

20
25

77

58
36

19

a. Based on Fisher's exact test with 50 animals in each of a control and test
group and assuming that all animals respond independently.
b. Difference between the response rates in the test and control groups
respectively.

·------------·--------·----------·-·---Source: Bickis, M., and Krewski, D., 1985, "Statistj::::al Design and Analysis
of the Long-Term Carcinogenicity Bioassay," in D.B. Clayson et al. (eds.),
Toxicological Risk Assessment, Vol. 1, Biological and Statistical Criteria,
CRC Press, Boca Raton, FL, pp. lzs=f47~

Particular tumors appear with a very high spontaneous incidence in certain
strains of rodentso Examples of these include lung adenomas in Strain A mice,
lymphomas in strain AKR mice, liver cell tumors in C3H/HeN male mice, mammary
tumors in C3H female mice, and testicular tumors in Fischer 344 male rats
(IRLG, 1979; IARC, 1980).
These sites are of limited usefulness for
identifying increased incidences of tumors in treated animals because nearly
all of the untreated controls may develop these tumors before they die. The
high occurrence of spontaneous tumors at these sites also limits the
&ppl icabil i ty of total tumor btaring animals as a parameter for identifying
carcinogens in chronic bioassays (IARC, 1980).
This limitation may be
addressed, in part, by studying the time-to-tumor response and the
multiplicity of tumors at each site
(IRLG, 1979).
Time- to-tum0r
ronsiderations may also be especially important when observing the proportion
of tumor bearing animals during the earlier periods of the bioassays, before
spontaneous tumors usually develop (IARC, 1980).
Because of the limited statistical sensitivity of animal bioassays, it is
necessary that they be conducted at doses and under experimental conditions
likely to yield the maximum tumor incidence (OSHA, 1980; NTP, 1984; CDHS,
1985; IRLG. 1979).
Dosing of animals should begin soon after weaning and
continue for a major portion of the animals' lifespans: 18 months for mice and
hamsters and 2 years for rats (OSTP, 1985). Because of the potentially long
latency periods associated with tumor development, negative results decrease
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in v~1ue as the exposure and observation periods are shortened, and become
practically meaningless if these periods are shorter than half the lifespans
c£ the animals (IP~G, 1979). Little attention has been given to variations in
the dosing sc.ht-:dules (for examp:e, continuous versus intermit tent exposures),
although they may have potentially significant influences on the tumor
response (NTP, 1984).
The grcat"er the ratio between the test expos-i1·e and t.he huinan e:"'posure,
the gr0ater is the safety margin ·provided by a negative result (IRLG, 1979).
The doses administered to a laboratory animal strain should thus include the
highest level that can be tolerated during lifetime administration without
altering the animals' normal longevity from effects other than carcinogenicity
(IRLG, 1979).
This dose level is commonly referred to as the "maximum
tolerated dose," or MI'D.
If the highest dose level administered is not the
MfD, the sensitivity of the assay may be greatly reduced (Haseman, 1985).
Levels which exceed the MI'D may result in premature mortality or depressed
weight gain, both of which could reduce tumor response and thus weaken the
sensitivity of the assay (IARC, 1980; IRLG, 1979; NTP, 1984). The policy
implications of the bioassay findings relative to increased mortality in the
dosed groups are presented in Table 11.9.

Table 11.9
Interpretation of the Unadjusted Analysis of Tumor Incidence
In Light of the Survival Analysis

().J

Association
with Treatlllffit

Mortality:
Association
with Treatment

A

+

+

Unadjusted test may underestimate tumorigenicity of treatment.

B

+

0

Unadjusted test gives valid picture of tumorigenicity of treatment.

c

+

tc011e
Type

1\Jntor:

D

+

E

0

F

G

0

+

H

0

0

0

Interpretation of the unadjusted test of tumor incidencea

TUmors found in treated groups may reflect longer survival of treated groups:
Time-adjusted analysis is indicated.
Apparent negative findin)(S in tumors may be due to shorter survival in treated
groups. Time-adjusted analysis and/or retest at lower doses is indicated.
Unadjusted test gives a valid picture of the possible tumor-preventive capacity
ot treatment.
Unadjusted test may underestimate the possible tumor-preventive capacity
of treatment.
High mortality in treated groups ~ay lead to unadjusted test missing a possible
tumorigen. Adjusted analysis and/or retest at lower doses is indicated.
Unadjusted test gives valid picture of lack of associaticn with treatm~t.
'Longer survival in treated groups may mask tumor-preventive carocity of
treatllleflt.

a Many of these interpretations assume that the MTD was used and that a
sufficient proportion of animals survived in sufficient numbers for an
appropriate length of time.

Source: Gart, J .J., et al., 1979, "Statistical Issues in Interpretation of
Chronic Bioassay Tests for Carcinogenicity," J. Nat' 1 Cancer Inst., Vol. 62,
pp. 957-974.
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It has been suggested that doses in excess of the MTD may lead to tumors
through either non-specific mechanisms or through mec..l-tanisms which are not
operative at lower doses (See OSHA, 1980). The evidence in support of these
hypotheses, however, is limited (OSHA, 1980), and sometimes even contradicted
by the actual bioassay data (IRLG, 1979).
Thus, the observation of
significant tumor increases in animals administered a substance in excess of
the MTD should be considered significant unless there is adequate evidence to
the contrary. Indeed, because excessive doses are likely to decrease the
sensitivity of the assay through premature mortality, a positive tumor
response in this situation may increase, rather than decrease, one's concern
about the substance's carcinogenic potential.
Concern over decreased
sensitivity can only be reduced if the carcinogenic respo~se can be
demonstrated to be an artifact of high dose administration.
Generally
accepted criteria for estimating the MfD from subchronic studies have been
developed by the National Toxicology Program (NTP, 1984) and by the
International Agency for Research on Cancer (IARC, 1980).
In addition to the MTD, bioassays should also include one or two
intermediate dose levels (NTP, 1984; IARC, 1980). These additional dose
levels are needed to ensure that the bioassay produces meaningful results if
the MTD was exceeded. They are also useful for describing the nature of the
dose-response, particularly if pharmacokinetic considerations are taken into
account (NTP, 1984).
Besides statistical findings, other important toxicological information
may be obtained from the cancer studies. These include the histological type
of the tumor, the proportion of benign and malignant tumors and, in the case
of animal bioassays, information on pre-neoplastic changes. Assessment of
such qualitative information may indicate a biologically relevant response in
the absence of statistical significance. Conversely, it may also find that a
statistically significant result may not be biologically significant.
Finally, it is hoped that qualitative information will expand the scientific
understanding of the biological mechanisms associated with the development of
particular tumors.
Generally, because tumors may arise from a single interaction between a
chemical and DNA, no threshold dose which is free of risk can be estimated for
a carcinogen which also produces genetic toxicity (NAS, 1977; USEPA, 1986a,
OSHA, 1980; OSTP, 1985; OTA, 1981). Whether or not a threshold actually
exists is a matter of considerable controversy.
It can be argued, for
example, that detoxification or DNA repair mechanisms should prevent any
permanent genetic damage when the concentration of a chemical carcinogen is
well below a level which would saturate these processes. On the other hand,
errors may occur in this repair process. Also, threshold levels cannot be
experimentally determined at present for the general population; they may vary
from tissue to tissue, from individual to individual, and be influenced by
other environmental agents operating through similar mechanisms. Therefore,
until the biological activity of these chemicals can be better described,
exposure to genotoxic carcinogens should be expressed in terms of "risk
levels" rather than "safe levels" (Hogan and Hoel, 1982)e Methods for
estimating risks for non-threshold effects are described in the Hazard
Assessment section (Section V).
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There are, however, important epigenetic factors which may influence the
initiation and promotion of tumors. These factors may be derived from either
hereditary or environmental determinants (Higginson, 1981). The importance of
initiating factors relative to epigenetic factors in tumor development is
still poorly understood (Higginson, 1981).
Chemicals may influence tumor
development in an epigenetic fashion regardless of how they perform on genetic
toxicity tests. Non-genotoxic carcinogens present special problems to the
assessment of risks associated with low exposure levels. Firstly, their role
in tumor development may not be detected if toxicological tests do not also
include appropriate initiating factors.
Secondly, even if they are
identified, the conceptual basis for their mechanisms of action is different
from that of the genotoxic carcinogens.
Too little is known about the
mechanisms of carcinogenesis, however, to adequately distinguish between the
effects of genotoxic and non-genotoxic carcinogens (OSTP, 1985). Moreover, it
is important to note that the three of the most potent carcinogens tested to
date
(2, 3, 7 ,8-tetrachorodibenzodioxin,
polybrominated
biphenyls,
and
reserpine), produce negative results in conventional genetic toxicity tests
(Tennant et al., 1987). Similarly to the genotoxic carcinogens, therefore, a
threshold may be assumed for these non-genotoxic carcinogens only if the
critical biochemical mechanisms can be identified and quantitatively evaluated
for different tissues, individuals, and . species.
Otherwise, in order to
conform to the principle of worst case risk assessment, a non-threshold
mechanism should be assumed.
Because tumor development may be dependent on multiple mechanisms, studies
concentrating on complete carcinogens, or on only one factor associated with
carcinogenesis, may lead to a misrepresentation of risk if potential modifying
factors are not adequately identified and addressed. These factors could be
better identified through improved methods of epidemiological surveillance.
Such improvements could result from an expanded expanding cancer registry
which
includes
country-wide
information
on exposure
to
potentially
carcinogenic substances. Such information may include .occupational history
proximity to hazardous chemical industries or waste sites, and history of
exposure to water or indoor air contaminants.
Because of the multistage
process of carcinogenisis, as well as its potentially long latency period,
however, identification of human carcinogens will continue to be a difficult
process.
Because of the many similarities in tumor development between
laboratory animals and human beings, however, much consideration should
continue to be placed on the findings from animal experiments.
11.1.3

Identification of Reproductive and Developmental Effects.

An estimated one in five couples are involuntarily sterile (Dixon, 1986).
Over one-third of the early embryos die and about 15 percent of recognized
pregnancies abort spontaneously (Dixon, 1986).
Over 1 percent of the
approximately 1.3 million live infants born in the United States annually die
\vithin the first year (:Manson, 1986). Seven percent have low birth weights
(Manson, 1986). Approximately 2 to 4 percent are born with major congenital
malformations (:Manson, 1986; NRC, 1983a). Another 3 percent are found to have
serious developmental effects by the end of the first year (USEPA, 1984).
When defects that only become apparent later in life are included, the
estimated frequency of major and minor malformations increases to about 16
percent (:Manson, 1986). The contribution of toxic chemical exposure to the
incidence of these adverse health effects is not well known.
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Reproductive toxicity may be defined as a "dysfunction induced by chemical
(as well as biological and physical) agents that affect the process of
gametogenesis from its earliest stage to implantation of the conceptus in the
endometrium" (Dixon, 1976).
As Figure 11.2 and Table 11.10 demonstrate,
successful reproduction is dependent on the interaction of several biological
processes.
Reproductive toxins may interfere with one or more of these
processes.
Direct associations between chemical exposure and reproductive
toxicity are difficult to establish, however, in human populations. This is
particularly true for environmental chemicals. Exposure patterns and levels
are seldom estimated with precision.
In addition, the influence of
potentially confounding factors has to be considered in the analysis.
Moreover, methods to reliably estimate damage to human fertility are not
readily available (Dixon, 1986), and animal models may not be sufficiently
sensitive to detect adverse reproductive effects in human beings (Dixon, 1986;
IRLG, 1986). Thus, a limited number of environmental chemicals have been
linked with reproductive effects in human beings.
Given the general paucity of information on this health parameter,
reproductive toxicity is generally evaluated along with the assessment of
developmental effects.
This combination is not meant to imply that the
mechanisms of toxicity are similar. Indeed, they are not, as reproductive
toxicity concerns the parent and developmental toxicity concerns the
conceptus. Thus, when the toxicological database is sufficient to separate
reproductive effects from developmental effects, a separate subchapter should
be devoted to the assessment of reproductive toxicity.
Once the conceptus is implanted in the endometrium, factors affecting
intrauterine growth are referred to as "developmental toxicity" (Manson,
1986). There are four general categories of developmental toxicity: death,
malformation, growth retardation, and functional deficit (Wilson, 1980;
Schardein, 1985; USEPA, 1986).
Developmental toxicity may result directly
from the effect of a toxin on the conceptus in the -absence of maternal
toxicity, indirectly as a secondary effect of maternal toxicity, or from a
combination of both.
All categories of developmental toxicity should be
investigated when assessing the potential developmental hazards, especially as
there are associations between these health effects categories (Wilson,
1973). Gro·wth retardation, for example, may be indicative of more severe
developmental effects (van den Berg and Yerushalmy, 1966; Scott and Usher,
1966; Low and Galbraith, 1974). Also, the prevalence of embryolethality may
be explained by the increased number of several malformations which predispose
the embryo to death (Wilson, 1980). Early toxic effects to the embryo may
increase the risk of lethality, possibly masking later developmental effects
(Wilson, 1973).
In general, embryotoxic effects have a characteristic distribution along
the dose-response curve (Wilson, 1980).
At low doses, no effects are
observed. As the dosage increases, both lethal and non-lethal effects begin
to appear, with lethal effects becoming increasingly more prevalent at higher
doses.
At the upper end of the dose-response curve, the possible
developmental effects of chemical exposure cannot be easily distinguished from
secondary effects resulting from maternal toxicity.
This relationship is
described in Figure 11.3.
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Figure 11.2. Schematic representation of the biologic processes that are
essential for normal reproduction.
Source: Dixon, R.L., 1986, "Toxic Responses of the Reproductive System," in
C.D. Klaasen et al. (eds.), Casarett and Doull's Toxicology, MacMillan
Publishing Company, New York. p. 448.

Table 11.10
Various Reproductive Functions Susceptible to Toxic Chemicals
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Figure 11.3.
Types of Respons-es that Occur when Pregnant Animals Are
Subjected to Increasing Dosage of a Biologically Active Chemical or Physical
Agent
Source: Wilson, J .G., 1980, "Environmental Effects on Intrauterine Death in
Animals," in I .H. Porter and E. B. Hook ( eds.), Human Embryonic and Fetal
Death, Academic Press, New York, p. 23.
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Figure 11.4. Groups of Curves Representing the Susceptibility of Particular
Organs and Organ Systems in Rat Embryos to a Hypothetical Teratogenic Agent
Given on Different Days of Gestation.
Source: Wilson, J.G., 1973, Environment and Birth Defects, Academic Press,
New York.
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}fuch emphasis in reproductive and developmental toxicology has been placed
on the teratogenic potential of a chemical, or the potential of a chemical to
produce malformations (Brown and Nigel, 1983).
As Figure 11.4 indicates,
organ systems differ in the intervals within the gestation periods at which
they are most vulnerable to teratogenic insult. Overall, the most critical
period of susceptibility ranges from shortly after the time of implantation to
the end of the embryonic stage of development (approximately the first two to
three months of gestation in human beings (Schardein, 1985)). It is during
this period that that most organogenesis takes place. Some tissues, however,
continue to differentiate beyond this time.
The cerebrum and cerebellum
continue differentiation even into the postnatal period (NRC, 1986), and the
lung continues to differentiate throughout childhood (Kattan, 1979).
The
immune, reproductive, gastrointestinal, and endocrine systems are also
incompletely developed at birth (WHO, 1986). These tissues, therefore, may
remain sensitive to developmental toxicants well beyond the embryonic stage.
A breakdown of malformations by etiology is presented in Table 11.·11. As
can be seen from the table, most causes of malformations in human beings are
unknown.
Furthermore, subtler manifestations of developmental toxicity may
also occur, but generally go unreported (USEPA, 1986d).
Epidemiological
studies currently lack an adequate database from which human developmental
toxins may be identified or compared with animal teratogens.
It is
unfortunate that adequate surveillance in this area is not being implemented,
as there are arguments that implementation would be relatively cost-effective
(H.R., 1986). Along with the enormous public health benefits associated with
the identification and control of developmental toxins, particularly those
which are able to produce genetic toxicity, such efforts may also reduce risks
of cancer and other chronic diseases.
The guidelines for assessing reproductive and developmental risks from
epidemiological investigations are similar to those associated with the
identification of carcinogens (IRLG, 1986). In light of .the limited database
available for epidemiological studies, the rapid association between a
teratogen and its effects in human beings depends either on a appreciable
number of cases at one time OF place, or an unusual if not unique defect or
association· of defects (Wilson, 1973). Yet, the pattern of defects observed
depends on the dose received as well as the time frame in which the dose is
administered.
Consequently, it is possible that teratogen may only be
sporadically expressed in human populations or may be expressed without a
\vell-defined pattern of. effect (Wilson, 1973).
Thus, it has not been
recommended that epidemiological investigations depend on sentinel effects
solely in the recognition of chemically-induced teratogenesis (Wilson, 1973).
Despite the lack of comparative data, there is a basis for using animal
tests to identify potential human developmental toxins.
Most known human
teratogens have also been teratogenic in at least one animal species (See
Table 11.12 (NRC, 1986; Schardein et al., 1985). The mouse and rat tests
produce the highest percentage of positive responses.
Also, the types of
effects produced in humans and those produced in laboratory animals are
correlated, as indicated by Table 11.13. Only specific anticancer drugs,
anticonvulsants, and lithium failed to produce a pattern of defects in at
least one animal species that is similar to the human response. (Schardein,
1985).
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Table Il.ll
Causes of

~lfor111e:tions

in f!uman Beings

Known genetic transmission

20%

Chromosomal aberration
Environmental causes:
radiations
infections
maternal metabolic imbalance
drugs and environmental chemicals

1%
2-3%
1-2%
4-6%

Potentiative interactions
Unknown

65-70%

?

Source: Schardein, J .L., Chemically Induced Birth Defects, Marcel Dekker,
Inc., New York, 1985. p. 2.

Table 11.12
Predictability of Laboratory Animal Mbdels for Putative Human Teratogensa
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Altbough there was a concordance found between the effects in hum8n beings
and the effects in some laboratory animal, there was far less concordance when
the responses of 1nd1vidual species were compared to the human response
(Schardein et al., 1985). These comparisons are presented in Table 11.13.
There is, therefore, no a priori way of determining which animal species is
most reflective of the numan response to a particular chemical (Schardein,
1985). This drawback may be addressed in the future more insj ght is gained
into the tuxicoiogical mechanisms and the phannaco~inet.ic ci.~.fferellces amcng
species (IRLG, 1986). Unless data are available to support an alternative
animal model, however, a human health . risk should be presumed if an adverse
reproductive outcome occurs in a well conducted animal study.

Table 11.13
Comparisons of Concordant Malformations between Human Beings
and Laboratory Animals

Concordant

Ter-atogen

Reference Malfonnation

AJ cohol

Craniofacial, limb, CV

r.t:>use, dog

Androgen i c/proges to genic
hormones

Pseudohermaphrodism (fem.)

Mouse, rat, guinea pig, pig
hamster, rabbit, dog, primate

Skeletal
Multiple visceral
Skeletal
Limb, ear

Rat
Mouse, rat, guinea pig
Rabbit, cat
Rat

Dog, pig
Rabbit, primate
Mouse, rat, primate
1-Puse

Multiple visceral
Urogenital
Digits
Renal, Limb, ear

r.t:>use, rat
Rat, rabbit, ferret

Mouse, rat
Mouse, rat
Rabbit, primate
1-Puse

Anticancer antimetabolites
Aminopterin
Fluorouracil
~thotrexate

Cytarabine
Anticancer alkylating agents
Busulfan
Chlorambucil
Cyclophosphamide
Mechlorethamine
Ant iconvu lsants
Hydantoins
Diones
Valproate

CNS

k~tithyroid

Hypothyroidism

agents

r.t:>use

Facial, mental
Facial, mental

Nonconcordant
Rat, guinea pig, pig

Rat, rabbit, rabbit
r.t:>use, primate
Mouse, rat, rabbit

Mouse, rat, rabbit, guinea pig

Uterine lesions

Mouse, rat, primate, ferret

Microcephaly, mental

r.t>use, rat, cat

Hamster

Thalid0111ide

Limb

Rabbit, primate

Mouse, rat, hamster, dog,
cat, pig, ferret

'.ithium

cv

D-Penicillamine

Skin lesion

Rat

Streptomycin antibiotics

Inner ear

Rat

CV, ear, brain

Rat, .ause, hamster, dog,
priute

DES

Methylmercury

Vi tall in A

ai..alogu~"S

Mouse
Hamster

Rabbit, guinea pig, pig

------------------------·--------Source: SCharde1n, J.L., et al., 1985, "Species Sensitivities and Prediction
of Teratogenic Potential," Environ. Health Perspect., Vol. 61 ,, p. 61.
11-23

(88)

As .,Jith chemical carci_nogens, guidelines have been developed to evaluate
the adequacy of reproductive and developmental toxicity studies (USEPA, 1986d;
IRLG, 1986; Sdlardein, 1985; Wilson, 1973, 1980). Many o£ the same concerns
a.ssociattd witi1 ~ens.itivity of the carcinogenicity bioassay apply to the
de\-eloph,ental toxicity studies as well. A summary of tes't endpoints for
evaluating developnental and maternal toxicity are presented in Tables 11.14
and 11.15. Tests to measure the transmission of hereditable changes have also
:.een developed, an.d (1re dcsc1 ibed e:isev-h~re (JSLJ'A, 198Gb; IARC, 1983; NkC,
1983b).
Enough animals should be included in the study to ensure adequate
sensitivity for detecting an effect. This typically includes at least twenty
animals per dose group (USEPA, 1986d).
Findings of positive associations
between dose and developmental effects with lower numbers of animals per dose
group should be seriously considered, as such findings indicate that a much
stronger response would have been observed had adequate numbers of animals
been used.
Also, it is recognized that in all animal species there is a detectable
incidence of spontaneously occurring developmental effects (Wilson, 1980;
IRLG, 1979). Concurrent controls should therefore be evaluated as part of the
assaye As with controls for chemical carcinogenicity studies, primary attention in developmental effects studies should be given to the effects in the
treated groups relative to the concurrent controls, especially if there is a
difference in the incidence rates between the concurrent and historical
controls.

Table 11.14
Endpoints of Maternal Toxicity

Mortaljty
Gestation Index (no. with
implants/no. with sperm
or seminal plugs
Body Weight
Treatment days (at least
first, middle, and
last treatment days
Organ Weights (in cases
of suspected organ
toxicity)
Absolute
Relative to hody
weight
Gross Necropsy and
histopathology

Fertility Index (no. with seminal plugs or
spenn/no. mated)
Gestation Length (when allowed to deliver
pups
Body Weight Change
Throughout Gestation
During Treatment (including increments
of time within treatment period)
Post-treatment to sacrifice
Corrected maternal body weight
(change throughout gestation minus
gravid uterine weight or litter
w~ight at sacrif~c~)
Food/Water Consumption (where relevant)
Clinical Evaluations (on days of
treatment and at sacrifice)
Types and Incidence of Clinical Signs
Enzyme Markers
Clinical Chemistries

Source: USEPA (U.S. Environmental Protection Agency). 1986d, "Guidelines for
the Health Assessment of Suspect Developmental Toxicants," Federal Register,
Vol. 51, pp. 34027-34040.
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Table 11.15
Endpoints of Developmental Toxicity

Litters with implants
No 1mplantat1on sites/dam
No. corpora lutea (CL)/dama
Percent preimp1antation loss
(CL - implantations) Xlooa
CL
No. and percent live offspring/
litter
No. and percent resorptions/litter
No. and percent litters with
resorptions
No. and percent late fetal deaths/
litter
No. & percent nonl i ve (late fetal
deaths &resorptions) implants/
litter
No. and percent litters with nonlive implants
No. and percent affected (non-live
& malfonned) implants/litter
No. and percent litters with
affected implants
No. and percent litters with total
resorptions
No. and percent stillbirths/litter

Litters with live offsfringb
No. a:M percent 1tters with
live offspring
Sex ratio/litter
No. and percent live
offspring/litter
Viability of offspringc
Mean offspring body weight/
litterC
Me~~ male body weight/litterC
~~an female body weight/litterC
No. and percent externally
malformed offspring/litter
No. and percent viscerally
malfromed offspring/litter
No. and percent skeletally
malformed offspring/litter
No. and percent malformed
offspring/litter
No. 3.nd percent litters with
malformed offspring
No. and percent malformed males/
litter
·
No. and percent malformed females/
litter
No. and percent :Jffspring "-'i th
variations/litter
No. and percent litters having
offspring with variations
Types and incidence of individual
rna If onna ti ons
1)~s and incidence of individual
variations
Individual offspring and their
malfonnations and variations
(grouped accouding to litter and
dose)
Clinical signsc
Gross necropsy and· histopathology

armportant when treatment begins prior to implantation. May be difficult in
mice
boffspring refers both to fetuses observed prior to term or to pups following
birth. The end points examin~d depend on the protocol used for each study.
CMeasured at selected intervals until termination of the study.

Source: USEPA (U.S. Environmental Protection Agency). 1986d, "Guidelines for
t'1e Beal th 1\ssessment of Suspect Developmental Toxicants," Federal Register,
Vol. 51, pp. 34027-34040.
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The highest dose level should result in some maternal toxicity, in order
to ensure that the test has the maximum sensitivity of detecting a positive
response (USEPA, 1986d). Lower dose levels should not be toxic to the dam,
and be sufficient to provide information from which a dose-response
relationship may be established (USEPA, 1986d). These levels should include a
no observed effect level as well as one or more dose levels in between the no
observed effect level and the highest dose level (USEPA, 1986d).
When
evaluating the dose response data, the greatest concern should be with those
agents which produce developmental toxicity at a dose that is not toxic to the
adult, as this implies that the developing organism is selectively affected or
more sensitive than the adult (USEPA, 1986d). Findings of developmental
effects at dose levels which are also toxic to the mother should be interpreted cautiously, as it is possible that the developmental effects are secondary to maternal toxicity (USEPA, 1986d). Should this be the case, the study
could imply that dose levels which do not cause toxicity in the mother should
not cause harm to the conceptus either. Findings of developmental toxicity
only at maternally toxic doses should not be summarily discounted, however, as
current information is inadequate to assume that developmental effects at
maternally toxic doses result only from maternal toxicity (USEPA, 1986d).
Because of the differences in species sensitivity to developmental toxins,
it is possible that testing on only one species may fail to identify a
substance that is toxic in other species, including human beings. It has been
recommended, therefore, that at least two species be tested (Wilson, 1973).
This is consistent with the protocol recommended for the animal testing of
carcinogens (IARC, 1980; NTP, 1984). It has also been recommended that at
least one species should be a non-rodent species (Schardein, 1985), preferably
a non-rodent/non-rabbit species (Calabrese, 1983; Wilson, 1973).
These
recommendations are based on the concern that the reproductive systems in
rodents and rabbits are similar, and differ significantly from the human
reproductive system.
The dosing schedule is generally restricted to the early part of
gestation, when most organogenesis is taking place and the organisms are most
susceptible to teratogenic insult (See Table 11.16). Yet, even within this
restricted interval, effects of repeated dosing may produce different
embryotoxic outcomes than a single dose administered at a critical time in
organogenesis. The ways in which these differences mig.ht occur are presented
in Table 11.17.
Several of these mechanisms include chemically-induced
alterations in metabolic rates. A list of some chemicals known to influence
metabolic rates is presented in Table 11.18. Of primary importance with
regard to study sensitivity is the possible induction of catabolizing enzymes
by high doses before the time of maximum susceptibility (Wilson, 1973). It
has been reconunended that, to address this concern, treatment intervals be
subdivided into 3-4 day time spans (Wilson, 1973).
Mul tigeneration studies have been recommended to identify cumulative and
genetic effects (Dixon, 1986; Manson, 1986). These studies are designed to
last for three generations and involve the administration of the test agent to
the first two generations (Dixon, 1986). The dosing of the· F0 generation
begins as soon as possible after weaning and acclimation, and continues until
all the F1 animals selected for the next phase of the study have been
weaned. Dosing of the F1 generation selected for breeding continues until
30 days after the F 2 animals have been weaned. Consequently, this protocol
increases the sensitivity of the assay to identify recessive genetic effects
and effects which may occur at any stage of the life cycle.
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Table 11.16
Critical Period of Organogenesis in Various Species
Days of
Organogenesis a

Species
Mouse
Hamster
Rat
Guinea Pig
Armadillo
Ferret
Rabbit
Cat
Rhesus Monkey
Baboon
Dog
Ovine
Bovine
Porcfne
Human
a.
b.

7-16
7-14
9-17
11-25
1-30
12-28
7-20
14-26
20-45
22-47
14-30
14-36
8-25
12-34

zo-ssb

Following Fertilization
Also may be given as day 35-70 after last menstrual period.

Source: Schardein, J.L., Chemically Induced Birth Defects, Marcel Dekker,
Inc., New York, 1985.

Table 11.17
Ways in Which Repeated Treatment Prior to the Peak Susceptible
Period of the Embryo May Produce Misleading Results

Time of treatment

Primary effect

Secondary effect capable of
altering test results

----------------------Interference with
No issue

1. Before implantation

2. Early organogenesis
3. Before peak
susceptibility
4. Before peak
susceptibility
5. Before peak
susceptibility
6. Before peak
susceptibility
7. Before peak
susceptibility

Source: Wilson, J.G., 1973,
York, pp. 137-171.

implantation
Early embryonic death
Induction of catabolizing en7ymes
Inhibition of catabolizing enzymes
Liver pathology or reduced function
Kidney pathology or
reduced function
Saturation of proteinbinding sites
Enviro~~ent

No issue
Reduced blood level
susceptible period
Increased blood level
susceptible period
Increased blood level
susceptible period
Increased blood level
susceptible period
Increased blood level
susceptible period

during
during
during
during
during

and Birth Defects, Academic Press, New

11-27

(88)

Table 11.18
Some Cherrical Agents Known to Influence Rates of :Metabolic Degradation
of Themselves And/Or Other Compounds After Repeated Dosage

--------·-··------··--------

Increase
metabolic degradation

Decrease
metabolic degradation

Barbiturates
SKF 525-A
Thyroxine
Chlorthione
Some insecticides (DDT, chlordane, aldrin, Iproniazid
dieldrin, heptachlor)
Metopirone
Some tranquilizers and antipsychotics
Actinomycin D
(meprobamate, Librium, chlorpromazine)
Puromycin
Some antihistamines (chlorcyclizine,
CCI.
diphenhydramine)
Triparanol
Several hypoglycemic agents
Chlorar:;phenico]
3, 1-Benzpyrene
Any that competitively inhibit
3-Methylcholanthrene
catabolic enz:;rrnes
Steroid hormones

Source: Wilson, J .G., 1973, Environment and Birth Defects, Academic Press,
New York, pp. 137-171.

In addition to teratogenicity, other measures of developmental or
reproductive toxicity could be utilized in the identification of substances
which could produce these hazards.
Such additional parameters are often
associated with teratogenicity, and occur more frequently and consistently in
animal experiments (Schardein, 1985).
For example, low pregnancy rate,
reduced litter size, and poor viability were observed in the early animal
tests with thalidomide in r~dents in the absence of teratogenicity (Schardein,
1985). Also, these parameters are more sensitive indicators of developmental
effects than are gross malformations (USEPA, 1986d). For example, under a
testing protocol which uses 20 animals per dose group, it is possible to
detect an increased incidence of malformations in the range of 5 to 12 times
above control levels, an increase of 3 to 6 times in the in utero death rate,
and a decrease of 0.15 to 0.25 times the fetal weight (USEP~86d). Other
factJrs may need to be :onsidcred, however, when evaluating c1anges jn fetal
weight. In polytocous animals, for example, fetal and neonatal weights are
,Jsu.::.lly L·Jversely correlated with litter size (USEPA, 1986d).
Also, the
average body weight of males is greater than that of females in the more
commonly used laboratory animals (USEPA, 1986d), thus warranting consideration
of the sex ratios.
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Sensitive developmental toxicity endpoints which are not commonly
investigated include those that measure subtle functional defects in organs or
organ systems (USEPA, 1986d). Often, these effects occur at levels below
those which cause gross malformations (USEPA, 1986d). Much of the work that
has been done has focused on behavioral effects, although the cardiopulmonary,
immune, endocrine, digestive, urinary, nervous, and reproductive systems are
also subject to alterations in functional competence (USEPA, 1986d).
Neurotoxicity is a significant concern in this regard, as laboratory animals
are poor surrogates for the identification of effects on complex human
neurological function.
Tests to measure effects on fertility have also been developed (Dixon,
1986, IRLG, 1986). Positive findings from these studies may have special
significance in that the fertility of humans is more susceptible to environmental chemicals than is the fertility of laboratory animals (Dixon, 1986;
IRLG, 1986). Laboratory animals, for example, produce sperm in considerable
excess over that required for normal reproductive function (IRLG, 1986).
11.1.4

Identification of Acute/Chronic Toxicity Effects.

Any organ or organ system in the body may experience toxic effects from
chemical exposure.
For most situations subject to risk assessment, the
predominant concern is for the identification of chronic health effects. Of
particular importance are those effects resulting from long-term exposure to
toxic substances at levels below those which produce acute toxicity. This
exposure situation warrants considerable attention for several reasons.
Firstly, the exposed population, as well as the number of potentially
hazardous chemicals to which this population is exposed, increases as the
exposure dose decreases. Also, as the exposure duration sufficient to produce
a toxic effect increases, so does the probability that those experiencing the
toxic effect are exposed to an increasing number of other risk factors as
well. This problem limits the ability of epidemiology to attribute an adverse
health outcome to a particular substance.
MOreover, registries of most
chronic diseases (other than cancer) are not kept. This further limits the
ability to identify toxic hazards even in the absence of other risk factors.
Finally, even if a toxic outcome is established in association \vith exposure
to a toxic substance, many years may have elapsed between the time of the
chemical's identification and the time of its introduction into the market.
The shortcomings of disease surveillance, combined with the inherent
limitations of animal studies (See Chapter 4.4), contribute to much of the
uncertainty and anxiety concerning the hazard identification of toxic
substances.
Traditional measurements of acute and chronic health effects have focused
on common manifestations of toxicity. These include such overt acute effects
as irritation, dermatological disorders, behavioral disturbances, central
nervous system depression, cardiopulmonary depression, and death. They also
include common biochemical indicators of visceral organ toxicity (such as
serum
liver
enzyme
levels).
As
the
scientific
understanding
of
chemically-induced health effects has expanded, however, an increasing number
of toxicological endpoints has been investigated. These endpoints include
effects
associated
with
genotoxic, · carcinogenic,
and
reproductive/
developmental risks discussed earlier. Such effects are not discussed in this
subchapter, except insofar as they were observed in studies along with other
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health effects not previously described. Addition&l endpoints also include
subtler toxic effects associated with reversible or irreversible tissue damage
(for example, neu1·cpathic or immunosuppressive effects).
A S'lffiffiary of
selected non-carcinogenic health endpoints for various target organs is
presented in Table 11.19.
Because different health effects are likely to result from different
toxicological tuechanisms, there ore limitations associated with the us~;: of one
endpoint or. group of endpoints as a surrogate for a substance's overall toxic
potential. This caveat is particularly relevant when evaluating lethality
studies (for example, LD50, LC50, LDlO), as there may be many toxicologically
significant endpoints which are not well correlated with acute lethality. For
example, because of the body's homeostatic responses to acute exposures, and
its ability to respond to insult following these exposures, the concerns
associated with chronic exposure may be quite different from those associated
with acute exposure.
Chronic effects may occur as a result of the
accumulation of subtle tissue damage through repetitive exposures, as a
consequence of adaptive mechanisms induced by the exposures, or from an
accumulation of a substance within the body to a level sufficient to cause an
acute response (Figure 11. 5).
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Figure 11.5.

Diagrammatic View of Dose and Corresponding Measure of Effect.

Source: Klaasen, C.D., 1986, "Distribution, Excretion, and Absorption of
Toxicants," in C.D. Klaasen et al. (eds.), Casarett and Doull's Toxicology,
MacMillan Publishing Company, New York. pp. 33-63.
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Table 11.19
Selected Parailleters Associated
with Toxicity to 'J"arious Organs and Organ Systems

Organ/Organ System

Parameters Indicative of an .Adverse Effect

Hematopoietic

Bone marrow depression, Abnormally high
count, Hypoxia, abnormal hemog"lobin

Immune

Alterations in lymphoid organ weight or histology,
quantitative changes in perpheral leukocyte counts and
differentials,
depressed
cellularity
of
l}Tiphoid
tissues, increased susceptability to infections by
opportunistic organisms, increased incidence of allergy
and autoimmunity

Cardiovascular

Changes in heart rate, conductivity, excitabi1ity, anc!
contractility, changes in cardiac output, changes in
arterial
blood
pressure,
hemorrhage,
thrombosis,
structural changes, hypersensitivity

Respiratory System

Irritation of the air passages, damage to cells lining
the airways, production of fibrosis, constriction of
airways through allergic responses

Nervous System

Alterations
in
functions:
coguitive,
somatosensory,
motor,
antonomic,
immune
structural damage

Eye

Lesions of the cornea, lens, and retina; tear secretion,
ocular pressure, electroretinogram; biochemical assays
of lens and aqueous humor; eye reflexes

Liver

Interference with bilirubin uptake, excretion and
conjugation; cytotoxic injury; cholestatic injury; fatty
liver; cirrhosis; phospholipidosis, vascular lesions;
chronic active hepatitis; subacute hepatic neurosis

Kidney

Decreased
elimination
of
wastes;
changes
in
extracellular fluid volume and electrolyte composition;
changes in hormone levels invul ved in systematic
metabolic ft.mcticns; changes in prostaglandin and kinin
levels

General Sources:

reticulocyte

sensory,
effects;

C.D. Klaasen et al. (eds.), 1986, Casarett and Doull's
Toxicology, Third Edition, MacMillan Publishing Company, New
York, 974 pp.; G.M. Cohen (ed.), 1986 Target Organ Toxicity,
Volumes I and II, CRC Press, Boca Raton, Florida; National
Research Council, Drinking Water and Health, Vol. 6,
National Academy Press, Washington, D.C., pp. 105-138.
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Most toxicological studies hav~ concerned effects on organs or organ
systems that receive the most intense exposure, either through direct contact
or through transport via the blood. Examples of these sites are the blood
itself, the skin and external organs, the pulmonary and cardiovascular
systems, the liver, and the kidney. Exposure intensity is not the only
parameter of concern, however, as tissues may vary widely in their response to
a given dose of a toxic substance. For example, certain tissues, such as
heart tissue (Balazs et al., 1986), are less able than the liver and kidney
tissues to protect themselves from the toxic effects of reactive metabolites.
Generally, the epidemiological assessment of health effects depends on
the ability of the studies to identify the populations exposed directly relate
the observed effects to actual health impairment.
Difficulties exist,
however, in the identification of sensitive health endpoints, in the adequate
assessment of exposure levels, and in separating the effects of a particular
exposure from those induced by exposure to other chemical, physical, or
biological agents. Despite these shortcomings, however, an important focus of
risk assessments should be the identification of sensitive indicators of
adverse health effects. Such 1 imitations are overcome through the use of
laboratory tests. As the health effect parameters become more sensitive,
however, their association with clinical effects becomes less clear. Thus, a
distinction has to be made between the significance of a change in a
particular health parameter and the overall health significance of this
change. Any chemically-induced perturbation in an organism, regardless of its
clinical significance, may contribute to a toxic outcome. Therefore, any
subtle but significant biological change may constitute an adverse health
effect. Evaluation of this change within the context of the substance's other
toxicological manifestations is required before conclusions can be made
regarding its importance to human health. This evaluation is conducted in the
Hazard Assessment section (Section V).
11.2

Identification of Multiple Chemical Exposure Effects.

Human beings are not typically exposed to ·a single compound of
toxicological concern. Rather, they are exposed to varying numbers of such
substances. These substances may enter the body through oral, pulmonary, and
dermal exposure routes. The human response) to any one chemical in this
exposure mixture may be either independent or dependent on the properties of
the other chemicals in the mixture. Independent responses which af feet the
same toxicological endpoint are additive in nature. The severity of the
response is a function of the toxic potencies of the individual chemicals.
Dependent responses are interactive in nature. When the response is greater
than what would be predicted by adding the potencies of the individual
chemicals, the response is considered synergistic. A special kind of this
interaction takes place when a chemical w1th no known contribution to a
particular toxicological effect increases the potency of another chemical
relative to that effect.
This particular synergistic response is
potentiation. When the interaction of chemicals results in a response which
IS less than what would be predicted from an additive model, the interaction
is considered to be antagonistic.
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The toxicological importance of a substance may also be altered
significantly when it precedes or follows exposure to another substance. In
addition to temporal variability, the nature of the interaction also depends
on the concentrations of the substances to which individuals are exposed.
Toluene, for example, may antagonize the toxicity of benzene when co-exposure
occurs at high concentrations (Goldstein, 1983). It does this by competing
with benzene for enzymes responsible for benzene's metabolic activation. At
lower concentrations, however, this antagonism should not occur because
metabolism would not be saturated. To the contrary, it is possible that
toluene could enhance benzene's toxicity at these lower concentrations,
through the induction of metabolizing e~zymes.
Chemical exposures associated with such 1 if estyle factors as diet and
smoking habits may also interact with a substance's toxicity. For example,
the synergistic effects of cigarette smoking on the carcinogenicity of
asbestos have been widely discussed (See, for example, OSHA, 1980). A low
carbohydrate diet increases hepatic metabolism of various chemicals, whereas a
high carbohydrate diet decreases it (Sato et al., 1983). Opposite effects to
those of carbohydrates were observed with ethanol (Sa to et al., 1983). These
lifestyle factors, therefore, may either enhance or decrease the toxicity of a
substance, depending on whether the effect of concern is caused by the parent
compound or its metabolite.
Consideration of interactive effects is a requisite element in the proper
assessment of specific exposure situations, and in the proper identification
of sensitive populations or exposure cohorts. Assessment of interactive
effects_has been hampered, however, by the focus on the toxicity of individual
compounds rather than on a matrix of risk factors.
Nonetheless, this
chemical-specific approach is taken because the assessment of the many
potential risk factors represents a complicated, time-consuming, and costly
process.
In the future, problems associated with the assessment of multiple
chemical exposures may be overcome by a clearer understanding of the
mechanisms of toxicity, and the influences which various environmental
stresses have on these mechanisms. Meanwhile, the key risk assessment issue
in this regard concerns the underprediction of the toxic effects associated
with these chemical exposures. The problem is addressed to some extent by the
policy that assessments should first consider the toxicological effects of
chemical mixtures when they can be identified with an adequate database. If
this cannot be done satisfactorily, attention should be given to the
interactive effects observed in the studies on individual chemicals.
Synergistic interactions, while infrequently reported, should be assessed when
information is available. Antagonistic interactions, although potentially
relevant with regard to specific exposure situations or population cohorts,
may not be generally applicable for risk assessment purposes.
Even when information on interactive effects is available, however, it may
be difficult to describe these interactions quantitatively.
For most
situations, therefore, independence of effects is usually assumed unless
adequate information exists to support a different assumption. While these
effects may either be additive or non-additive in nature, proper hazard
identification warrants that they should be assumed additive unless the
available data indicate otherwise.
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11.3

Identification of Special Risk Populations

For any given substance, populations exist which may be especially
vulnerable to its toxic effects. -These populations may be at special risk
either because of their exposure circumstances or because of their inherent
sensitivity to the substance's biological effects. Individuals may thus vary
widely in their responses to toxic chemicals.
Specific factors which may influence a chemical's toxicity include
genettcs, age, sex, health status, diet and nutrition, lifestyle, occupation,
and environmental setting.
Infants and elderly people, and those with
compromised liver function, have diminished metabolic capability (Sipes and
Gandolfi, 1986).
They also have altered susceptibility to neurotoxic
disorders (NRC, 1986). Hereditary factors may have a direct or indirect role
in the development of many chronic diseases (NRC, 1983b).
Certain
occupational toxicants may interact in unpredictable ways with other
chemicals. Malnutrition is factor in the development of neurotoxic responses
(NRC, 1986).
Malnutrition and infection diminish one's immune system. A
simplified representation of this variability is presented in Figure 11.6.
Estimation of an exposure level which protects the population from the
harmful effects of a substance must consider these potentially l..vide
differences in susceptibility. Variations in sensi ti vi ty may be caused by a
combination of pharmacokinetic and pharmacodynrunic factors, leading to
potentially marked differences in the shape of the dose-response curve for
different human subpopulations (Gillette, 1985).
Sensitive populations may also exist by virtue of increased activity
levels.
By increasing the absorption rate for inhaled substances, and
decreasing the blood flow rate to the liver, increased activity levels modify
the delivered dose of a substance. This m9dification in pharmacokinetics is
especially important when considering threshold effects associated with
short-term inhalation exposures; increased activity would decrease the time
necessary to achieve equilibrium in blood and tissue concentrations.
Infants represent a special risk population for several reasons. Relative
to older children and adults, they absorb chemicals more readily from the
gastrointestinal tract, but have lower protein binding efficiencies are less
able to metabolize and excrete them (WHO, 1986). Toxic substances may also
exert adverse effects on organ systems still undergoing develop~ent, such as
the nervous,
immunologic,
gastrointestinal,
and
respiratory
systems.
Furthermore, as Figure 11.7 shmvs, weight gain in infants is higher than any
other age group.
Weight gain is evidenced by a period of rapid cell
division. This period of rapid growth also takes place at a time when the
body's metabolic and immunologic capabilities are not fully developed (WHO,
1986), thus leaving the infant more potentially vulnerable to tumor
inititators and other genetic toxins. Infants may also be at special risk by
virtue of their relatively high degree of oral and dermal contact with toxic
substances in the environment. This issue was raised in Chapter 8.
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Unfortunately, lack of data, as well as an inadequate conceptual
understanding of the mechanisms behind many chemically-induced effects,
usually prevents a rigorous determination of risk in sensitive human
populations. To compensate for these shortcomings, conservative assumptions
and methodologies must be incorporated into the risk assessment. Among these
is the assumption that some proportion of the human population will be at
least as sensitive to the effects of a chemical as the most sensitive animal
species investigated in a laboratory setting (Gillette, 1985).

Highly

Sensitive

Moderately
SensitivE:

Insensitive

___________________________\

Figure 11.6.
Population.

Variations in Response to Environmental Stress Among the General
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12.

Health Effects of Reaction Products

Some chemicals may be transformed into toxic substances as a result of
chemical or biological reactions in the environment. A popular example of
this is the atmospheric transformation of sulfur dioxide into sulfates.
Reaction products, such as sulfates, are identified in the Exposure Assessment
section (Chapter 9.1). The health effects of these reaction products should
be reviewed, as the assessment should consider situations in which human
exposure to a chemical's breakdown products occurs. The findings from this
review of the health data, along with the findings from the exposure
assessment, may form the basis for recommending that these reaction products
undergo formal assessment themselves. The framework for this process has
already been established in the Maine Bureau of Health's Hazardous Air
Pollutant Program (Anderson, 1986). Consideration of breakdown products also
has importance relative to Maine's groundwater monitoring program for
pesticides.
Ethylene thiourea, for example, an animal carcinogen and
teratogen, is a breakdown product of widely used dithiocarbamate pesticides.
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13.

Environmental Effects

Most risk assessment issues concern the direct human health effects of
chemical exposure. There may be impacts, however, which indirectly affect
human health by disrupting the environmental support systems.
These
disruptions may either be associated with alterations in environmental
chemistry, or with impacts on biological systems. While these modifications
could be very subtle, they could also be the most significant of all effects
caused by toxic substances. For impacts on the climate, large segments of the
world's population may be affected, but with no direct relationship between
exposure and effect. Some impacts, such as the extinction of a species or
depletion of the ozone layer, may be irreversible or require centuries to
reverse.
Because of the difficulty in interpreting the parameters which
measure these effects, however, there is a significant concern that the
significance of such effects will not be understood in time to prevent serious
environmental damage.
13.1

Effects on Environmental Chemistry.

The chemical equilibrium of the environment is maintained by a variety of
chemical reaction cycles.
Substances which are emitted in large enough
quantities, or whose envirorunental persistence is relatively long, may cause
significant alterations in these reaction cycles. For example, hydrocarbon
and nitrogen oxide emissions in the lower· atmosphere can lead to the build-up
of ozone to toxic levels by inhibiting reactions which destroy this gas. On
the other hand, emissions of chlorofluorocarbons into the upper atmosphere may
enhance the destruction of ozone, thus depleting the shield which protects the
earth from harmful ultraviolet rays.
In addition to identifying sensitive
reaction cycles, the assessment of the impacts on environmental chemistry is
further complicated by the possibility that some chemicals may e~~ance,
whereas others may inhibit, the same reaction cycle.
13.2

Ecosystem Effects.

Substances may affect ecological systems, either by direct effects on
sensitive plant and animal species, or by disrupting the biological
interactions which occur among these species. Such ecosytem effects involve
agricultural, terrestrial, freshwater, saltwater, and aerial species.
For
example, depletion of certain lichen species around London \vas an indicator of
the air pollution in that city as far back as the mid nineteenth century.
Surveys of chemical effects on plants and animals have also helped in the
identification of potential and actual exposures to hazardous wastes. The
effects of chlorinated pesticides, such as DDT, on the survival of terrestrial
wildlife has been well documented.
Investigations concerning the effects of a substance on the environment
may thus serve a variety of purposes. Firstly, they may identify adverse
effects not related to human toxicity, but which significantly alter the
functioning of systems which support human life. They may also indicate a
source of exposure with potentially adverse implications for human health.
Finally, they may provide additional toxicological insight regarding how
certain substances may affect human health. For risk assessment purposes, the
findings of these studies have the greatest relevance when the qualitative
assessment of chemical hazard is conducted (See Chapter 15).
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14.

Structure-Activity Relationships

Most relevant information concerning health effects is drawn from studies
of individual compounds.
Toxicological information on certain compounds,
however, may be supplemented through the study of related compounds. These
compounds are related in the abilities to induce the same biological effect,
and may either be structurally similar or dissimilar (Tichy, 1983). The magnitude of certain toxic effects may depend more on their physical properties
than on their specific biochemical reactivities (Tichy, 1983). The correlation between the threshold limit values (TLVs) and blood air partition coefficients for a number of chlorinated hydrocarbons is described in Figure 14.1.
This relationship suggests that the general toxicity of these compounds
may be predicted on the basis of their relative solubilities. In other cases,
however, basing predictions of toxicity on structural similarities may lead to
misleading conclusions. Benzo-a-pyrene, for example, is a potent mutagen and
animal carcinogen whereas a structurally similar compound, benzo•e-pyrene, has
not been found to be carcinogenic (IARC, 1983). This difference may be
attributable to differences in the ways in which the compounds are activated
to toxic metabolites (Selkirk and MacLeod, 1979). Conversely, structurally
dissimilar compounds may produce similar biological effects, as is thE case
with the wide variety of compounds which can induce prolife~ation of
peroxi soma 1 enzymes (Reddy and Lal wa i, 19 83). Thus, while in formation on
structure-activity relationships may be useful in risk assessment, the data
should be cautiously interpreted.
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SECT I ON V:

HAZARD ASSESSMENT

The Hazard Assessment comprises both a qualitative and quantitative
evaluation of the health risks associated with exposure to toxic substances.
Of the two, the qualitative assessment involves a discussion of hazard that is
more specific to the substance of interest. Due to limited databases for most
chemicals, quantitative assessments usually must rely on generally accepted
procedures which are applicable to a wide variety of chemicals. These include
the use of default uncertainty factors when estimating the degree of health
hazard in sensitive human populations, as well as default low dose
extrapolation models for estimating the health risks associated with
non-threshold effects. Despite its limitations, however, the quantitative
risk assessment findings have more practical relevance for risk management and
risk communication purposes than do the findings of the qualitative risk
assessments. Issues associated with this situation are discussed in the Risk
Characterization section (Section VI).
15.

Appraisal of Hazard Identification Studies.

In the appraisal of the Hazard Identification studies, all potential
health effects of concern are evaluated with reference to the overall
biological significance of chemical exposure. By comparing the findings of
the studies, the consistency of the toxic response pattern can be evaluated.
In this comparison, the severities of the toxicological endpoints are
assessed, along with the abilities of the studies to detect these endpoints
and the dose-response relationships found. This evaluation then forms the
basis for a discussion of the mechanisms of action. After the empirical and
conceptual basis for a chemically- induced health effect is evaluated, the
strength of the association (or weight of evidence) between exposure and the
occurrence of that effect in human beings is determined.
15.1 Comparison of Study Findings.
It is important that all the toxicologically relevant information
identified in the assessment be evaluated. This evaluation should include a
discussion of the non-positive as well as positive studies. Differences in
study findings may result from differences in study design, study quality, the
species, strain, or sex under investigation, the level of histopathological
examination, the endpoints evaluated, and the likelihood of detecting an
effect. This evaluation should also include a discussion of other known or
suspected risk factors for the health effects identified in the previous
section.
Two factors affecting the results observed in the health studies are the
design of the studies and the particular health endpoints measured. The first
factor can b~ addressed by statistical comparisons of the various studies to
determine their abilities to detect a particular effect. The second factor is
important because various _tests have been developed to identify and measure
the potential for a substance to cause particular health effects. These tests
may vary si,gnificantly in their sensitivities to detect these effects.
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Spirometry tests of lung function, for example, may not be sensitive enough to
detect subtle changes in airway resistance (Berkow, 1982). Because the lower
respiratory tract is particularly susceptible to damage, failure to detect an
effect from spirometry tests does not necessarily imply the absence of an
effect. On the other hand, if an effect is observed from spirometry tests, it·
is a good indication that significant lung damage has occurred.
Thus,
consideration of test sensi ti vi ty is important when determining the effect
severity and in subsequent derivations of action levels.
Aside from the evaluation of the individual health endpoints, the
consideration of the spectrum of identified health effects is also a relevant
area of discussion in the appraisal of health hazards. Assessment of the full
range of health effects which a substance may produce is helpful when
postulating a mechanism of action (See Chapter 15.2).
Different health
effects may be correlated with one another (for example, genetic toxicity,
carcinogenicity, and developmental toxicity).
Therefore, this particular
assessment may provide important evidence for weight of evidence determinations, even in the absence of a precisely defined toxicological mechanism.
The dose-response relationship is still another important area of
investigation with regard to the appraisal of the hazard identification
studies. Generally stated, as the dose of the chemical increases, so should
its toxicity. The most obvious explanation for the lack of a consistently
positive relationship between chemical exposure and health effect is that the
chemical causes no toxicity. Yet, the absence of a consistent dose-response
relationship may also be caused by a number of other factors. These include
competing mechanisms, pharmacokinetic characteristics, and statistical
limitations created by a small sample sizee Such factors should be assessed
when evaluating the nature of the dose-response curve.
The shape of the dose response curve may provide valuable qualitative
information concerning the nature of the response. The steepness of the curve
may be useful in estimating threshold or no effect levels. Comparisons
between different dose-response curves may also provide information concerning
the relationships between pharmacokinetic and toxicological responses, or the
inter-relationships between the different toxic responses. Similar to the
benefit gained by comparing the spectrum of toxic responses, comparisons of
dose-response relationships may also be useful in describing possible
mechanisms of action, as well as in the overall weight of evidence
determinations. An example of a relationship between the metabolism and
hepatotoxicity of tetrachloroethylene is described in Figure 15.1.
The
parallels between metabolite formation and hepatotoxicity suggest that a
metabolite of tetracloroethylene might responsible for its toxicity to the
liver.
15.2

Evaluation of Health Effect Severity.

An assessment of the hazard identification findings should include an
analysis of health effect severity. This analysis is necessary for two
principal reasons. Firstly, it could provide much toxicologically relevant
information from a relatively limited database, such as might be associated
with a single well-conducted animal bioassay for . carcinogenicity. Secondly,
it should provide a basis for gauging a quantitative degree of health concern,
as is needed when action levels are derived for chemical exposures using
various uncertainty and modifying factors.
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Figure 15 .1.
Relationship Between Tetrachloroethylene (PER) Dose and
Toxicokinetic Parameters in Mice. a) relationship between PER dose and the
amount of total urinary metabolite excreted per day; b) relationship between
PER dose and the increase in liver weight.
Source: BuLen, J.A. and O'Flaherty, E.J., 198:3, "Delineation of the Role of
Metabolism in the Hepatotoxicity of Trichloroethylene and Perchloroethylene: A
Dose-Effect Study," Toxicol. Appl. Pharmacal., Vol. 78, pp. 105-122.

There are se\·eral parameters associated with cancer bioassays which may
provide a qualitative concern regarding the potency of the carcinogenic
response. These parameters are described in Table 15.1. Not all qualitative
indicators of carcinogenic potency correlate well with quantitative potency
estimates (Gold et al., 1986). Many potent carcinogens, however, have been
found to cause tumors in multiple species and multiple sites, with relatively
short latency periods, and with a large proportion of malignant tumors (MUnro
and Krewski, 1981).
They have also demonstrated significant biological
activity in short-ter~ tests (Munro and Krewski, 1981).
Squire (1981) developed a quantitative ranking system for animal
carcinogens based on qualitative indicators of potency. According to his
system, qualitative indicators of carcinogenicity, such as the ones listed in
Table 15.1, are given numerical weights. The maximum score a chemical could
receive is 100. Recommended regulatory actions would become progressively
more severe as the numerical ranking becomes closer to 100. A score of 100,
for example, may be very likely to result in a recommendation to ban the
chemical. Although this system does not directly translate bioassay result
into a measure of a human cancer risk level, it does provide a method for
assessing the relative potencies of carcinogens based on qualitative
considerations.
At the present time, however, this quantitative approach
appears to be too arbitrary for risk assessment purposes.
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Qualitative criteria have also been developed for comparing the relative
severities of developmental effects. The severity of the effects generally
follows the paradigm established by Wilson (1973): in order of increasing
potency, effects range from revers~ble embryotoxici ty and fetotoxici ty, to
teratogenicity, to fetal death. Severity indices for developmental effects
can be derived by taking the logarithm of the ratio between the lowest adult
toxic (or lethal) dose and the lowest developmental dose (NRC, 1986).
Finally, indices have been developed from which chemicals can be compared
on the basis of their acute or chronic toxicity. For example', indices which
compare relative general toxicity potencies have been developed by several
regulatory agencies (USEPA, 1981). A summary of these systems is presented in
Table 15.2.
While this table only includes values based on oral and
inhalation exposure, criteria regarding dermal exposures have also been
established (USEPA, 1981), and should be followed accordingly. Criteria for
evaluating the severity of an acute/chronic effect have been developed by the
Massachusetts Department of Envirorunental Quality Engineering (MDEQE, 1985),
and are presented in Table 15.3.
15.3 Evaluation of the Evidence Regarding Mechanisms of Action.
Ideally, all of the toxicological effects identified in the Hazard
Identification section should be explained by some sort of biochemical
mechanism.
The extent to which these mechanisms can be derived from
scientific studies is limited by an incomplete understanding of normal
biological processes, and by an incomplete understanding of the biochemical
Therefore, an adequate
processes leading to chemically-induced illness.
understanding of the toxicological mechanisms is not a prerequisite to the
assessment of chemically-induced adverse health effects.
When sufficient data are available to describe the mechanism of action,
however, they can provide a sound scientific basis for interpreting the
results of the health effects studies. This information can also represent a
starting point for evaluating the effects of a large number of chemicals on a
particular health parameter.
Furthermore, it may provide the basis for
predicting how certain chemicals may interact with one another. As important
and promising as information regarding the mechanism of action can be to risk
assessment, it should be used with caution.
Specifically, hypotheses
regarding mechanisms of action should not be used to discount the findings of
well conducted toxicological or epidemiological studies, unless there is
reasonable certainty that t~~ toxic effect only occurs throu~~ those
mechanisms.
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Table 15.1.
Important Characteristics of Carcinogenic Potency.

a)

b)
c)
d)
e)

f)
g)
h)
i)
j)

k)

The proportion of animals bearing neoplasms at each exposure level.
The nunber of neoplasms per animal.
The number of different types of neoplasm.
The nunber of species affected.
The magnitude of the dose at which the carcinogen~c response occurs.
The proportion of malignant and benign lesions.
The nature and degree of other pathological cr~nges.
The organ or target tissue in which the carcinogenic response occurs.
It should be recognized that an increase in the number of tumors of a
type which occurs spontaneous 1y in a high proportion of the strain of
animal being used (e.g., liver tumors or pulmonary adenomas in certain
strains of mice) carries less weight in the estimation of potency than
does the appearance of tumors in other organs.
The latency period before tumor development.
The shorter the latency
period the more potent is the chemical.
The sensitivity of the experimental model.
G1emical similarity to other kno~u carcinogens.
GEnetic toxicity and activity in short-tenn tests for carcinogenicity.
Biochemical reactivity with DNA, R~A, am protein.
Further infonnatior: obtained from othtr toxicological studies such as
kinetic am metabolic data.
The significance of these in the
estima.tion of potency to man is not clear in every case. Fundamental
differences in genetic make-up bet·ween animaJs am man, which can lead
to wide variations in response to the action of chemicals, inclu:ie
differences in illiDune arrl hormonal status, among others.

Sources:
Munro, I .C., and Krewski, D. R., 1981, "Risk Assessment and
Regulatory Decision Making,"
Food ·cosmetic Toxicol., Vol. 19, p. 556;
Purchase, I.F.H., 1985, "CarcfiiO'gen1c R1sk Assessment:
A Toxicologist's
View," in D.G. Hoel et al. (eds.), Risk Quantification and Regulatory Policy,
Cold Spring Harbor Laboratory, pp. lsr=f82.
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Table 15.2
Acute Toxicity Tests for Selected Federal Regulatory Programs

CATEGORY A:

Mists, IA.lsts, and Fumes

OSHA

Highlr Toxic

if. ITA

Poison A or B

F.HSA

Highly Toxic

FIFRA

Toxic

IV

I

RCRA

Acutel~

Hazardous
.2

.02

CATEGORY B:

Toxic

2

20

200

LCso(mg/L)

Vapors and Gases

OSHA

Highly
Toxic

FHSA

Highly
Toxic

Toxic I
Toxic

Hazardous
20
CATEGORY C:

200

2000

20,000

2oo,ooo

LCso(ppm)

Oral Toxicity

Highly
Toxic

OSHA

Toxic

Poison

~ITA

A or B

FIFRA

I

IV

Hazardous

Rc:M

Acutely
Hazardous

s
OSHA
H-ITA
FHSA

FIFRA
CWA
RCRA

50

500

5000

so,ooo

LDso (mg/kg)

Occupational Safety and Health Act
Hazardous ~~terials Transportation Act
Federal Hazardous Sustances Act
Federal Insecticide, Fungicide, and Rodenticide Act
Clean Water Act
Resource Conservation and Recovery Act

Source; USEPA (U.S.
Environmental Protection Agency),
1981, Chemical
Substances Designation, Vol. I: Overview and Analysis, Washington, D.C., pp

108-109.
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Table 15.3.
Severity Ranking for Acute/Chronic Effects
One Point:

Mild or Transient Irritant Effects (e.g. runny nose,
eye irritation, coughing).

Two Points:

MOderate to Severe Irritant Effects; Mild to Moderate
Transient
systemic
effects;
effects
generally
considered to be reversible (e.g., bronchitis,
anoxia,
incoordination,
fatigue,
dizziness,
reversible kidney effects).

Three Points:

Irreversible Pulmonary Effects; Serious Systemic
Effects; chronic or persistent effects; cumulative
effects; effects involving multiple sites or organ
systems
(e.g.,
cirrhosis,
emphysema,
epilepsy,
peripheral nerve damage).

Source:
MDEQE
(Massachusetts
Department
of
Environmental
Quality
Engineering),
1985,
Chemical
Health
Effects
Assessment Methodology,
Massachusetts Department of Environmental Quality Engineering, Boston, Mass.,
p. 99.

15.4 Weight of Evidence Determinations.
Weight of evidence refers to likelihood that particular health effects
occur in human populations as a result of chemical exposure. Weight of
evidence determinations do not directly consider potency.
Rather, they
determine the data adequacy concerning the association between toxic substance
exposure and a particular adverse health effect. Judgments are made with
respect to both human and animal studies, and can be classified as
"sufficient," "limited," "inconclusive," "inadequate," or "negative." These
judgments, therefore, reflect the conclusions made in the evaluation of
individual studies (See Chapter 5.1).
The weight of evidence from epidemiological and toxicological studies
increases with the strength of the association, the presence of a
dose-response relationship, and the number and proportion of corroborating
studies. Replicated studies reduce the possibility that apparently positive
results were observed by chance alone. Replicated studies done by different
investigators further add to the weight of evidence by addressing any
intralaboratory biases. The strongest evidence is derived from studies on
human populations. With respect to animal studies, if an effect can be
induced in different sexes, strains, or species, the likelihood that the
effect will also occur in human populations is increased. In vitro studies
are also used in weight of evidence determinations. Generally, they are used
as evidence in support of epidemiological or toxicological studies. They are
useful when assessing similarities in activity among structurally related
compounds or in postulating possible mechanisms of action.
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For all health effects, weight of evidence determinations should
distinguish between primary effects and secondary effects which may result
from an initial toxic effect on the cell. These determinations also need to
consider the possibility that significant toxicity may prevent the effect of
concern from being detectable or becoming manifest. Preliminary assays in
genetic toxicity experiments should be able to determine substance dose levels
which result in significant cytotoxicity (WHO, 1985). Likewise, subchronic
assays should be run to determine maximum tolerated doses for cancer bioassays
and maternally toxic doses for experiments on developmental toxicitye

15.4.1

Genetic Toxicity.

Weight of evidence for genetic toxicity refers to the likelihood that
exposure to a chemical will result in some sort of DNA damage. The weight of
evidence increases as the test systems showing a positive response more
closely reflect actual human exposures.
Within this context, two issues
warrant special consideration. The first issue concerns the preference for
experimental conditions which reflect the response of the entire organism, as
opposed to the response of cells cultured in vitro. This preference is based
on the fact that there are physiological fi:lfluences on toxicity which cannot
be studied in vitro.
The second issue concerns the preference for species most closely related
phylogenetically to human beings. This preference is based on the fact that
potential differences in cell biology may exist which could lead to misleading
interpretations of the test results.
Of particular importance is the
difference between procaryotic and eucaryotic cell types. Eucaryotes differ
from procaryotes with respect to many characteristics.
For example,
eucaryotic cells contain a nuclear membrane, have multiple chromosomes, have
histones bound to these chromosomes, have large numbers of repetitive
nucleotide sequences, divide by mitosis, and contain several organelles such
as lysosomes (Calabrese, 1983; Stanier et al., 1976). These differences could
account for significant variations in the responses of these two cell types to
genetic toxins.
Eucaryotic organisms may also differ in their responses to genetic
toxins. For example, human beings exhibit substantially greater DNA exc1s1on
repair capacity than do rodents (Calabrese, 1983). On the other hand, human
peripheral lymphocytic chromosomes have been found to be twice as sensitive
than those of mice to the induction of translocations by ionizing radiation
(Calabrese, 1983). Techniques to directly and accurately measure the effects
of suspected genetic toxins on human populations are currently being
developed, and may soon be available for widespread use (Thilly and Call,
1986; OTA, 1986).
In addition to the overall preference for phylogenetic closeness and in
vivo experiments, findings from all well conducted experiments should be
exa'iiiined for reproducibility, a consistent dose-response curve, and the type
of genetic lesion produced (WHO, 1985). Whole animal experiments may lack
sufficient sensitivity for detecting potentially genotoxic compounds, despite
the fact that these experiments consider in vivo conditions (WHO, 1985).
Furthermore, although reflective of responses--In procaryotic organisms,
results from bacterial assays correlate strongly with known carcinogens and
non-carcinogens in eucaryotic organisms (MCCann et al., 1975; Purchase et al.,
1978).
McCann et al. (1975) found that approximately 90 percent of
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carcinogens were also bacterial mutagens and that 90 percent of
non-carcinogens failed to show mutagenic activity, when Salmonella typhimurium
was used as the test organism. These findings were corroborated by Purchase
et al. (1978). The ability of the Salmonella assay to detect carcinogens may
even be greater if certain classes of compounds are excluded (OTA, 1981).
This high degree of correlation has been recently questioned, as more
chemicals have been tested and found not to conform to this paradigm (Tennant
et al., 1987). Nonetheless, the correspondence between the Salmonella assay
and the animal cancer bioassay findings reinforces the need to consider
bacterial assays in carcinogenicity assessments.
Conversely, a lack of
mutagenicity in the bacterial assays should not necessarily alter the weight
of evidence conclusions drawn from well conducted animal bioassays.
The Massachusetts Department of Environmental Quality Engineering
developed weight of evidence guidelines based on various national and
international risk assessment committees (MDEQE, 1985). These guidelines are
presented in Table 15.4, with expanded documentation presented in Table 15.5.
While the U.S. Environmental Protection Agency has no specific reco~~endations
for the evaluation of mutagenicity test results relevant to chronic diseases
such as cancer (USEPA, 1986a), it has developed guidelines relating
specifically to germ cell mutations (USEPA, 1986b). These guidelines are
presented in Table 15.6.
A separate weight of evidence determination for genetic toxicity may be
unnecessary when positive toxicological or epidemiological data are available
on carcinogenicity, developmental toxicity, and other potentially relevant
chronic effects. In the absence of such information regarding these effects,
the guidelines presented above provide a useful basis for making weight of
evidence determinations regarding genetic toxicity. The presentation of this
evidence should also be accompanied by statement regarding the level of
testing.
By doing so,
the assessment
could distinguish between
classifications based on the weighing of positive and negative results and
those based on lack of data.
15.4.2

Carcinogenicity.

The weight of evidence determination for tarcinogenici ty concerns \vhether
or not a substance can be considered as a human carcinogen. Epidemiological
studies and animal bioassays are the primary areas of investigation from which
weight of evidence determinations are made. Both areas, however, are subject
to limitations regarding their abilities to demonstrate causal connections
Epidemiological studies have
between human exposure and carcinogenesis.
limited abilities to rigorously characterize exposed and non-exposed
populations, to identify enough of these individuals to produce statistically
meaningful results, and to separate the potential effects of a particular
substance from those of other risk factors. Studies designed to address these
obstacles generally require large amounts of time and resources to follow
study populations over time.
Animal bioassays are limited by the fact that they are not direct
qualitative or quantitative measures of a human response. Such limitations
are becoming increasingly relevant in light of the growing numbers of
chemicals identified in the animal studies as being potentially carcinogenic.
Only about 30 chemicals or chemically-related processes have been positively
associated with human cancer, while a few hundred have been found to be
carcinogenic in laboratory animals (IARC, 1982; NTP, 1985).
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Table 15.4
Scoring for Mutagenicity According to the MDEQE'S Chemical Health
Effects Assessment Methodology

Category

Letter
Code
Score

Test Type and Number of Positive
Results
Group I:

Two or More

A.

-~------ or ---------------------------------

i

Sufficient
Evidence

!

!

I
I

I Substantial
i Evidence
l

l
I

Group I I:
Four or More
A
-------- or --------------------------------Group III:
Six or More
A.
-------- or --------------------------------Group I:
One
-------- and ~-------------------------------·
A.
Group I I:
One or More
·
-------- or ----------------------------------------Group I:
One
-------- and --------------------------------•
A.
Group II I :
Two
:
One
B
Group I:
-------- or ----------------------------------------Group II:
Three
i B
-------- or ----------------------------------------Group III:
FourorFive
! B
-------- or ----------------------------------------Group II:
One or Two
i
and ---------------------------------.,
B
Group I II:
Three
i
------- e

I

----------~----------------------------~~----1

r

Suggestive
Evidence

I,

Group II:
Ole or Two
I C
--------or ---------------------------------J-------1
Group III:
Two or Three
C
I
-------- or ---------------------------------·------- j

I

~~~~-~~'and
~~-~~-~~----------------------1
C I
Group I I I:
One or Two
___j
1

Limited
Evidence

Group I II :

One

Inadequate
Evidence

No Data or Non-positive Data

!

D

:

E

~IDEQE (Massachusetts Department of Environmental Quality Engineering), 1985,
Chemical Health Effects Assessment Hethodology, Massachusetts Department of
Environmental Quality Engineering, Boston, Mass., p. 167.
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Table 15.5
Categories of MUtagenicity Tests Used in MDEQE'S
Weight of Evidence Protocol
, TEST DESCRIPTION/WE

Group I:

Mammalian, In Vivo

Mouse Specific Locus Test
Mouse Spot Test
Dom1nant Skeletal Mutation
Dominant Cataract Assay
Dominant Lethal Test - Rodents
Heritable Translocation Test - Rodents
Micronucleus Test - Mouse
Group II:

Primary Short-Term Tests

Chinese Hamster LunQ (V79) Cells, All Loci
Chinese Hamster Ovacy (CHO) Cells
Mouse Lymphoma (LS178Y) Cells, TK Locus
S. typhimurium, histidine reversion (Ames Test - TA98, Tl\100, TA1535, Tl\1537-8)
E. coli (WP2/WP2 uvra) - reverse mutation
Sex-Linked Recessive Lethal Test - Drosophila m.
Host-~ediated Assay Studies
Mammalian Cytogenetics, bone marrow/lymphocyte or leucocyte
Ma~~alian Cytogenetics, oocyte, early err:]ryo/male germ cell
Mammalian Cytogenetics, lymphocyte, leucocyte/cell culture
Mammalian Cytogenetics, all mammalian
!>1icronucleus Test, 1ymphocyte
Micronucleus Test, mammalian cell
Heretible (reciprocal) Translocation Test - Drosophila
Sister Chromatid Exchange - lymphocyte
Sister Chromatid Exchange- cells/embryonic lung fibroblasts (WI-38)/lymphocyte
Sister Chromatid Exchange - in vivo/in vitro
A. nidulans - cross over studies
S. cerevisiae, homozygous - recombination/gene conversion
E. coli pol A (~3110-P3478) - with 59/without 59
B. subtilis rec (H17-~5/17A4ST) - spot test
Human Sperm Morphology
Cell Transformation Studies - B.UB/C-3T3 I C3H/10Tl/2
Cell Transformation Studies - mouse prostate
Cell Transformation Studies - Syrian hamster embryo
Cell Transformation Studies - SA7 Fischer rat cells
Group II I: Secondary Short-Term Tests
Forward/Reverse Mutation, S. cerevisiae (YEF/YER) &S. pombe (YEY/YEZ)
Fon.-ard/Reverse Mutation, 1\. nidulans
Forward/Reverse Mutation, N. crassa
Plant Gene Mutation Studies
Body Fluid Ass1y - urine
Aneuploidy Studies, whole sex chromosome - loss/~ain
Aneuploidy Studies, S. cerevisiae/ A. nidulans/ N. crassa
Micronucleus Test - plants
Plant Chromosome Studies
Mammalian Sperm ~orphology - mouse/rabhit/rat
Mammalian Sperm Morphology - mouse Fl assay
Unscheduled DNA Synthesis - human diploid fibroblast
Unscheduled DNA Synthesis - mouse germ cells
Unsch~duled DNA Synthesis - rat primary hepatocyte

Source: MDEQE (M:l.ssaChusetts Department of Environmental Quality Ei-lg1neering)
1985, Chemical Health Effects Assessment Methodology, Massachusetts Department
of Envirorunental Quality Engineering, Boston, Mass., p. 161.
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Table 15.6
Weight of Evidence Hierarchy for Germ Cell Mutations.

1. Positive data derived from human germ-cell mutagenicity studies, when
available, will constitute the highest level of evidence for human
mutagenicity.
2. Valid positive results from studies on heritable mutational events (of any
kind) in mammalian germ cells.
3. Valid positive results from mammalian germ-cell chromosome aberration
studies that do not include an intergeneration test.
4. Sufficient evidence for a chemical's interaction with
cells, together with valid positive mutagenicity test results
systems, at least one of which is mammalian (in vitro or
positive results may both be for gene mutations or both
aberrations; if one is for gene mutations and the other
aberrations, both must be from mammalian systems.

mammalian germ
from two assay
in vivo). The
l:or~romosome

for chromosome

5. Suggestive evidence for a chemical's interaction with mammalian germ
cells, together with valid positive mutagenicity evidence from two assay
systems as described under 4, above. Alternatively, positive mutagenicity
evidence of less strength than defined under 4, above, when combined with
sufficient evidence for a chemical's interaction with mammalian germ cells.
6. Positive mutagenicity test results of less strength than defined under 4,
combined with suggestive evidence for a chemical's interaction with mammalian
germ cells.
7. Although definitive proof of non-mutagenicity is not possible, a chemical
could be classified operationally as a non-mutagen for human germ cells, if it
gives valid negative test results for all endpoints of con~ern.

8. Inadequate evidence bearing on either mutagenicity or chemical interaction
with mammalian germ cells.

Source: USEPA (U.S. Environmental Protection Agency). 1986b, "Guidelines for
Mutagenicity Risk Assessment," Federal Register, Vol. 51, pp. 34005-34012.
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According to the u. S. Environmental Protection Agency (USEPA, 1986a) and
the International Agency for Research on Cancer (!ARC, 1982), in the absence
of adequate human evidence, a chemical which is found to cause cancer in
laboratory animals should be presumed to cause cancer in human beings as
well. The strength of the association, however, depends on the weight given
to the animal studies and to the negative epidemiological studies. Criteria
for assessing the weight of evidence for chemical carcinogens have been
developed by both agencies (USEPA, 1986a; !ARC, 1987; !ARC, 1982). The two
classification systems are very similar, especially" when the USEPA criteria
are compared with the more recent !ARC criteria (!ARC, 1987). The only major
difference is that !ARC considers as limited evidence those "neoplasms which
may occur spontaneously in high incidences in certain strains," whereas USEPA
considers this evidence sufficient unless other information is available to
justify a lower classification.. The reasoning employed by the USEPA is more
consistent with the principles of worst case risk assessment than the
reasoning employed by !ARC. The USEPA criteria, therefore, are adopted by the
Maine Bureau of Health to provide general policy guidance. These USEPA
criteria for evaluating human and animal evidence are presented in Tables 15.7
and 15.8.
Three issues pertaining to these criteria require special attention. The
first issue concerns the criteria which must be met before a causal
association can be inferred from epidemiological studies. Again according to
the U. S. Environmental Protection Agency (USEPA, 1986b) and the International
Agency for Research on Cancer (!ARC, 1982), three criteria must be met : (1)
there is no identified bias which could explain the association, (2) the
possibility of confounding has been considered and ruled out as explaining the
association, and (3) the association is unlikely to be due to chance.
The second issue concerns the ·distinction between benign and malignant
tumors in animal studies. Although USEPA and !ARC placed specific emphasis on
the presence of malignant tumors, this distinction may only be warranted in
special circumstances. No chemical has yet been identified that produces only
benign neoplasms (Williams and Weisburger, 1986). Also, many chemicals which
induce primarily benign tumors in one species or strain induce malignant
tumors in other species or strains (CDHS, 1985). Furthermore, truly benign
tumors in rodents are consider to be rare and may actually represent· a stage
in the progression to malignant tumors (OSTP, 1985). Finally, !ARC has stated
that the discrimination between benign and malignant tumors is not as
important an issue as it was once considered to be (!ARC, 1980). Thus, the
incidence of only benign tumors should be·considered as evidence in support of
the presumption of human carcinogenicity. When benign and malignant tumors
appear together, their incidences may be combined, subject to established
guidelines (NTP, 1984).
The third issue concerns the occurrence of false positives in animal
studies. Typical bioassay protocols require analysis of 20 to 30 sites in
both sexes of two species at two dosage levels (OSTP, 1985). The possibility
needs to be addressed, therefore, that a statistically significant response
may occur by chance. For a random binomial distribution in which 20 sites are
evaluated at a 0.05 significance level, the probability of a false positive is
about 0.64 for a single dose-sex-species combination, and about 0.87 for both
sexes (Gart et al., 1979). Tests done at multiple doses yield even larger
probabilities for false positives, according to this random distribution
assumption (Gart et al., 1979). This argument has been criticized, however,
on the grounds that the bioassay data represent counts, not continuous data
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Assessment of Evidence for Carcinogenicity from Studies in Human Beings
i. Sufficient evidence of carcinogemClty, which iMicates that there
is a causal relat1onsh1p between the agent and human cancer.
ii. Limited evidence of carcinogenicity, which indicates that a causal
interpretation 1s credible, but that alternative explanations, such as chance,
bias, or confounding, could not adequately be excluded.
iii. Inade~ate evidence, which indicates that one of three conditions
prevailed: (a) ~ere were few pertinent data; (b) the available studies, while
showing evidence of association, did not exclude chance, bias, or confounding,
and therefore a causal interpretation is not credible.
iv. No Data, which indicates that data are not available.
v. No EVIdence, which ir¥iicates that no association was foum between
exposure ana an 1ncreased risk. of cancer in well-designed and well-conducted
independent analytical epidemiological studies.

Source: USEPA (U.S. Environmental Protection Agency). 1986a, "Guidelines for
Carcinogen Risk Assessment," Federal Register, Vol. 51, pp. 33991-34003.
Adapted from: IARC (International Agency for Research on Cancer), 1982,
Chemicals, Industrial Processes and Industries Associated with Cancer in
Humans, !ARC Monographs Supplement 4,Lyon, France. 292 pp.

Table 15.8
Assessment of Evidence for Carcinogenicity from Studies in Experimental

-~imals

i. Sufficient evidence of carcinogenicity, which indicates that there
is an increased Incwence of malignant ttJDours or canbined malignant anJ
benign tumors:
(a) in multiple species or .st_rains;. or (b). in ~ultiple
experiments (e.g, with different routes of adm1nlstrat1on ?r ~s1ng different
dose levels); or (c) to an unusual degree with regard to 1nc1dence, s1te or
type of tumour, or age at onset. Additional evidence may be provided by data
on dose-response effects, as well as information from short-term tests or on
chemical structure.
11. Limited evidence of carcinogenicity, which means that the data
suggest a carc1nogen1c effect but are ~imited because:
(a) the s~udi~s
involve a single species, strain or expenment and do not meet the en ten a
for sufficient evidence described in i(c); (b) the experiments are restricted
by inadequate dosage levels, inade~ate .duration of ex~sure to t.he agent,
-·inade~ate period of follow-up, poor surVlva1, too few ammals, or Inadequate
reporting; or (c) an increase in the ~ncid~nc~ of benign tumors only.
.
iii.
Inadecpate evidence~ w!'nch 1nd1cate.s that becau.se of maJor
q.~alitative or quantltatlve hmltatlons, the st~d1es ~annot be 1nterpreted as
showing either the presence or absence of a carc1nogen1c effect.
iv. No data, which indicates that data are not available.
v. No evr<Ience, which indicates that there is no increased incidence of
neoplasms Tn at least two well-designed and well-conducted animal studies in
different species.

Source: USEPA (U.S. Environmental Protection Agency). 1986a, "Guidelines for
Carcinogen Risk Assessment," Federal Register, Vol. 51, pp. 33991-34003.
Adapted from: IARC (International Agency for Research on Cancer), 1982
Chemicals, Industrial Processes and Industries Associated with Cancer i~
!±:.01ans, IARC ~bnographs Supplement 4,Lyon, France. 292 pp.
c
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(OSTP, 198S; Gart et al., 1979). When the nature of the _bioassay data is
considered, many investigators believe that the overall false positive rate
does not greatly exceed O.OS (Gart et al., 1979; OSTP, 198S). One reason for
this concerns the background rate of tumor formation in laboratory animals.
There are relatively few sites in commonly treated laboratory animals for
which enough tumor bearing animals would be observed so that one could find by
chance alone a significantly increased tumor incidence at the O.OS level (Gart
et al., 1979). For these sites (for example, those sites with background
tumor rates above S percent), certain considerations may apply to ensure that
the elevated response did not occur by chance. These include the requirement
of corroboration of the response from other bioassays, or the imposition of a
more stringent significance level. Haseman (198S), for example, recommended
that a chemical be regarded as carcinogenic if it produces a high dose
increase in a common tumor that is statistically significant at the 0. 01
level, or a high dose increase in in an uncommon tumor that is statistically
significant at the 0 .OS level. Another recommendation is the use of the
Bonferroni correction, which divides the significance level by the number of
dose groups (Gart, 1979). According to this modification, if the significance
level for an elevated tumor response in a one dose experiment is 0 .OS, the
significance level for an elevated tumor response in a two dose experiment
would be 0.02S. Such adaptations to statitistical tests should be considered
when evaluating the likelihood of a false positive finding in a bioassay.
In addition to the criteria developed for evaluating human and animal
evidence, criteria have also been developed by the U. S. Environmental
Protection Agency (USEPA, 1986a) and the International Agency for Research on
Cancer (Vaino, 1987) to determine the overall weight of evidence criteria
regarding a substance's human carcinogenic potential. These classification
systems, which are presented in Tables lS .9 and lS .10, rely largely on the
criteria which were developed for evaluating human and animal evidence.
Overall, the IARC classification system appears to place less weight on the
animal evidence than does the USEPA. Both systems, however, are designed to
be flexible in order to incorporate other relevant data into the weight of
evidence determination.
It is, therefore, difficult to establish precisely
how various substances will be evaluated according to these different·
classification systems.
Although useful to a cancer policy, the guidance provided by the weight of
evidence criteria just described may still not address all concerns relevant
to a proper determination of human carcinogenic potential. Criteria are
needed to help avoid arbitrary judgments. They can provide the assessment
process with a basis for deciding which chemicals clearly should or should not
be considered as human carcinogens. Often, however, the carcinogenicity data
bases associated with a particular substance are not easily amenable to strict
classification. A thorough analysis of the data is generally required in
these situations.

lS-lS

(88)

* Quoting the USEPA, "the above assignments are presented for illustrative
purposes. There may be nuances in the classification of both animal and human
data indicating that different categorizations than those given in the table
should be assigned. Furthermore, these assignments are tentative and may be
In this regard all relevant information
modified by ancillary evidence.
should be evaluated to determine if the designation of the overall weight of
evidence needs to be modified. Relevant factors to be included along with the
tumor data from human and animal studies include structure-activity
relationships, short-term test findings, results of appropriate physiological,
biochemical, and toxicological observations, and comparative metabolism and
pharmacokinetic studies. The nature of these findings may cause an adjustment
of the overall categorization of the weight of evidence."
Group A Human Carcinogen
Group B Probable Human Carcinogen
Group Bl - Reserved for agents for which there is limited evidence of carcinogenicity from epidemiologic studies.
Group B2 - Reserved for agents for which there is sufficient evidence from
animal studies and for which there is inadequate evidence, or no
data from epidemiologic studies.
Group C Possible Human Carcinogen
Group D Not Classifiable as to Human Carcinogenicity
GroupE Evidence_of Non-Carcinogenicity for Humans

Source: USEPA (U.S. Environmental Protection A.gency). 1986a, "Guidelines for
Carcinogen Risk Assessment," Federal Register, Vol. 51, pp. 33991-34003.
15-16

(88)

Table 15.10
IARC Classification System for Assessing the Overall Weight of
Evidence for Human Carcinogenicity

Strength of Evidence from Animal Studies
Sufficient
Strength

Limited

Inadequate

No Data

Negative

Sufficient

1

1

1

1

1

Limited

2A

2A*/2B

2A*/2B

2A*/2B

2A*/2B

Inadequate

2A**/2B

zB+/3

3

3

3/4+

No Data

2A**/2B

zB+/3

3

3

3/4+

3

3/4+

3/4+

4

of
Evidence
from
Human
Studies
Negative

3

* = "exceptionally" solely on the basis of limited evidence in humans.
** = "exceptionally" when strengthened by supporting relevant data.
+ = "in some circumstances" when strengthened by supporting relevant data.
Group
Group
Group
Group
Group

1
2A
2B
3
4

Carcinogenic to Humans
Probably Carcinogenic to Humans
Possibly Carcinogenic to Humans
Not Classifiable as to its Carcinogenicity to Humans
Probably not Carcinogenic to Humans

Source:
H. Vaino, Chief, Unit of Carcinogen Identification and Evaluation,
International Agency for Research on Cancer,
Letter to Elizabeth Bourque,
Massachusetts Department of Public Health, January 20, 1987.
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15.4.3

Reproductive and Developmental Toxicity.

The weight of evidence determination for reproductive effects concerns
whether or not a substance can be considered as a human reproductive toxin. A
similar determination is made regarding developmental effects.
These
determinations rely primarily on evidence from animal studies, as reproductive
and developmental toxicity endpoints have been inadequately monitored in human
populations (Workshop, 1986; Dixon, 1986).
In contrast to the weight of
evidence determinations for carcinogenicity, no international or federal
criteria exist to evaluate the weight of evidence regarding these effects. As
a general principle, a substance associated with a significant increase in a
developmental effect in any well conducted animal bioassay should indicate a
human health concern. Furthermore, the substance should be considered as a
human reproductive or developmental toxin unless it can be adequately
demonstrated that the response occurred by chance or that the observed
response is not relevant to human risk assessment.
The probability that an adverse reproductive outcome occurred by chance
depends in part on the number of endpoints evaluated. Although a general
consideration for the evaluation of all health effects, chance occurrence is
particularly important in relation to these effects. Several toxicological
endpoints have been identified (See Chapter 11.2 .3). Furthermore, many of
these endpoints are not independent events. Examples of this interdependency
include the relationship between fetal weight and litter size, and the
competition between teratogenicity and embryolethali ty as the dosage levels
increase.
Such considerations need to be addressed when assessing the
biological significance of elevations in adverse reproductive outcomes.
When assessing the relevance of an adverse reproductive or developmental
effect, the degree of consistency among the studies should also be
considered. With regard to animal studies, the strength of the association
between exposure and effect increases with the proportion of positive studies
and the severity of the response observed. Special consideration is warranted
when similar studies produce conflicting results. In the absence of adequate
data on human beings, however, positive findings from a well conducted animal
bioassay may constitute a sufficient basis for presuming that the substance
could cause adverse developmental effects in human beings.
The human data base, although generally limited, should also be considered
in the weight of evidence determination. A small number of chemicals have
been directly identified as posing reproductive or developmental risks to
human beings (See, for example, Schardein, 1985; Dixon, 1986). Also, although
laboratory animals may be considered sufficiently sensitive as far as
detecting potential human teratogens, they may vary considerably in their
specificity to chemicals with no known human teratogenic potential. Only 28
percent of the chemicals no known human teratogenic potential were also found
to be negative in all animals tested for teratogenicity (Brown and Nigel,
1983). It is currently unknown the extent to which this reflects a true lack
of specificity in the animal models, differences in dosing regimens, or the
limited nature of the human data base for teratogens (Brown and Nigel, 1983;
IRLG, 1986; NRC, 1986). Therefore, human evidence is usually inadeqate to
negate the findings of reproductive or developmental toxicity in experimental
animals.
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15.4.4 Other Acute/Chronic Toxicity.
Weight of evidence determinations may be made for effects other than
mutagenicity, carcinogenicity, or reproductive and developmental toxicity.
Health concerns associated with exposure to toxic substances encompass more
than these three endpoints. Often, however, at tent ion is given to these
effects because they represent sensitive indicators of an adverse health
impact in response to chemical exposures.
Any substance can be toxic if it is administered at high enough doses, as
Paracelsus noted several hundred years ago. A substance may induce different
toxic responses through different mechanisms, however. Hexane, for example,
may directly cause narcosis; it may also cause peripheral neuropathy after
being metabolized
to
1,2-hexanedione
(Clayton and Clayton,
1982).
Toxicological mechanisms which are responsible for acute lethality, for
example, may not be relevant to the evaluation of subtler acute or chronic
effects (such as sensitive, but biologically significant, neurologic or
immunologic toxicity). Yet, information is not generally available regarding
the subtle, non-carcinogenic, long-term effects of chemicals on different
organ systems. This may represent a serious deficiency in the toxicological
data base for a chemical. A discussion of the weight of evidence for such
toxic interactions, therefore, should address the extent of the data base, and
the sensitivity of tests in which positive results were observed.
In the absence of adequate human evidence, the strength of the association
between exposure and a particular effect increases with the proportion of
animals showing a positive response. It should be emphasized, hov.rever, that
there is no a priori method to determine whether or not a response in a
laboratory an1mal IS Indicative of a human response. As with the assessment
of carcinogenic or developmental effects, animal models may differ markedly in
their abilities to identify acute or chronic effects in human beings (Connelly
and Bridges, 1986). While it is possible that a substance may produce an
effect in laboratory animals which is not relevant to human beings, it is also
possible that several, if not all, of the animals tested may not be as
susceptible as human beings to a chemical exposure. Examples of cases in
which animal models have failed to predict human responses are presented in
Table 15.11.
Unless there is sufficient information to the contrary,
therefore, it must be assumed that human beings are at least as susceptible as
the most susceptible animal species to chemical exposure effects.
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Table 15.11
Some Failures in Laboratory Species to Predict Human Toxicity

Toxic Outcome Observed
in Human Beings
Azauracil
Benzene
Clioquinol
Dinitrophenol
Napthylamine
Oral Contraceptives
Practalol
Thalid_omide
TCDD

CNS Disturbances
Leukemia
Eye Lesions
Cataracts
Bladder Cancer
Thrombosis
Skin, Eye, Intestinal Lesions
Fetal Abnormalities
Chloracne
Mouse

Laboratory Species
Testing Negative
All Mammals Tested
All Mammals Tested
All Mammals Tested
All Mammals Tested
Rats and Rabbits
All Species Tested
All Species Tested
Most Rat Strains
All but Hairless

Source: Connelly, J . C., and Bridges, J.W . , 1986, "Species Variation in Target
Organ Toxicity," in G.M. Cohen (ed.), Target Organ Toxicity, Vol. I, CRC Press
Boca Raton, FL, p. 91.
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16.

Quantitative Evaluation of Dose-Response Relationships.

The quantitative evaluation of the dose-response relationships focuses on
those studies which can quantitatively correlate health effects with
exposure. First, criteria are needed in order to determine which studies are
adequate for quantitative risk assessment. Also, procedures are needed to
estimate equivalent doses when the quantitative assessment involves
extrapolations between species or between different exposure regimens. The
remainder of the quantitative evaluation is concerned with the derivation of
action levels. Action levels are derived from studies on relatively small
populations of human beings or laboratory animals, but are expected to
represent quantitative indices of health concern for the entire population.
Therefore, consideration should be given to the intraspecies and interspecies
variability in toxicity.
This consideration is addressed through two
approaches: 1) the application of uncertainty factors to the data in the
experimental range and 2) low dose extrapolation of the dose-response curve by
using mathematical models.
16.1

Selection of Studies for Quantitative Risk Assessment.

Once a weight of evidence determination has found that there is a positive
association between chemical exposure and a particular health effect, an
assessment of the degree of associated health hazard as a function of exposure
dose should be conducted. Before a quantitative assessment can be done,
however, a determination has to be made regarding which of the studies can be
used in this assessment.
Selection criteria should consider two risk
assessment policy objectives: 1) the need for the assessment to provide
conservative, worst-case risk estimates in the face of scientific uncertainty,
and 2) the need for the assessment to reflect the best scientific
understanding of the issue.
The first objective is addressed by selecting the studies which show the
most sensitive toxic responses, and by selecting the experimental groups which
are the most susceptible to exposure related effects. Identification and
quantification of subtle effects reduces the uncertainty in the estimation of
action levels. Basing the risk estimates on the most susceptible experimental
group reduces the likelihood that the response in human populations is
underestimated. The second objective is addressed by selecting studies which
are superior in terms of design and conduct, which most closely reflect or
predict the human responses, which are most applicable to the exposure route
of concern, and which provide the best quantitative estimates of
dose-response. · The need to consider these two policy objective often results
in the selection of multiple studies relevant to a specific health effect. It
is a matter of scientific judgment as to which of the resulting risk estimates
is the most appropriate for the characterization of human health risks.
Situations often arise in which no studies on a particular substance are
considered adequate for quantitative risk assessment. In these cases, risk
characterization must rely solely on qualitative considerations. Default
action levels, based on the presumption that public health risks should be
kept to a minimum when data are inadequate to evaluate risks, may be developed
for these substances. These action levels may lack the scientific
justification necessary to be considered in a risk assessment policy. They
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should, nonetheless, be considered within the context of an overall public
health policy.
16.2

Calculation of Equivalent Exposure Units.

In order for toxic effects to be precisely compared quantitatively,
equivalent dose units have to be derived between the test population and the
human population of concern.
The most direct measure of chemical dose
involves the concentration of either the chemical or its toxic metabolite of
the chemical at a site of action. Often, however, data are insufficient to
calculate this value for either population, and surrogate estimates need to be
derived. Such surrogates may be the administered·dose, the absorbed dose, the
absorbed dose adjusted for interspecies differences in pharmacokinetics, or
the metabolized dose.
The administered dose of the parent chemical is frequently used as a
surrogate for the dose of the active chemical (either the parent chemical or
one or more of its metabolites) at the site of action. This dose may be
expressed in a variety of ways. Inhalation studies, for example, commonly
express administered dose in terms of a mass of chemical per unit volume of
air (e.g., mill igrams/m3) or volume of chemical per unit volume of air (e.g.
parts per million). Oral studies may express administered dose in terms of
the chemical concentration in food or water (e.g. parts per million).
A consideration in the calculation of an equivalent administered exposure
dose between the study population and the human population of concern is the
need to adjust for differences in chemical uptake. For a given concentration
of a substance in air, food, or water, the actual intake differs significantly
between human beings and laboratory animals, and between adults, children and
infants. Mimimum food, water, and air intake requirements vary in relation to
body size (Guyton, 1947; Adolph, 1949). Adjustments are therefore needed to
address the relationship between body size and intake rates.
Further
adjustments may be needed to address other factors associated with intake
differences. These include differences in activity levels, and in food and
water consumption patterns. Inhalation rates for selected human and rodent
populations are presented in Table 16.1.
Depending on the comparisons
required of the assessment, intake parameters other than those listed in Table
16.2 may need to be considered as well.
With this information, the
administered dose can be standardized to body mass, such as the mass of
chemical administered per unit body weight per day (mg/kg/day).
While the admininstered dose is usually identified in the health effects
studies, it may not correlate well with the toxicological response. Reliance
on the administered dose may lead to imprecise estimates of human health risks
if pharmacological differences associated with different absorption or
different metabolic characteristics are not considered. The absorbed and
delivered doses may vary with the exposure routes, dose levels, or species.
Metabolic differences within species and between species may also signficantly
influence the amount of the proximal toxin that reaches the site of action.
If the proximal toxin is the parent compound, the concentration of the active
compound at the site of action decreases as metabolism increases.
If a
metabolite is the proximal toxin, the concentration of the active compound at
the site of action increases as metabolism increases.
The quantitative
association between dose and response can thus be greatly improved by efforts
to estimate the dose of the chemical actually delivered to the site of action.
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Table 16.1
Inhalation Rates for Selected Human and Rodent Populations

Population
70 Kilogram Adulta
10 Kilogram Infantb
Rat (300 grams)C
Mouse (30 grams)C

Pulmonary Ventilation
L/min
m3/day

Alveolar Ventilation
L/min
m3/day

15
2.8
0.15
0.027

10
1.9
0.10
0 . 018

22
4.0
0.22
0.039

15
2.7
0.13
0.026

a Source:

I. Astrand, 1983, "Effect of Physical Exercise on Uptake,
Distribution and Elimination of Vapors
in Man," in V.
Fiserova-Bergerova (ed.), Modeling of Inhalation Exposure to
Vapors:
Uptake, Distribution, and ~limination, Vol. 2, pp.
107-130. These calculations assume-r6 liours at rest and 8 hours at
a light activity level.

b Source:

International Commission on Radiological Protection, 1975, Report
of the Task Group on Reference Man, Pergamon Press, Oxford, p.
346.---These calculatiOns assume 14-nlours at rest and 10 hours at a
light activity level.

c Source:

A.C. Guyton, 1947, "Measurement of the Respiratory Volumes of
Laboratory Animals," Amer. J. Physiol., Vol. 150, pp. 70-77. The
allometric equation is_:__ Resp. Vol. (ml/min)

= 2.10 x Bw3/4

If information is inadequate to quantitatively estimate an absorbed or
metabolized dose for either the study population or the human population of
concern, the standardized administered dose represents the best basis from
which equivalent exposures can be derived from the available data. When
adequate, however, pharmacokinetic data may help to relate the ~dministered
dose to the absorbed dose and, further, to the dose of the active compound at
the tissue exhibiting the toxic response. For certain well studied compounds,
adequate pharmacokinetic data are available from animal studies. Frequently,
however, information is lacking from which a qualitative and quantitative
profile of human absorption and metabolism can be constructed, particularly at
environmental exposure levels.
Assumptions consistent with worst case
assessment methodologies therefore have to be made regarding the actual extent
of human absorption, distribution, and metabolism.
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In certain instances, the pharmacological and toxicological data may
indicate that a scaling factor applied to the absorbed dose is appropriate
when dose comparisons are made between species. A commonly used scaling
factor is based on interspecies differences in surface area. The typical
surface area adjustment, presented in the following equation, uniformly
reduces the weight-adjusted dosage for human beings compared with that
determined for smaller laboratory test animals (NRC, 1986).
Human Dose (mg/kg)

Animal Dose (mg/kg) x (animal bw/human bw)l/3

=

This adjustment is based on the assumption that surface area is a function of
the body weight raised to the two-thirds power. Because of differences in
body shape between animals, this allometric relationship is not a precise one
(Calabrese, 1983; Lu, 1985). It has been a useful approximation, however, in
certain clinical applications. Figure 16.1 demonstrates the effect of the
surface area adjustment on the interspecies scaling factor.
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Figure 16.1. Experimental Animal Weights Versus an Interspecies Scaling
Factor Using the Surface Area Relationship. Enclosed areas along the function
represent general ranges of average body weights of experimental animals.
Rabbit values are represented by the box with solid lines.
Source:
Dourson, M.L., and Stara, J.F., 1983, "Regulatory History and
Experimental Support of Uncertainty (Safety) Factors," Reg. Toxicol.
Pharmacol., Vol. 3, p. 229.
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The surface area- adjustment has been found to remove much of the
interspecies variability associated with the toxicity and effectiveness of
certain non-metabolizable anticancer drugs (Freireich et al., 1966; Pinkel,
1958). It also pr9duces a stronger correlation among species than a straight
body weight extrapolation with regard to several physiological parameters,
including blood flow (Ramsey and Anderson, 1984), enzyme activity (Calabrese,
1983), renal clearance (Adolph, 1949), and drug half-lives and concentrations
in plasma and tissue (Calabrese, 1983). According to the National Research
Council (NRC, 1986), for certain compounds, a specified effect level in human
beings may be estimated from the corresponding effect level in rodents after
this surface area adjustment is applied.
There are limitations, however, regarding the application of surface area
adjustments in interspecies scaling. Specific interspecies differences in
absorption, metabolism, distribution, or excretion may render the surface area
adjustment inappropriate for quantitative risk assessment.
Thus, the
adjustment should only be used when there is evidence that adjusting for _
surface area related differences would provide a better estimate of delivered
dose than alternative approaches. It is possible, for example, that a more
specific scaling factor than the general surface area adjustment may be
derived from the available information. Particularly, if the pharmacokinetic
studies show that metabolism is significantly different between the test
animals and human beings, interspecies adjustments should reflect those
differences. On the other hand, if there are no data to justify the use of a
scaling factor, estimates of delivered dose should rely estimates of absorbed
or administered dose.
Uncertainties associated with the estimation of the delivered dose of a
toxic chemical to the site of action may be reduced through the use of
pharmacokinetic modelling.
Before such modelling is accepted as the
quantitative basis for the assessment of the dose-response relationship,
however, the parameters which provide the basis for the model output should be
carefully examined. Such consideration is particularly relevant if the models
are developed primarily from animal data, or if the findings from high dose
exposures are to be applied to low dose exposure situations. Failure to
consider these differences could result in imprecise estimates of delivered
dose in the human populations of concern.
16.3 Derivation of Action Levels Using Mathematical Models.
Most risk assessment applications require the estimation of health risks
at dose levefs below those in the experimental dose ranges. Two methods are
currently used to address this issue.
The first method involves the
application of mathematical models to extrapolate the dose response curve
below the experimental range. The second method involves the application of
uncertainty factors to either the lowest observed adverse effect level (LOAEL)
or the no observed adverse effect level (NOAEL) in the study population in
order to derive and estimated no adverse effect level (ENAEL) for sensitive
human populations.

c
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Of the two low dose risk estimation approaches, the mathematical modelling
approach is preferable if the ef feet is presumed to exhibit no threshold, or
if adequate experimental data are available and enough is known about the
toxic effect to presume the shape of the dose response curve at
sub-experimental doses. This approach is preferable because it makes use of
more dose-response data. Therefore, it conforms more closely to the key risk
assessment policy objectives of considering all the available data and
ensuring that the risk assessment findings reflect the best scientific
understanding of a chemical's toxicity. When information is inadequate to
extrapolate the dose-response into the low dose region, however, the
uncertainty factor method must be employed. While the uncertainty factor
approach may not make as much use of the toxicological data as the
mathematical modelling approach, it is also true that the available
information in these situations does not permit more sophisticated risk
assessment techniques to be employed. Thus, when data are inadequate for low
dose extrapolation using mathematical models,
the best
scientific
understanding is limited to the relatively crude uncertainty factor method.
This method is described following the discussion on mathematical models.
Most practical applications of low dose mathematical modelling have
involved the estimation of cancer risks. Cancer risk assessment has relied on
this method because its non-threshold assumption is inconsistent with the
population threshold assumption implicit in the uncertainty factor method. On
the other hand, models have been developed which employ a population threshold
assumption with regard to both quantal and continuous data (Crump, 1984; NRC,
1986). These models also consider all the dose-response data and experimental
factors such as sample size. They may prove to be very useful if adequate
dose-response data are available, particularly if uncertainty exists regarding
the determination of the no observed adverse effect level. They are not
generally used at the present time, however, primarily because sufficient data
rarely exist for such an extrapolation (Dourson et al., 1986; NRC, 1977).
At the present time, carcinogenicity is the only health effect for which a
non-threshold assumption has been generally applied.
Although genetic
toxicity is also presumed exhibit no threshold, this health endpoint is not
usually employed in the derivation of action levels. Findings from laboratory
studies indicate that intrauterine death, as well as other embryotoxic
effects, follow a dose-response relationship with an apparent threshold at
some level below the experimental dose range (Wilson, 1980). Therefore, no
effect levels for developmental effects in human beings may be estimated from
the dose response data or from the application of uncertainty factors to no
observed effect or lowest observed effect levels in the animal studies (IRLG,
1986).
No criteria have been developed to determine when mathematical models can
be applied to non-carcinogenic effects data. Conversely, criteria have not
been sufficiently developed to determine when the uncertainty factor method
should be applied to carcinogenicity data. Thus, in the absence of sufficient
information to the contrary, low dose extrapolation for carcinogenicity should
involve
mathematical
modelling
while
low
dose
extrapolation
for
non-carcinogenic effects should involve the use of uncertainty factors.
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16.3.1

The Selection of the Appropriate Mathematical Model.

Two general types of mathematical models are commonly used in 10\v dose
extrapolation for carcinogenic effects:
tolerance distribution models
(including the probit, logit, and Weibull models), and mechanistic or
stochastic models (including the one-hit, multi-hit, and multi-stage models).
The tolerance distribution models are based on the assumption that each
individual in the population has his own tolerance to the substance, and that
these tolerances follow some distribution function, such as the normal
distribution. The mechanistic models are premised on the assumption that a
positive response for each aniQial is the result of the random occurrence of
one or more biological events. Although these two modelling concepts rest on
different premises, it is possible for a mechanistic argument to lead to a
tolerance distribution (USEPA, 1987). For example, the gamma multi-hit model
follows the same distribution regardless of whether one assumes a random
occurrence of "hits", or whether one assumes that each individual in the
population has a particular tolerance level to a chemical (USEPA, 1987).
Thus, the distinction between the mechanistic and tolerance distribution
models is not always clear (USEPA, 1987).
Adaptations of the tolerance distribution and mechanistic model types have
been developed for certain situations. For example, the population threshold
models mentioned above are var~ations on these models (Crump, 1984). Also,
time-to-tumor models (including the Weibull distribution, Armitage-Doll,
Hartley-Sielken models) are adapt ions of the tolerance distribution models,
with adjustments made for latency periods (Hogan and Hoel, 1982; Park and
.Snee, 1983; Munro and Krewski, 1981; Krewski et al., 1983). The time-to-tumor
models have the potential to provide more complete information regarding the
actual carcinogenic process.
Sufficient uncertainty currently . exists
regarding the ability of bioassays to consistently determine time-to-tumor,
however, that their applicability may be limited in most risk assessments
(OSTP, 1985; USEPA, 1986a).
The mechanisms of carcinogenicity are still not precisely understood,
despite an increased understanding regarding the overall initiation,
development, and progression of neoplasms. Thus, both tolerance distribution
and mechanistic models lack empirical justification. All models may fit the
experimental range generally well, although they may produce widely divergent
estimates of risk in the low dose region (USEPA, 1986a; OSTP, 1985). A
general description of the basic curves generated by low dose extrapolation
models is presented in Figure 16.2. The threshold curve (Curve A) is not
currently considered to adequately reflect the risks associated with low level
exposure to carcinogens. This conclusion may change for at least certain
carcinogens, however, when issues associated with the mechanisms of
chemically-induced carcinogenesis become better resolved. Supralinear models,
such as those conforming to Curve D, are not generally considered to be
biologically plausible (OTA, 1981). Therefore, the most commonly discussed
low dose extrapolation models are characterized by either a linear or
sublinear curve in the low dose region.
Both linear and sublinear low dose extrapolation models generate curves
which cross the origin and therefore, are consistent with a non-threshold
assumption for the population. Determ~ning the shape of the curve in the
sub-experimental range, however, requires consideration of the uncertainty
associated with the observed dose-response. Most extrapolation models depend
16-7

(88)

on few data points. Cancer bioassay· results, for example, generally include
only two data points in addition to the control. Even when adequate data are
available, extrapolation models must consider variations in individual
sensitivity. There is, therefore, uncertainty as to the true shape of the
dose-response curve. The upper 95 percent confidence limit is generally used
to estimate the upper bound on what the true dose-response relationship is.
If the normal distribution of responses in the exposed population reflects the
general population distribution, then there is only a 5 percent probability
that the response of the general population is greater than that predicted by
using the upper 95 percent confidence limit of the dose response curve.
Another concern which must be addressed when determining the shape of the
cancer dose-response curve at sub-experimental doses is whether the chemical
is acting independently or addi ti vely to the background response. Because
chemical carcinogens do not behave uniquely, it is likely that any exposure
could act in a simple additive way with background risks (Brown, 1975; Crump,
1985). Although certain studies (e.g. Russell et al., 1982) indicate that
sublinear responses to low doses of carcinogens may occur, the shape of the
dose-response curve in the low dose region is an still unresolved issue (NRC,
1986). After a review of this issue, the National Research Council has
concluded that, as a general rule, low dose extrapolation models for chemical
carcinogens should incorporate the assumption of background additivity (NRC,
1986). The assumption of additivity generally leads to the assumption of low
dose linearity as well (~linro and Krewski, 1981).
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Figure 16.2.
Four Dose-Response Relationships Postulated for Low-Dose
Extrapolation. a) Threshold; b) Probit (Sublinear); c) Linear; d) Gamma k = 0.5 (Supralinear).
Source: Tomatis, L., et al., 1982, "Experimental Studies in the Assessment of
Human Risk," in D. Shottenfeld and JeF. Fraumeni, Jr. (eds.), Cancer
Epidemiology and Prevention, W.B. Saunders Company, Philadelphia, p. 68.
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Of the mechanistic models, the multistage models are the most commonly
used and accepted (Peto, 1977; OSHA, 1980; USEPA, 1986a). Conceptually, they
are the most consistent with our current understanding of the multistage
nature of carcinogenesis (Day and Brown, 1980; Hogan and Hoel, 1982). A
specific variation of these models, the linearized multistage model,
incorporates the assumption of low dose linearity through restrictions placed
on its upper 95 percent confidence limit. The upper 95 percent confidence
limit of the dose-response curve is determined by maximizing the linear term
of the model. Of the other models, the multi-hit model is generally less
conservative than the multistage model (Munro and Krewski, 1981). It has also
been criticized as having significant practical problems with its application,
including the estimation under certain situations of a supralinear
dose-response in the low dose region (OSTP, 1985). The one-hit model is more
conservative than the multistage model, although it has been criticized·as not
adequately reflecting tumor responses in the experimental region (OSTP,
1985). A modification designed to address this shortcoming of the one hit
model is a straight linear extrapolation from the lowest observed response
rate to the background rate or origin (Hogan and Hoel, 1982; Hallenbeck and
Cunningham, 1986; Gaylor, 1985).
The only assumption needed is that the
dose-response curve from which the linear extrapolation is made is convex.
Like the one-hit model, however, the 1 inear extrapolation technique has been
criticized as not being sufficiently reflective of the observed data and for
being overly conservative and for not making use of all the available
dose-response data (Hogan and Hoel, 1982; OSTP, 1985).
The tolerance distribution models have been used in describing a variety
of toxicological phenomena. The probi t model, for example, is used in the
detemination of median lethal dose levels levels among experimental animals
(Tomatis et al., 1982). These models, therefore, may have applicability when
evaluating response patterns for threshold effects. Despite the fact that it
precisely reflects laboratory data in the observed response region, this model
tends to become very flat at low doses, and therefore predicts risk values
that are substantially lower than those calculated from the linearized
mechanistic models. An adaptation of the probit model was developed by Mantel
and Bryan (1961) to address this possible shortcoming • According to this
model, carcinogenic risks are estimated from an upper confidence limit on an
extrapolated dose-response curve with a slope of one.
Although this
modification was considered by the authors to add sufficient conservatism into
the modelling process, this may not be necessarily true.
The logit and
Weibull models generally tend to be more conservative than the probit model at
low doses, with the Wei bull model being the most conservative of the three
(USEPA, 1987).
The selection of the appropriate low dose extrapolation model for cancer
risk assessment purposes thus depends on a number of considerations. Firstly,
the selection must conform to the general risk assessment policy objectives of
adopting a conservative approach regarding scientific uncertainty, of
considering as much of the relevant available data as possible, and of
ensuring that the risk assessment findings reflect the best scientific
understanding of the chemical's toxicity.
Also, the selection should
specifically consider that the upper 95 percent confidence limit on risk be
used to account for uncertainties in the dose-response, and that the
dose-response curve be linear at low doses.
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The tolerance distribution models may not be sui table for two reasons:
they are not as conservative as the multistage model, and they may not
generate a linear dose-response curve at low doses, even if the upper 95
percent confidence limit on risk is used (MUnro a~d Krewski, 1981). With the
exception of the multi -stage model, the mechanistic models warrant concerns
because they generally do not consider all of the available dose-response
data. On the other hand, the linearized multistage model is relatively
conservative and ensures low dose linearity when risks are based on its upper
95 percent confidence limit.
Also, it considers all of the available
dose-response information and is conceptually consistent with the current
scientific understanding of the multistage process of carcinogenicity. In the
absence of sufficient to indicate the use of an alternative model for low dose
cancer risk assessment, therefore, the 1 inearized multistage model should be
selected .
Despite the widespread use of mathematical models in cancer risk
assessment, there is still considerable uncertainty concerning the role of low
level chemical exposure in the development of human cancers. For the most
part, these models rely on general curve fitting procedures with basic
assumptions concerning biological variability and the activity of carcinogens
in the sub-experimental dose range.
It is difficult, for example, to
quantitatively correlate mathematical modelling with possible biological
differences between early and late stage, genotoxic and non-genotoxic, or
chemical and biological carcinogens. It is also difficult to quantitatively
consider other potential factors such as genetic susceptibility, hormonal
balance, immunologic competence, and nutritional influences. Ongoing research
is directed towards the development of mathematical models which more closely
reflect human carcinogenesis than the current models (Armitage, 1985). Future
risk assessment policy revisions should consider these newer models within the
general policy objectives of worst case risk assessment and having the
assessments reflect the best scientific understanding of a chemical's toxicity.
16.3.2 The Determination of Appropriate Model Input Information.
Several variables concerning dose and response are required as input into
low dose extrapolation models for carcinogenesis. Specifically with· regard to
the linearized multistage model, these variables include the number of animals
per dose group (including the control group), the number of animals with the
tumor of interest in each group, the dose levels, the degree of the
polynomial, and the type of risk to be determined (extra risk or additional
risk). The process for deriving appropriat~_ dose estimates is discussed in
Chapter 16.2. Policy issues concerning the process by which appropriate
response parameters are estimated focus specifically on the proper assessement
of tumor incidence. Issues identified thus far by the Maine Bureau of Health
pertain to the selection of the appropriate biological endpoints, to
adjustments which may be necessary regarding the raw tumor incidence data, and
to the use of additional or extra risk~ Other policy issues associated with
the choice of model inputs will be incorporated into the policy if discussion
is determined to be necessary.
Selection of Appropriate Biological Endpoints. One issue associated with
the estimation-of tumor incidence in response to chemical exposure concerns
how tumors are grouped for quantitative assessment. With regard to animal
bioassays, two basic approaches are generally available. The first approach
to grouping tumors considers that cancer is a group of distinct neoplastic
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diseases, and that the endpoint of interest is the elevation of a specific
tumor type or site. According to this approach, incidence data for any tumor
site or type may be used in low dose extrapolation. The conclusion could be
made from the results of this extrapolation that the risk associated with any
specific tumor site and type should be no greater than the risk associated
with the most sensitive type/site response. The major limitation of this
approach is that the resulting risk estimates may not adequately predict the
increased incidence of any type of cancer associated with exposure to a
potential carcinogen.
On the other hand, data are generally available
regarding the tumor incidence rates at specific sites, thus making this
approach applicable for routine risk assessment purposes.
The second approach to tumor grouping considers that cancer is the
endpoint of interest and that elevation in overall cancer incidence is the
appropriate parameter for quantitatively assessing the cancer response.
Measures of this response include: 1) comparisons of total tumor bearing
animals among the exposed and control populations, and 2) the pooling of all
animals with significantly elevated tumor sites or types relative to the
untreated controls. The first measure of overall cancer response is subject
to the limitation imposed by the fact that some sites (for example, the rat
testes) have a very high background incidence. This high background incidence
could mask the significance of a treatment related effect between treated and
control populations unless, possibly, the tumor response is measured
relatively early in the study (IARC, 1980).
The limitation imposed on
quantitative assessment by tumor types with high background rates may be
overcome by using the second measure of the overall tumor response. Pooling
significantly elevated tumor sites or types is recommended by the U.S.
Environmental Protection Agency (USEPA, 1986a) and, when adequate data are
available, represents an appropriate measure of total carcinogenic risk. On
the other hand, the exact number of animals with significantly elevated tumor
responses may be difficult to determine from the bioassay data.
Pooling
should address the requirement that an animal with a significantly elevated
tumor response at multiple sites not be counted more than once. When multiple
sites are significantly elevated, information is often unavailable concerning
the incidence pattern in each animal. In addition, depending on the tumor
rates for the individual sites or types in the cGntrol animals, pooling the
data may result in a less . conservative estimate of cancer risk than an
estimate based on the most sensitive tumor response.
Cancer risk estimates derived from epidemiological studies may use both
the tumor-specific approach and the approach of pooling significantly elevated
tumors at specific sites. The issues associated with the selection of tumor
incidence data from epidemiological studies are similar to those associated
with the animal bioassays. Yet, before epidemiological data can be used in
modelling procedures, additional concerns specific to the analysis should be
addressed.
These concerns involve variations in background tumor rates
attributable to such factors as age, lifestyle, genetic make-up, and other
potentially confounding influences.
The choice of whether or not to use the specific tumor incidences depends
on the data availability. If adequate data are available to pool the tumor
incidences at specific sites, the use of these data into low dose
extrapolation models could provide an estimate of overall cancer risk. The
process of estimating overall cancer risks when adequate information is
available is consistent with basic risk assessment policy objectives.
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Inclusion of pooled data does~ not necessarily mean, however, that the
resulting cancer risks estimates are given preference to those based on tumor
specific information. Such a decision should also consider the design and
conduct of the study, the specific tumors involved, and the relative degree of
conservatism afforded by these two approaches.
Another policy issue pertaining to the quantitative evaluation of tumor
incidence is the segregation of tumors according to their stages of
development.. Given that benign tu!flors for a specific site and type usually
represent a stage in the development of malignant tumors, the incidences of
benign and malignant tumors generally should be combined in or.der to derive a
conservative estimate of potential cancer risk. On the other hand, separate
analyses of these tumor stages could provide a better understanding of the
severity of the carcinogenic response. Both combined and separate analyses,
therefore, could be complementary to each other as long as the objectives of
worst case risk assessment are fulfilled. Guidelines for combining specific
benign and malignant tumors have been developed by the National Toxicology
Program (NTP, 1984), and should be followed so that inappropriate groupings of
benign and malignant tumors can be avoided.
Adjustments of Tumor Incidence Data from Animal Bioassays. After the
appropriate biological endpoints for mathematical modelling purposes have been
determined, adjustments in the tumor incidence rates may_ sometimes be
required. An important adjustment addresses premature mortality. In light of
the latency period associated with carcinogenicity, it is possible that some
animals may die before a tumor has had a chance to develop.
Thus, \vhen
determining the actual number of animals at risk in the bioassay, these early
deaths need to be excluded. Such a consideration also applies to the analysis
of interim sacrifices, as it is unknown what proportion of the non-tumor
bearing animals would have developed tumors had they been allowed ·to live
until the end of the study. The issue of premature mortality can be most
readily addressed by elimating from the analysis all animals which died before
the appearance of the first tumor and all interim sacrifices.
Additional Risk Versus Extra Risk.
The final consideration regarding
model Input Information IS whether tJ.1e cancer risk estimates should be based
on additional risk or extra risk. The additional risk approach estimates the
cancer risk over background:
Additional Risk = P(d) - P(O).
The extra risk approach estimates the cancer risk among those individuals who
would not develop cancer in the absence of exposure to the carcinogen:
Extra Risk=

(P(d) - P(0))/(1 - P(O)).

Extra risk is used to account for tumors with high background rates relative
to the human population (for example, liver tumors in B6C3Fl mice). In these
situations, extra risk estimates should be used, as this adjustment addresses
potential inherent interspecies differences in susceptibility to cancer. When
background tumor rates in experimental animals are very low, there is little
difference between cancer risk estimates based on additional risk and extra
risk.

16-12

(88)

16.3.3

Presentation of the Mathematical MOdelling Results.

Given basic input information, mathematical models may produce a variety
of information outputs.
The 1 inearized multi -stage model output provides
estimates of parameters describing the shape of the dose-response curve, and
the upper 95 percent confidence limit on that curve. It also provides estimates of dose levels corresponding to a given level of risk, and risk levels
corresponding to a given dose. The specification of action levels for carcinogens varies from agency to agency. As a general policy, however, the Maine
Bureau of Health considers an exposure level corresponding to a lifetime
cancer risk of one per one hundred thousand as a basis for a public health
concern. At a minimum, the exposure level corresponding to this cancer risk
level should be presented.
The equation for the maximum likelihood estimate (MLE) describes the shape
' of the dose-response curve which provides the best fit to the experimental
data. This value represents only a point estimate of risk and lacks the
confidence associated with the upper bound risk estimate. Nonetheless, the
MLE should be presented along with the 95 percent confidence limit in order to
provide an indication of the correspondence between the upper bound on risk
and the experimental data. At a minimum, the cancer risk estimates presented
should include those based on worst case assumptions, as such estimates are
necessary if the risk assessment is to reflect a conservative approach to
scientific uncertainty. It is possible, however, that more than one MLE and
upper confidence limit on risk may be presented, depending on the uncertainty
regarding the input variables. Inclusion of multiple risk estimates may add
to the assessment by providing a quantitative indication of the range of
uncertainty associated with the estimation of potential human cancer risk.
Cancer risk estimates derived from animal bioassays are usually based on
tumor incidences associated with lifetime exposures.
In addition, most
epidemiological studies consider exposure durations which last for a
significant portion of a normal human lifespan. These exposure periods should
be reflected in the presentation of the human cancer risk estimate by basing
the estimate on lifetime exposure. Often, cancer risk estimates may be needed
for less than lifetime exposure periods. As there is generally inadequate
information from which to compare cancer risks resulting from long-term
exposure to those resulting from shorter term exposure, cancer risks for less
than lifetime exposures should be based on the product of exposure dose and
exposure duration unless a more precise estimate of cancer risk can be
derived. Also, for cancer risks to be translated from a mg/kg/day dose to an
exposure concentration in an environmental medium, a reference body weight is
needed for the general population. A general procedure in this regard is to
base cancer risks on a reference adult weight of 70 kilograms unless another
reference weight is shown to be preferable to a given risk assessment.
16.4

Derivation of Action Levels Using the Uncertainty Factor Approach.

Uncertainty factors should be used when available chemical-specific health
data are inadequate to estimate either a no effect or a de minimus exposure
level for a threshold effect in the general population~ The uncertainty
factor·approach rests on two basic assumptions. The first assumption is that
a population threshold exists below which chemical exposure causes no adverse
health impacts.
The second assumption is that for any given area of
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uncertainty, chemical exposure produces the most toxic response that can
reasonably be estimated from the available health data. Current scientific
understanding of chemical carcinogenesis does not generally allow for the
assumption of a population threshold.
Therefore, the uncertainty factor
approach should only be used in the assessment of potential human cancer risks
when sufficient scientific justification is available, or when interim
guidance is needed for suspected carcinogens which lack an adequate
quantitative data base for cancer risk estimation purposes (See Chapter
16.4.5).
Risk extrapolation procedures for non-carcinogenic effects involve the
identification of sensitive health effects, the determination of either a
lowest observed adverse effect level (LOAEL) or a no observed adverse effect
level (NOAEL), and the application of appropriate uncertainty factors to
address the probability that certain subgroups of the population may respond
more sensitively then what is indicated by the experimental data. It then
follows that a level below that which causes the most sensitive response in
sensitive populations should also protect human beings from all adverse
effects resulting from exposure to a particular chemical.
Four concerns may have to be addressed by the uncertainty factor approach
in reference to any given health effect: 1) the estimation of a response level
in sensitive human populations from the available epidemiological or animal
toxicology studies, 2) the estimation of a no adverse effect level in
sensitive human populations when only LOAELs are available, 3) the estimation
of a chronic no adverse effect level when only sub~hronic data are available,
and 4) the estimation of a no adverse effect level for a sensitive health
effect when only data on relatively more severe health effects are available.
Depending on the nature of the data base, some or all of these concerns should
be addressed in the risk assessment. The final outcome of this procedure is
the derivation of an estimated no adverse effect level (ENAEL) for the general
population with regard to a particular sensitive health endpoint and exposure
duration.
The development of appropriate criteria for use in the uncertainty factor
approach is presented in the following discussion. In certain cases, the risk
assessment may be unable to use the uncertainty factor approach because of an
inadequate health effects data base. Interim guidance may still be needed,
however, for risk management purposes. Recommendations concerning procedures
for developing interim guidance on inadequately studied chemicals are
discussed in Chapter 16.4.5.
16.4.1

Consideration of Intraspecies and Interspecies Variability.

The major area of uncertainty in the derivation of action levels for
threshold effects concerns the potentially wide range of population
variability in both susceptibility and sensi ti vi ty to the adverse effects of
chemical exposure. Few chemicals have been so extensively studied that their
entire range of health effects in human populations can be precisely defined.
Therefore, an adverse observed in an animal population should also be presumed
to occur in at least some human population, unless adequate information exists
to demonstrate that the effect is a species-specific response. If human data
are available, the policy issue concerns the potential range of variability
between the study population and a sensitive human population. In estimating
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these ranges in variability, it is reasonable to assume that more uncertainty
is associated with the extrapolation of animal data than with the extrapolation of human data.
If it is assumed that there is a general qualitative correspondence
between human susceptibility to a toxic effect and the occurrence of that
effect in some laboratory species, risk assessment concerns then focus on the
quantitative correspondence between the response in any given laboratory model
or human population and the response in sensitive human populations. If it is
further assumed that the response in laboratory animals is quantitatively
similar to some human population, the risk assessment policy issue becomes one
of determining the potential range of variability between the animal response
and the response of a sensitive human population.
According to the procedure just described, consideration of intraspecies
and interspecies differences begins with an estimate of the human variability
in sensitivity to the toxic effects of chemical exposure. A factor of 10 has
commonly be used to account for variations in sensitivity among human
populations (NRC, 1977; Dourson and Stara, 1983; Hogan and Hoel, 1982). It is
possible, however, that this factor may be inadequate to protect certain
sensitive populations. Gillette (1985) noted that even among small groups of
test subjects, clearance of environmental chemicals may easily vary 20- to
50-fold. Calabrese (1983) examined variations on human responses to certain
xenobiotics as well as 'differences in risks to diseases for specific sensitive
populations. He noted that variations in human responses may range up to two
or three orders of magnitude, and that a 10-fold uncertainty factor may
sometimes be inadequate for up to 20 percent of the human population.
Indirect estimates of the range of human variability have been made based
on animal models. Dour son and Stara (1983) conducted a probi t analysis on
acute rat lethality data for 490 toxicants. The slopes ranged from 1.4 to
64. They then calculated the dose reductions required to drop the median
response (e.g., the LDSO) to a level which would result in deaths of only the
most sensitive members of the population (LD13). The frequencies of the
slopes plotted against the dose adjustments needed to reduce lethality to the
LD13 level.
These results are presented in Figure 16.3.
The authors
calculated that for approximately 92 percent of the slopes, a 10-fold
reduction in dose would drop the response to below the LD13. Furthermore,
they stated that average slope of 7.8 needed only a 2.4-fold reduction in dose
to reach this level. On the basis of this information, they concluded that
the 10-fold factor may be overly conservative with respect to the "average"
chemical, but sufficient to protect the population from most chemicals.
There are limitations associated with the use of such animal models for
the purpose of estimating the potential human variability in responses to
toxic chemicals. Firstly, the data base used by Dourson and Stara are based
on a relatively homogenous population of rats. Furthermore, the toxicological
endpoint (LDSO) may not correlate well with more sensitive measures of
toxicity. Finally, when compared with the human studies, it appears that the
animal studies may significantly underestimate the potential human variability.
In light of these considerations, an appropriate conceptual model for
assessing intraspecies and interspecies differences is one that focuses on the
wide variability in the human responses to chemical exposures. A hundred-fold
range of variability would include most populations. In the absence of
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Uncertainties Associated with Intraspecies and Interspecies Differences in
Response to Toxic Chemical Exposure.
The graph assumes a lognormal
distribution in human sensitivity.
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comparative interspecies data, it must be assumed that animals may be up to
100 times less sensitive to the effects of exposure than a sensitive human
population. As there is less uncertainty associated with predictions based on
human data, it is less likely that the mean response observed in an
epidemiological study would represent the least sensitive response among human
populations. Rather, it is more likely that a 10-fold uncertainty factor
would adequately address potential intraspecies difference among human
beings. An illustration of the conceptual basis for using intraspecies and
intraspecies uncertainty factors is presented in Figure 16.4.
Tpese uncertainty factors are consistent with those generally used by the
National Academy of Sciences (NRC, 1977) and the U.S. Environmental Protection
Agency (Dour son and Stara, 19 83). The approach just described effectively
provides a 10-fold interspecies uncertainty factor to estimate an average
response in human populations from animal data. Justification for this factor
is provided by studies which have compared similar toxic responses between
human beings and laboratory animals (Dourson and Stara, 1983).
Such
comparisons have raised speculations that interspecies differences may result
from factors correlated with animal surface area (Dourson and Stara, 1983).
If this is true, it is also possible that species are equally sensitive to a
given chemical when the doses at the site of action are equivalent. Thus, if
adjustments have been made to account for interspecies differences in
delivered dose, and it can be demonstrated that the experimental animal is as
equaliy sensitive as human beings after such adjustments have been made, then
a modification of this uncertainty factor may be warranted. Often, however,
the distinction cannot be made concerning the relative contributions of
delivered dose differences and inherent differences in sensi ti vi ty to the
overall assessment of interspecies variability.
In these cases, the
uncertainty factor for animal data should not be modified, regardless of the
way in which equivalent dose units are expressed.
16.4.2

Databases Which Lack NOAELS.

Another issues associated with quantitative assessment using the
uncertainty factor approach is the derivation of the estimated no adverse
effect level for exposed populations in studies which lack adequately derived
no observed adverse effect levels (NOAELS). The NOAEL is dependent on the
sample size, as the two are inversely related to one another (M..mro and
Krewski, 1981; Hogan and Hoel, 1982). If, for example, the actual probability
of a toxic response occurring at a specific dose is 7 percent, and if 10
animals were exposed, there would be a 50 percent chance that all of the
exposed animals would fail to show the response (Hogan and Hoel, 1982). Thus,
if the data do not contain a NOAEL for a particular effect, or if the
postulated NOAEL is in question, an uncertainty factor should be applied to
the LOAEL.
Confidence in the estimation of no adverse effect levels may be increased
through analysis of the shape of the dose response curve. An assessment of
the curve's trend helps in some cases to distinguish between a lowest observed
adverse effect level (LOAEL) and a no observed adverse effect level (NOAEL).
Structure-activity data may also provide additional information for evaluating
the dose-response curve.
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Comparisons have been made regarding the relationships between LOAELS and
NOAELS, based on rat toxicology studies involving 33 different chemicals
(Dour son and Stara, 1983). A summary of the results is presented in Figure
16.5. The results show that all ratios were 10 or less, with most being 5 or
less. The quality of these data are subject to the same caveats as those
associated with the quality of the NOAEL data. Also, it is unknown to ltvhat
extent these comparisons reflect true ratios of LOAELS to NOAELS and to \vhat
extent these findings are influenced by general dose selection procedures.
Nonetheless, on the basis of this limited data base, it seems reasonable to
apply a factor of 5 or 10, depending on the available dose-response
information, when estimating a no effect level from a lowest observed effect
level.
16.4.3 Databases Which Lack Chronic NOAELS or LOAELS.
A third concern relevant to the uncertainty factor approach involves the
estimation of chronic action levels in the absence of adequately conducted
chronic effects studies. In these cases, such estimates must rely on the
results from studies using shorter exposure durations. It is possible that
exposure limits designed to protect the public from subacute or subchronic
effects of a particular chemical may not be adequate if populations are
chronically exposed. Therefore, uncertainty factors should be applied to
NOAELS or LOAELS identified in subacute or subchronic studies. These factors
address the possibility that longer term exposures may produce adverse health
effects at lower concentrations than those which produced subacute or
subchronic effects.
The quantitative basis for this uncertainty factor comes from a studies
which compared the lowest (signified in the study as "minimal") observed
effect levels in rats exposed to the same chemical for varying exposure
periods (Weil et al., 1969; Weiland McCollister 1963). Specifically, these
studies compared the lowest observed effect levels in rats for 1-day
(subacute), 90-day (subchronic), and 2-year exposure periods. The comparisons
used data on 20 compounds, predominantly pesticides and surfactants. Weil et
al. (1969) derived equations to predict the median and upper 95 percent
confidence limits on the lowest observed effect levels to adjust from a 7-day
exposure to a 90-day exposure and from either a 7-day or 90-day exposure to a
2-year exposure. Their findings are presented in Table 16.2. The findings of
the Weil and McCollister (1963) study, as adapted by Dourson and Stara (1983),
are presented in Figure 16.6.
These comparisons (Weil et al., 1969; Weil and McCollister 1963; Dourson
and Stara, 1983) indicate that a factor of 10 should be adequate to adjust
NOAELS or LOAELS from either a subacute to a subchronic exposure duration, or
from a subchronic to a chronic exposure duration.
According to these
comparisons, a factor of 35 should be adequate when adjusting from a subacute
to a chronic effect. The subacute to subchronic uncertainty factor should be
considered with much caution, however, as it is possible that critical health
effects associated with longer term exposures would not be adequately
identified in subacute tests.
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Figure 16.5. Frequency of Studies Versus the Ratio of the LOAEL to NOAEL
After Either Subchronic, Chronic, of Composite Subchronic and Chronic
Exposures.
Source:
Dourson, M.L., and Stara , J • F • , 19 83 , "Regulatory History and
Experimental Support of Uncertainty (Safety) Factors," Reg. Toxicol.
Pharmacol., Vol. 3, p. 233.
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Table 16.2
Predicted Median and Upper Limit to Achieve
a Minimum Effect (M.E.) Level

Source:

Value
Value

For 90-Day
Feeding Study

For 2-Year
Feeding Study

Median

M.E.7/3.0

M.E. 9o/1.8 or M.E. 7/S.4

95 th
Percentile

M.E.7/6.2

M.E.9o/5.7 or M.E.7,/35.3

Weil, C.S., et al., 1969, "Relationship between Single-Peroral,
One-Week, and Ninety-Day Rat Feeding Studies," Toxicol. Appl.
Pharmacol., Vol. 14, pp. 426-431.

16.4.4 Databases Without Adequate Information of Sensitive Effects.
When comparative information is available, the uncertainty factor approa~h
should consider the severity and sensitivity of the effect. Some target
organs and organ systems, such as the nervous and reproductive systems, may
manifest a wide spectrum of toxic responses (NRC, 1986). Databases sufficient
to characterize these responses are generally limited, however (NRC, 1986).
It may be likely, therefore, that substances associated with neurotoxicity or
reproductive/develo~~ental toxicity through limited testing may also cause
subtler effects on these systems which current testing procedures do not
detect.
No formal guidance has been developed concerning the use of uncertainty
factors to address effect severity and sensitivity. Until formal guidance is
developed, the determination of whether or not an uncertainty factor should be
applied, how large that uncertainty factor should be, is an issue specific to
the individual risk assessments. Determinations regarding such uncertainty
factors should rest largely on the understanding of the quantitative
relationships between progressively more severe toxicological responses
associated with a given organ or organ system. If there is no quantitative
basis for the establishment of an uncertainty factor, this shortcoming should
be discussed in the Risk Characterization (Section VI).
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Figure 16.6. Frequency of Studies Versus the Ratio of Subchronic to Chronic
Exposures for Either NOAELS, LOAELS, or Composite NOAEL-LOAEL Values.
Source:
Dourson, M.L., and Stara, J.F., 1983, "Regulatory History and
Experimental Support of Uncertainty (Safety) Factors," Reg. Toxicol.
Pharmacol., Vol. 3, p. 231.

General guidance regarding the progression of concern regarding effect
severity has been outlined by the Massachusetts Department of Environmental
Quality Engineering (MDEQE, 1985). This guidance appears in MDEQE's paradigm
acute/chronic effects, presented in Table 15.3. According to this outline,
mild or transient effects are assigned a severity value of 1 (or representing
the least severe effect).
Irreversible effects are assigned the highest
severity value of 3. A value of 2 is assigned to intermediate effects.
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16.4.5 Default Procedures Using the Uncertainty Factor Approach.
There may be several situations in which no adequate quantitative data are
available for quantitative risk extrapolation. If action levels are required
of the assessment, the use of alternative approaches is warranted. These may
involve the use of structure-activity data or generic default approaches. The
State of Michigan (SAAC, 1981), for example, estimated an uncertainty factor
of 0.00002 to be applied to LD50 or LCSO data in order to derive an acceptable
exposure level for non-criteria air pollutants which fall into this category.
This factor was based on the finding by MacNamara (1976) that the upper 95
percent confidence limit of the ratips between the no observed adverse effect
level to the LD50 was 0.002.
Further application of a hundred-fold
uncertainty factor to this upper confidence limit results in the recommended
default uncertainty factor.
The use of uncertainty factors is not generally recommended when deriving
action levels for known or suspected carcinogens. There may be certain
situations, however, when adequate information is unavailable for the
quantitative assessment of carcinogenic effects. Factors of as high as 5,000
applied to the no observed adverse effect level (NOAEL) have been recommended
to provide interim public health guidance in these situations (Hogan and Hoel,
Such factors have been criticized for being arbitrary and not
1982).
sufficiently conservative with regard to non-threshold effects. On the other
hand, little guidance is available· concerning the assessment of potential
carcinogens with an inadequate quantitative data base. Until such guidance
becomes available, therefore, an uncertainty factor of 5, 000 may be used to
set an upper bound on exposure when adequate quantitative data are lacking and
interim guidance is needed. The lower bound on exposure to known or suspected
carcinogens should be zero.
16.4.6 Presentation of the Results from the Uncertainty Factor Approach.
After the appropriate uncertainty factors have been selected and
quantified, a summary of the risk derivation process should be presented.
This summary should include the estimated no adverse effect levels (ENAELS)
for each health effect and exposure duration of concern. The uncertainty
factors and interspecies adjustments should be presented in such a way that
the quantitative relationship between the ENAEL and the experimental findings
is clear. The uncertainty factors factors established in this risk assessment
policy are presented in Table 16.3.
The ENAEL may vary depending on the the reference human population which
serves as the basis for that level. This is because air, water, and food
intake requirements decrease per unit of body weight as body weight
increases. Thus, for a given concentration of a chemical in these media, a
small child would be expected to receive a greater intake on a mg/kg basis
than an adult.
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Intake differences are particularly relevant when acute, subacute, or
subchronic effects are considered. Chronic effect levels are usually based on
studies which are carried out over the lifetime, or a large proportion of the
lifetime, of an experimental cohort. The reference human population for these
effects, therefore, is usually the average adult weighing 70 kilograms (NRC,
1977). The reference population for acute, subacute, or subchronic effects is
generally the 10 kilogram infant (NRC, 1977). When developmental effects are
being specifically considered, the reference human population is the 60
kilogram female. The intake doses for these reference human populations
should be derived in Chapter 16.2.

Table 16.3
Summary of the Uncertainty Factors Used in the Quantitative
Assessment of Threshold Effects*

Factor

Parameter
Interspecies
·Sensitive Populations
LOAEL to NOAEL
Subacute to Subchronic Exposure
Subchronic to Chronic Exposure
Severity/Sensitivity of Observed Effect

10
10
5' 10

10
10
variable

* See text for explanation.

16-23

(88)

SECTION VI:

RISK CHARACTERIZATION

Risk characterization, according to the National Research Council (NRC,
1983a), is "the description of the nature and often the magnitude of human
risk, including attendant uncertainty." Thus, in the risk characterization
section, three areas of risk assessment are integrated: 1) the quantitative
relationship between dose and effect, based on the existing data;
2) the
quantitative estimates of population exposure to a substance; and 3) the
assessment of the critical areas of uncertainty associated with the risk
assessment. The characterization of health risks may be largely dependent on
the way in which uncertainty is quantitatively integrated into the
dose-response assessment and the exposure assessment. The worst case risk
assessment reflects the maximum degree to which uncertainty is quantitatively
considered. The risk assessment has the obligation to present the worst case
assessment, as it represents the highest upper bound estimate of health risk,
given the limitations imposed by scientific uncertainty and science policy
choices made in deciding worst case assumptions. Characterizations based on
assumptions less extreme than the worst case may be presented as part of a
general description of the uncertainty surrounding the action levels.
In
presenting these alternative characterizations, however, the assessment should
clearly state both the arguments and evidence which indicate why the
alternatives may give a better estimate of the actual risk than the worst case
assumption, and the arguments and evidence which support why the the worst
case assumption should be favored.
The worst case assumptions which form the basis of the risk
characterization may vary according to the policy choices made in deciding
what these assumptions are. The risk characterization could therefore benefit
from a comparison of the assessment's worst case characterization with those
of other assessments. This comparison could provide risk managers with a
perspective concerning the areas of scientific consensus and disagreement
regarding the risk assessment findings, and the particular risk assessment
issues that underlie these areas of agreement and disagreement. In addition,
comparisons with existing standards and guidelines, as well as with the health
concerns associated with alternatives to the substance of concern in the risk
assessment, may provide the risk manager with additional perspectives from
which the assessment's findings may be interpreted.

17.

Risk Assessment Findings.

The risk assessment findings comprise a summary of what is known and what
is not known about the substance's health risks. These findings include the
conclusions that can be drawn from the exposure assessment, hazard
identification, and hazard assessment sections.
The findings are then
compared to those of other assessments.
Following this comparison is ·a
qualitative appraisal of the existing data base.
This appraisal is very
important to the assessment, as it provides a context for evaluating the
extent to which the derived action levelss reflect overall health concerns.
It also provides the context for characterizing the specific risk assessment
areas which, if addressed more extensively, would be most likely to lessen the
uncertainty associated with the recommended action levels.
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17.1

Characterization of Health Risks Associated with Exposure.

The characterization of health risks associated with exposure integrates
the findings from the quantitative estimates of exposure (Chapter 9) and the
quantitative health risk assessment (Chapter 16). Health risks should be
presented for each health effect evaluated and for each exposure duration of
concern. The criterion which connects a health endpoint, an exposure level,
and an exposure duration is the action level. Depending on the particular
health effect, the action level may be expressed as an estimated no adverse
effect level (ENAEL) or as a cancer risk level. In either case, the action
level, when compared to a particular exposure level and duration, provides the
basis for determining whether a current or projected exposure warrants a
public health concern.
The quantitative characterization of health risks should be accompanied by
a discussion of the qualitative factors related to the derivation of the
action levels. These factors include the toxicological importance of the
health endpoints, the study populations used in the risk extrapolation (for
example,
laboratory
animals,
occupational
cohorts,
sensitive
human
populations), the population subgroups most susceptible to exposure-related
effects, and the types of risk factors which could influence the substance's
toxicity.
In addition to the characterization of human health risks,
the
environmental and ecological impacts associated with the substance could be
characterized.
Such characterizations are warranted for two reasons.
Firstly, they serve to provide a more complete description of the adverse
impacts resulting from the presence of a particular substance in the
envirorunent o
Secondly, adverse impacts on the environment may indirectly
affect human health by causing disruptions in the basis processes which
sustain human life. Thus, the complete characterization of the human health
impacts associated with exposure to a particular substance should include
indirect, as well as direct, human health impacts.
17.2

Comparison with Findings of Previous Assessments.

The comparison of the risk assessment findings with the findings of
previous assessments provides a context for evaluating the areas of scientific
consensus and disagreement regarding the health risks of a particular
substance. Differences may occur as a result of different risk assessment
policy choices or because of new findings. The reasons for these differences
should be discussed. When differences occur as a result of different pol icy
choices, the discussion should address the scientific issues underlying these
choices, and why the policy choice made in the assessment is preferable to the
other choices. Specifically, the discussion should focus on comparing the
assessments with respect to general policy objectives of considering all the
relevant data, of having the assessment reflect the best scientific
understanding of the issue, and of having the assessment reflect a
conservative approach to the evaluation of scientific uncertainty.
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17.3 Appraisal of Current Data Base.
The characterization of human health risks associated with exposure should
be understood within the context of what is still not known about the
substance's toxicity and exposure potential.
Depending on the level of
investigation given to a particular chemical, the amount of scientific
ignorance may prove to be more significant than the actual data used in
deriving the action levels. Every area of a risk assessment could probably be
improved by more information.
The main objective of the appraisal of
uncertainty, however, is to present a summary of those key areas of the risk
assessment for which adequate information was found to be lacking. The
presentation of this information represents a key element of the risk
assessment, for it stresses the importance that the process of evaluating
health risks is continually open to improvement. A discussion of these areas
of uncertainty associated with the risk assessment should help the risk
manager to understand better the differences among risk assessments, and the
degree to which future findings could change the current characterization of
health risks.
·
Much of the toxicological data is derived from studies in which human
beings or laboratory animals were exposed to relatively high doses of a
substance. These studies, at least the human studies, may have direct
relevance
for
individuals
in occupational
environments.
Yet,
the
environmental situations of most concern are generally characterized by
long-term, low level exposures to pollutants. Application of toxicological
data to the assessment of ambient exposures, therefore, must consider toxicity
differences resulting from different exposure levels, routes, and durations as
well as possible interspecies and intraspecies variations in sensitivity.
Such considerations are especially important in light of the fact that most
risk assessments must rely on data generated from animal studies. The use of
animal data introduces uncertainty into the estimation of human risk, as
animals may vary widely in their responses to toxins. There is generally no a
priori way of determining which animal will be the most predictive of a
part1cular toxic response in human beings. Further uncertainty is introduced
if the the animals are exposed to a chemical by a route different from normal
human exposures.

There are approximately 70,000 synthetic chemicals in commerce, of which
25,000 are in common use (NRC, 1983a, 1983b). Approximately 500 to 1,000 new
chemicals are introduced annually in the marketplace (OTA, 1981). Risk
assessments are generally expected to derive acceptable exposure limits for
the general population from a limited database. A recent study by the
National Research Council (NRC, 1984), however, concluded that adequate
information for complete health assessments exists for only 18 percent of
1,900 pharmaceutical products, 10 percent of 3,350 pesticide ingredients, 5
percent of 8,600 food additives, and 2 percent of 3,400 cosmetic ingredients.
Only a very small percentage of chemicals in the environment have been tested
for carcinogenicity (NAS, 1983), teratogenicity (Schardein, 1985), or
neurotoxicity (Anger and Johnson, 1986).
Investigations concerning the
interactive effects of chemicals have been rare (USEPA, 1984). A summary of
the NRC findings is presented in Figure 17.1 (NRC, 1984).
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Estimated Mean Percent
in the Select Universe

Size of
Category

Category
Pesticides and Inert
Ingredients of Pesticide
Formulations

3,350

Cosmetic Ingredients

3,410

Drugs and Excipients
Used in Drug Formulations

1,815

36

25

8,627

Food Additives

46

12,860

Chemicals in Commerce:
At Least 1 Million
Pounds/Year

11

13,911

Chemicals in Commerce:
Leu than 1 Million
Pounds/Year

12

12

76

21,752

Chemicals in Commerce:
Production Unknown or
Inaccessible

Complete
Health
Hazard
Assessment
Possible

78

11

10

Partial
Health
Hazard
Assessment
Possible

Minimal
Toxicity
Information
Available

Figure 17.1.
Ability to Conduct
Substances in Seven Categories.

8

82

Some
Toxicity
Information
Available
(But below Minimal)

Health-Hazard

Assessment

No Toxicity
Information
Available

of

Selected

Source: NRC. (National Research Council), 1984, Toxicity Testing: Strategies
to Determine Needs and Priori ties, National Academy Press, Washington, D.C.,

P:ll8.
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18.

Comparison of Findings with Existing Standards and Guidelines.

Existing standards and guidelines- reflect, to varying degrees, the
findings of previous assessme~ts.
They may differ substantially from
assessment findings, however, dependfng on how largely non-health related
concerns were considered in their development. Such concerns may include risk
management issues of technological feasibility, the degree of protection to be
provided to the population, or the sampling and analytical limitations
associated with substance identification and quantification. In addition,
some guidelines may be based on default risk extrapolation procedures which
are not directly comparable to the low-dose extrapolation procedures used in
formal risk assessments. The ways in which the risk assessment findings
differ from existing standards and guidelines may need to be explained.
Specific attention should be focused on the extent to which the consideration
of risk management criteria accounts for these differences.
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19.

Risks Associated with Alternative

Substances~

A concern relevant to the entire process of risk assessment involves the
degree of attention given to the substance undergoing investigation relative
to other substances. It is· possible, for example, that a risk management
decision might encourage the use of an alternative substance with equal or
even greater toxicity than the substance assessed, but without a corresponding
level of analysis applied to it. This concern is especially relevant if the
action levels indicate that severe use restrictions may be warranted for the
substance undergoing assessment.
Deciding whether or not the health risks of alternative substances should
be considered in the risk assessment depends on the assessment's stated
purpose and scope.
If such considerations are to be made, the assessment
should define the level of analysis to be given to these substances.
In
general, the analysis need only be sufficient to alert the risk manager to the
potential health concerns of the alternatives. Particularly, the analysis
should emphasize the data availability and general findings for the following
health effects categories: genetic toxicity, carcinogenicity, reproductive and
developmental toxicity, and other acute/chronic toxicity. This task may be
accomplished by a review of secondary sources and, possibly, a literature
search using relevant computer databanks. In addition, efforts have been made
to develop comparative databases for chemicals which produce similar health
effects (see, for example, Gold et al. (1984) and Ames et al. (1987) for
carcinogenic compounds). Reference to these databases may be useful in order
to provide the risk manager with a broader perspective of the health
implications associated with different public policy choices. Separate risk
assessments on the alternatives may be required, however,. before specific
comparisons of ·health risks can be made between these substances and the
substance undergoing assessment.
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20.

Conclusions.

The conclusions of the risk assessment shoutd present the key findings of
the investigation. The ultimate conclusion of the risk assessment should be
whether or not an actual or projected exposure to a substance presents a
public health concern. Regardless of the determination, a description of the
evidence upon which this conclusion is based should be presented.
This
description should include a summary of the scientific uncertainties
associated with this evidence. If the exposure is associated with a public
health concern, the conclusions should also specify the health effects ·of
concern, a description of the severity of the effects, and a description of
the populations at risk.
Conclusions are relatively easy to make when the available information
demonstrates that exposure of a specified level of a substance will or will
not present a public health concern. These determinations may be applicable
for certain well studied compounds.
For the preponderance of chemicals,
however, there is inadequate information on either exposure or toxicity. This
shortcoming may place limitations of vary degrees on the conclusions that can
be drawn from the data.
Depending on the level of scientific ignorance, risk assessment findings
may or may not be useful in the development of an appropriate public health
response to a chemical exposure situation. The measure of an effective public
health response is its ability to maintain or reduce incidences of premature
deaths and preventable adverse health effects. In order to best satisfy this
criterion, the general public health policy should be that all avoidable
exposures to toxic substances be prevented, except for those exposures in
which a public health benefit can be realized. Risk assessment findings are
thus most applicable to public health policy decisions either when an exposure
cannot be prevented or when' a preventable exposure has already occurred. The
conclusions of the risks assessments should be interpreted within the context
of this overall public health policy goal.
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